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Abstract 
Multiple sclerosis (MS) is a complex demyelinating disease associated with chronic 
inflammation of the central nervous system (CNS), axonal loss, and brain atrophy. The CD4+ and 
CD8+ T cells that are present in the demyelinating lesions are considered to mediate demyelination 
and axonal damage. An autoimmune process likely contributes to CNS tissue damage in MS, 
although direct evidence for this is still lacking. A major focus of my work is to understand the 
mechanisms by which autoreactive T cells contribute to CNS tissue damage. 
Although CD8+ T cells mediate effector functions through production of cytokines or by 
direct cytotoxicity, the mechanisms by which they can cause CNS tissue damage are elusive. In 
order to assess whether CNS-infiltrating CD8+ T cells could directly induce oligodendrocyte death 
and demyelination, we developed an original mouse model combining selective expression of 
influenza hemagglutinin (HA) as a neo-self-Ag in oligodendrocytes with transgenic mice 
expressing a HA-specific TcR on CD8+ T cells. We demonstrate directly the potential of CD8+ T 
cells to induce oligodendrocyte death in-vivo, as a likely consequence of direct antigen-recognition. 
Untill recently, CD4+ T helper cells have been held responsible for MS 
immunopathogenesis, partly because certain MHC class II alleles clearly predispose for developing 
MS. We investigated the pathogenic traits of the CD4+ T cell response targeting the 
immunodominant epitope of myelin oligodendrocyte protein (MOG). To this end we obtained 2D2 
TcR-transgenic C57BL/6 mice, which harbor a large population of MOG-specific CD4+ T cells and 
spontaneously develop optic neuritis and at a lower prevalence, EAE. Strikingly when we crossed 
these 2D2 mice with MOG-deficient mice (MOG-/-), we discovered that the 2D2 TcR-transgenic 
mice developed spontaneous EAE regardless of the presence or absence of the target self-antigen 
MOG. Therefore we hypothesized, that the 2D2 TcR specific for MOG35-55 recognizes a second 
CNS antigen. Furthermore, we were able to reveal, that MOG35-55 peptide shares sequence 
homology with a stretch of neurofilament-medium (NF-M), a cytoskeletal protein expressed in 
neurons and axons. In addition, this epitope derived from NF-M shares 2D2 TcR contact residues 
with MOG35-55 when presented in the context of I-Ab. Surprisingly, NF-M15-35 peptide showed 
heteroclitic response when presented to 2D2 T cells. To test the in-vivo relevance of this 
observation, we transfer in vitro differentiated Th1 cells from 2D2-Rag2-/- mice in C57BL/6,  
MOG-/-, and MOG-/- x NF-M-/- mice. We observed no clinical sign of disease in MOG-/- x NF-M-/- 
mice, while MOG-/- mice developed slowly progressive disease with delayed onset, as compared to 
C57BL/6 mice, which developed early classical EAE, suggesting that recognition of MOG and NF-
M by the 2D2 CD4+ T cells contribute to disease phenotype and severity. 
We refer to this novel observation of self-mimicry, as ‘Cumulative autoimmunity’ where an 
autoimmune response target two self-autoantigens in the same tissue, resulting in enhanced CNS 
tissue damage. 
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Introduction 
 
1. Introduction: 
The immune system has two major components, an innate arm and an adaptive arm. 
The innate immune system is a universal and ancient form of host defense against infection. 
Innate immune system recognition relies on a limited number of germline-encoded 
receptors. These receptors evolved to recognize conserved metabolites produced by 
pathogens, but not by the host. Recognition of these molecular structures allows the 
immune system to distinguish infectious nonself from noninfectious self. Innate immunity 
covers many areas of host defense against pathogenic microbes, including the recognition 
of pathogen-associated molecular patterns (PAMPs) (Janeway, 1989). In contrast, the 
adaptive immune system involves great variability and rearrangement of receptor gene 
segments to generate receptors, which yield myriad of antibodies or T cell receptors (TcRs) 
of exquisite specificity for each of potential antigens, additionally the adaptive immune 
system is characterized by immunological memory. However, the adaptive immune 
response is also responsible for allergy, autoimmunity, and the rejection of allograft.  
Because the innate immune responses do not depend on gene rearrangements, they 
occur much more rapidly than adaptive immune responses and do so in more stereotyped 
way, without tailoring a specific receptor to neutralize the danger signal in the form of 
antigen. Instead, in innate immunity, the danger signal (a motif from infectious microbes) 
can trigger toll-like receptors (TLRs), C-type lectin receptors (CLRs) to a membrane-based 
sensor of danger (Hemmi et al., 2000). In addition, the innate immune system has a 
cytosolic system to sense danger, the Nod-like receptors (NLRs), an intracellular system. 
The inflammosome is where signals from the TLR system and the NLR system are 
integrated. The major constituent of the inflammosome is the cytokine interleukin-1 
(Church et al., 2008; Lamkanfi and Dixit, 2009; Martinon et al., 2009). The innate immune 
system is made of many cell types, such as macrophages, dendritic cells (DCs), mast cells, 
neutrophils, eosinophils and NK cells. These cells can become activated during an 
inflammatory response, which is a consistent sign of infection with a pathogenic microbe. 
Such cells rapidly differentiate into short-lived effector cells whose main role is to get rid of 
the infection. However, in certain cases, the innate immune system is unable to deal with 
the infection, and activation of an adaptive immune response becomes necessary. In these 
cases, the innate immune system can instruct the adaptive immune system about the nature 
10
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of the pathogenic challenge. It does so through cytokines and chemokines and the 
expression of costimulatory molecules, such as CD80 and CD86, on the surface of 
specialized antigen-presenting cells (APCs), with DCs as the most important ones that 
alarm from infection in virtually all tissues (Banchereau and Steinman, 1998; Fearon and 
Locksley, 1996; Janeway, 1989).  
The central nervous system (CNS) provides special anatomic barriers to the 
movement of cells from the vascular compartment to the parenchyma. A group of 
autoimmune diseases of the brain and spinal cord that represents useful model for constitute 
a situation which involve antigen-specific T cells and an orchestrated antibody response to 
CNS components of the brain or spinal cord. My work is mainly focus on the autoimmune 
diseases where the brain and spinal cord itself are attacked. 
 
1.1 Generation of T-cell responses: 
1.1.1. Structure of the major components involved in antigen recognition 
1.1.1.1 The major histocompatibility complex 
The major histocompatibility locus has evolved to be polygenic and highly 
polymorphic, and is located on the short arm of chromosome 6 in humans, and on 
chromosome 17 in mice (Artzt, 1986; Klein et al., 1982; Ziegler, 1997). In humans the 
major histocompatibility complex (MHC) I locus contains 3 classical class I genes, named 
human leukocyte antigen-A (HLA-A), HLA-B, HLA-C and non-classical HLA-E and 
HLA-G, while the MHC II locus comprises HLA-DR, HLA-DQ and HLA-DP. In mice, the 
MHC I locus contains 3 main genes, H-2L, H-2D and H-2K, while the MHC II region 
comprises 2 main genes H-2IE and H-2IA, generally abbreviated to IE and IA (Bodmer et 
al., 1997; Trowsdale and Campbell, 1992). 
Both classes of MHC molecules are heterodimers with similar architectures and are 
composed of three domains, one α-helix/β-sheet superdomain that forms the peptide-
binding site and two immunoglobulin (Ig)-like domains (Fig.1) (Bjorkman et al., 1987b; 
Brown et al., 1993; Fremont et al., 1996; Madden et al., 1993; Matsumura et al., 1992; Stern 
and Wiley, 1994). The overall architecture is the same in both MHC classes, where a seven-
11
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stranded β-sheet represents the floor of the peptide-binding groove, and the sides are 
formed by two long α-helices, that straddle the β-sheet.  
In MHC class I molecules, the peptide-binding site is constructed from the heavy 
chain only, and an additional 12-kDa light chain subunit, β2-microglobulin (β2m), associates 
with the α3 domain of the heavy chain (Fig.1). β2m is a nonglycosylated protein of about 
100 amino acids encoded on chromosome 15 in humans and chromosome 2 in mice. Only 
one allele is known in humans, while there are seven in mice. There appears to be little 
functional significance of the polymorphisms in β2m, although they may subtly affect MHC 
class I structure or peptide binding because different β2m alleles can alter cytotoxic T 
lymphocyte (CTL) recognition of some antigens (Perarnau et al., 1990). β2m has no 
transmembrane domain and is not covalently associated with the extracellular region of the 
heavy chain. Because of this, the conformation of the heavy chain is highly dependent on 
the presence or absence of β2m chain. The membrane-proximal α3 region of the heavy chain 
is an Ig-like domain that contains a binding site for the CD8 receptor on CTL. The α1 and 
α2 domains, which are distal to the membrane and interact with the TcR on CTL, fold 
together to form a groove that binds and displays peptides. A β-pleated sheet forms the base 
of the cleft, and the walls are made of two α helices. The allelic polymorphisms in heavy 
chain primarily occur in those residues in and around this cleft, and in this manner, they 
alter the peptide-binding specificity of the class I molecules (Bjorkman et al., 1987a; 
Parham et al., 1995). The crystal structure of the MHC class I proteins revealed how a 
single type of molecule could bind and present so many different peptides. Many of the 
molecular interactions are with the peptide's main chain atoms and amino and carboxy 
termini, which are features common to all peptides. In addition a limited number of peptide 
side-chains extend into pockets along the groove thus imparting some specificity to peptide 
binding, although many different peptides can be accommodated (Wilson and Fremont, 
1993), and determine general motifs of the peptides capable of binding to particular MHC 
class I molecules (Falk et al., 1991). The groove is generally long enough to accommodate 
8 or 9 residues in an extended conformation (Madden et al., 1991) with the termini and the 
so-called anchor residues buried in specificity pockets that differ from allele to allele 
(Fremont et al., 1992; Madden et al., 1993). This binding mode leaves the upward-pointing 
peptide side chains available for direct interaction with the TcR. Longer peptides can either 
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bind by extension at the C terminus (Stern et al., 1994) or due to the fixing of their termini, 
bulge out of the binding groove, providing additional surface area for TcR recognition 
(Speir et al., 2001; Tynan et al., 2005). 
 
(a) MHC I  (b) MHC II  (c) CD1  
       
 
Figure 1: Architecture of MHC-like molecules 
(a) Class I molecules consist of a heavy chain (blue) and a light β2m chain (orange). The 
peptide-binding site is formed exclusively by elements of the heavy chain (b) Class II 
molecules; the peptide-binding site is assembled of both subunits. (Rudolph et. al. 2006) (c) 
Nonclassical MHC molecule mouse CD1d crystal structure loaded with a synthetic variant 
of alpha-galactosylceramide (alpha-GalCer) (Barral et. al. 2007) 
 
In contrast, the MHC class II molecule are assembled from two heavy chains (αβ) in 
which the peptide-binding groove is open at either end, and the peptide termini are not fixed 
so that bound peptides are usually significantly longer than in MHC class I (Fig.1). The 
MHC class II allows presentation of peptides of 13-18 residues. The peptide backbone in 
MHC class II is confined mainly to a poly-proline type II conformation (Stern et al., 1994) 
and resides slightly deeper in the binding groove. Thus, the bound peptide is more 
accessible for TcR inspection in MHC class I due to its ability to bulge out of the groove, 
even for 9-mer peptides, however, in MHC class II the termini particularly the N-terminal 
extension, can play a major role in the TcR interaction. 
T cells are sensitive to small numbers of antigenic pMHC ligands that are distributed 
among an excess of endogenous pMHC complexes on the surface of APCs. Recognition of 
antigens in the peptide-binding groove of surface-expressed MHC class I and class II 
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molecules by specific TcRs is central to T-cell activation. Two distinct pathways are used 
by MHC class I and class II molecules for the presentation of peptide antigens to CD8+ and 
CD4+ T cells, respectively (Ackerman and Cresswell, 2004; Kloetzel and Ossendorp, 2004; 
Rock et al., 2004; Watts, 2004). The MHC class I antigen presentation pathway is active in 
almost all cell types, providing a mechanism for displaying at the cell surface a sample of 
peptides derived from proteins that are being synthesized in the cell and are acquired during 
initial assembly in the endoplasmic reticulum (Cresswell et al., 2005; Kloetzel and 
Ossendorp, 2004; Rock et al., 2004). The MHC class II pathway is constitutively active 
only in professional APCs, including DCs, B cells, macrophages and thymic epithelial cells. 
The peptide presented by MHC class II molecules are derived from proteins that gain access 
to endosomal compartments, providing a way for CD4+ T cells to respond to exogenous 
antigens internalized by APCs. The α-chain and β-chain of MHC II molecules are 
synthesized in the endoplasmic reticulum (ER) and associate with invariant chain (CD74) 
for proper folding, trafficking and protection of the antigen-binding groove (Bryant and 
Ploegh, 2004; Cresswell, 1996; Jensen et al., 1999; Watts, 2004). 
A third lineage of antigen presenting molecules, distinct from MHC class I and 
MHC class II has been identified as CD1, which involves CD1a, CD1b, CD1c, CD1d and 
CD1e, and present both foreign and self-lipid antigens to T cells. The CD1 proteins share 
sequence homology and overall domain structure with MHC class I molecules, being 
constitute of a heavy chain with three extracellular domains that are non-covalently 
associated with β2m (Zeng et al., 1997) (Fig.1). On the basis of sequence analysis, the CD1 
isoforms can be classified into three groups: group 1 constitutes of CD1a, CD1b and CD1c; 
group 2 constitutes CD1d; and group 3 constitutes CD1e. In humans all five CD1 isoforms 
(CD1a–CD1e) have been identified, whereas muroid rodents express only CD1d that 
include CD1d1 and CD1d2 (Porcelli, 1995). Group 1 CD1 molecules mainly present lipid 
antigens to clonally diverse T cells that mediate adaptive immunity to the vast range of 
microbial lipid antigens (Beckman et al., 1994; Sieling et al., 1995). By contrast, CD1d 
molecules present lipid antigens to natural killer T (NKT) cells (Bendelac et al., 1995). 
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1.1.1.2 The T cell receptor 
TcRs are cell surface heterodimers consisting of either disulfide-linked α and β or 
γ and δ -chains (Brenner et al., 1986; Chien et al., 1987; Hedrick et al., 1984; Koning et al., 
1987; Saito et al., 1984; Winoto and Baltimore, 1989; Yanagi et al., 1984). Sequence 
analyses correctly predicted that TcRs would share a domain organization and binding 
mode similar to those of antibody Fab fragments (Davis and Bjorkman, 1988).  
The αβ TcR comprises 2 membrane proximal constant (C) regions and 2 membrane 
distal variable (V) Ig-like domain regions (Garboczi et al., 1996; Garcia et al., 1996a). The 
pairing of the membrane distal α and β chain variable regions resembles the Ig variable 
domain, such that the αβ combining site resembles the Ig-combining site (Fig.2). The loops 
connecting the β sheets located within the pMHC contact area consists of regions with 
highly variable amino acid sequences, called complementarity-determining regions (CDRs). 
The αβ TcR binds pMHC with relatively low affinity (1–100µM) through CDRs presented 
in their variable domains. 
Interaction between TcR and pMHC based on the three-dimensional structure of the 
pMHC moiety and X-ray crystallographic structure (Davis and Bjorkman, 1988; Machius et 
al., 2001) show that CDR1 and CDR2 of both the α and β chains of the TcR interact 
preferentially with the helices of the MHC molecule and that contacts to the bound peptide 
are made essentially by CDR3 alone (Garboczi et al., 1996; Garcia et al., 1996a; Teng et al., 
1998; Wilson and Garcia, 1997). 
The first crystal structures of TcRs with MHC class I molecules led to proposals that 
the TcR orientation is approximately diagonal with a mean around 35° (Rudolph and 
Wilson, 2002). By contrast, in the first MHC class II complexes, the orientation was 
described as being closer to 90° (Hennecke et al., 2000; Reinherz et al., 1999) suggesting a 
different binding mode between the MHC classes (Wang and Reinherz, 2002). 
Insight into the structural changes that supplement TcR-pMHC engagement must 
include crystal structures of the same TcR in its free and bound forms or of the same TcR 
bound to different pMHCs. Until recently, only two well-studied systems, the 2C and A6 
TcRs, fullfilled these requirements. The 2C system allowed comparison of the free 2C TcR 
(Garcia et al., 1996a) with an agonist (Garcia et al., 1998) and a superagonist peptide 
(Degano et al., 2000) in complex with the same H-2Kb MHC. This comparison disclosed a 
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functional hotspot between the CDR3 loops in the 2C TcR that finely discriminated 
between side chains and conformations of centrally located peptide residues through 
increased complementarity and additional hydrogen bonds. In the A6 system, altered 
peptide ligands (APLs) induced only subtle conformational changes in the TcR. In both the 
2C and A6 systems, conformational changes are restricted mainly to the CDR3 loop 
regions, and the largest conformational differences were observed when comparing free 
versus bound TcRs (Rudolph and Wilson, 2002).  
Many studies revealed substantial degeneracy in TcR recognition (Hemmer et al., 
1998; Hunt et al., 1992; Loftus et al., 1999; Pinilla et al., 1999). Multiple structures 
comparing bound and unbound TcRs have shown, that the CDR 3 loops are flexible (Garcia 
et al., 1998; Reiser et al., 2003). Thus, the conformational flexibility of these regions may 
enable polyspecificity through induced-fit recognition of multiple peptides within the 
binding cleft of the same MHC molecule. 
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Figure 2: Structural comparison of αβ  and γδ  TCRs. 
The top panel is a view down into the binding site, highlighted by the CDR loops. The 
bottom panel is rotated 90° around the horizontal axis. The light and heavy chains are 
shaded in light and dark gray, respectively. (Wilson et al. 2002)  
 
Compared with αβ TcRs, much less is known about γδ TcRs (Fig.2). The biological 
function of the γδ TcRs is also ill defined. γδ  T cells appear to respond to bacterial and 
parasitic infections (Morita et al., 1995) and primarily recognize phosphate-containing 
antigens (phosphoantigens) from mycobacteria by an unknown mechanism (Belmant et al., 
1999; Morita et al., 1995). 
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1.1.1.3 The CD3 complex 
The TcR is a complex consisting of the variable αβ chains noncovalently associated 
with the nonpolymorphic CD3 proteins. The CD3 proteins exist as a series of dimers 
including γε, δε, and ζζ associated with a single αβ heterodimer. These subunits lack 
enzymatic activity, but transduce signals via their immunoreceptor tyrosine-based activation 
motifs (ITAMs) (Reth, 1989). Tyrosine phosphorylation of the ITAMs serves as docking 
sites for interactions with other proteins. The earliest step in intracellular signaling 
following TcR ligation is the activation of src-family kinases p56lck and p59Fyn protein 
tyrosine kinases (PTKs), leading to phosphorylation of the CD3 ITAMs, followed by 
recruitment of Syk kinase family member ZAP-70 (ζ-associated phosphoprotein of 70 kDa) 
(Fig.3). 
The phosphorylated CD3ζ is a recruitment site of the ZAP-70 PTK (Chan et al., 
1992). The engagement of the TcR leads to Src family PTK activity resulting in ITAM 
phosphorylation and recruitment of ZAP-70. This converted the TcR: CD3 with no intrinsic 
enzymatic function into an active PTK associated molecular complex able to phosphorylate 
a spectrum of substrates leading to a myriad of downstream signals that, when integrated 
appropriately along with signals from other co-receptors, lead to T cell activation 
(Iwashima et al., 1994). 
ZAP-70 targets are the transmembrane adapter protein linker for the activation of T 
cells (LAT) and the cytosolic adapter protein Src homology2 (SH2) domain–containing 
leukocyte phosphoprotein of 76 kDa (SLP-76) (Bubeck Wardenburg et al., 1996; Zhang et 
al., 1998). These two adapters form the backbone of the complex that organizes effector 
molecules in a way that allows the activation of multiple signaling pathways. The loss of 
either LAT or SLP-76 results in a nearly complete loss of TcR signal transduction 
reminiscent of Syk/ZAP-70 or Lck/Fyn double-deficient T cells (Koretzky et al., 2006; 
Sommers et al., 2004; Zhang et al., 1999). LAT contains nine tyrosines that are 
phosphorylated upon TcR engagement, which bind the C-terminal SH2 domain of PLCγ1, 
the p85 subunit of phosphoinositide 3-kinase (PI3K), and the adapters growth factor 
receptor-bound protein 2 (GRB2) and GRB2-related adapter downstream of Shc (Gads) 
(Sommers et al., 2004). SLP-76 is then recruited to phosphorylated LAT via their mutual 
binding partner Gads (Liu et al., 1999). This proximal signaling complex results in the 
18
Introduction 
 
activation of PLCγ1-dependent pathways including Ca2+ and diacylglycerol (DAG) induced 
responses, cytoskeletal rearrangements, and integrin activation pathways. 
Following TcR ligation, PLCγ1 is found in the proximal signaling complex bound to 
SLP-76, Vav1, and LAT, where it is phosphorylated and activated by Itk. Activated PLCγ1 
then hydrolyzes the membrane lipid producing the second messengers IP3 (inositol 1,4,5-
triphosphate) and DAG. These two messengers are essential for T cell function (Fig.3). 
 
 
Figure 3: The CD3 complex and T cell receptor signalling 
Ligation of the TcR/CD3 results in activation of Src and Syk family PTKs associated with 
the intracellular CD3 domains that then activate PLCγ1 and Ras-dependent pathways (a) 
TcR signalling in mid 1990s (b) How the TcR couples to downstream pathways (c) The 
molecular basis for Ca2+ influx (d) The positive feedback loop responsible for Ras 
activation. (Smith-Garvin et.al. 2009) 
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Ca2+ ions are universal second messengers in eukaryotic cells. The IP3 generated by 
TcR-stimulated PLCγ1 activity stimulates Ca2+ permeable ion channel receptors (IP3R) on 
the ER membrane, leading to the release of ER Ca2+ stores into the cytoplasm. Depletion of 
ER Ca2+ triggers a sustained influx of extracellular Ca2+ through the activation of plasma 
membrane Ca2+ release-activated Ca2+ (CRAC) channels in a process known as store-
operated Ca2+ entry (SOCE) (Oh-hora and Rao, 2008). 
TcR-induced production of DAG results in the activation of two major pathways 
involving Ras and PKCθ. Ras is a guanine nucleotide–binding protein and is required for 
the activation of the serine-threonine kinase Raf-1, which initiates a mitogen-associated 
protein kinase (MAPK) phosphorylation and activation cascade (Genot and Cantrell, 2000).  
 
1.1.1.4  The CD4 and CD8 co-receptors 
The two major subsets of T lymphocytes in the peripheral immune system, the 
helper and cytotoxic T cells, are defined by their expression of either the CD4 or the CD8 
glycoprotein, respectively. Expression of these molecules, which serve as coreceptors by 
interacting with membrane-proximal domains of the MHC molecules (Garcia et al., 1996b; 
Genot and Cantrell, 2000), thus permitting simultaneous interaction of the TcR and either 
CD4 or CD8 with MHC.  
The CD4 is an integral membrane glycoprotein of 55-60 kDa. The primary structure 
in humans was deduced from T cell cDNA libraries (Maddon et al., 1987), and indicated a 
protein of 458 amino acids. The first 25 amino acids include a cleavage signal, which after 
cleavage results in a mature protein of 433 amino acids. Aligning the cDNA sequence with 
X-ray crystallography indicated, that the 4 domains of CD4 are similar to the Ig superfamily 
(Brady and Barclay, 1996; Maddon et al., 1987). Domain 1 and 3 were classified as variable  
(V) domains due to their similarities with the Ig variable region, domain 2 and 4 were 
classified as constant (C) domains (Williams and Barclay, 1988). The two membrane distal 
domains (D1 and D2) are, like the two membrane proximal domains (D3 and D4), rigidly 
packed together, whereas the connection between domain 2 and 3 is flexible. Interestingly, 
crystallography revealed CD4 to dimerise via cross-binding of D4 (Wu et al., 1997).   
CD8 is a transmembrane glycoprotein composed of a CD8 αα homodimer or a CD8 
αβ heterodimer. Each CD8 monomer, CD8α or CD8β, consists of an Ig-V-like domain, an 
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extended O-glycosylated stalk region, a single-pass transmembrane domain, and a short 
cytoplasmic region. The Ig domains of CD8 bind MHC class I at a site distant from the 
TcR-binding site (Chang et al., 2005). CD8αα and CD8αβ bind most but not all MHC class 
I and class I-like molecules and usually with a similar affinity/avidity (Kern et al., 1999). A 
notable exception is the tenfold higher affinity of CD8αα to the mouse MHC I-like protein, 
thymus-leukemia, than CD8αβ (Leishman et al., 2001).  
The co-receptor model proposed CD4 and CD8 to function as co-receptors able to 
migrate to and interact with the TcR, as well as transduce an independent signal necessary 
for complete TcR activation (Janeway et al., 1989). In accordance with this model, D3 of 
CD4 has been identified to interact with the TcR/CD3 complex (Mittler et al., 1989; Vignali 
et al., 1996; Vignali and Vignali, 1999), whereas D1 binds monomorphic regions on the 
MHC class II molecule (Doyle and Strominger, 1987; Fleury et al., 1996). Similarly, the 
CD8 co-receptor interacts with MHC class I (Gao et al., 1997). 
The T-cell immune response is initiated upon engagement of the TcR and coreceptor 
CD4 or CD8, by cognate pMHC complexes presented by APCs. TcR/coreceptor 
engagement induces the activation of biochemical signaling pathways that, in combination 
with signals from costimulatory molecules and cytokine receptors, direct the outcome of the 
response. The intracellular region of CD4 and CD8 binds to Lck (Rudd et al., 1988; 
Veillette et al., 1988) and Fyn (zur Hausen et al., 1997). Activation of the these two kinases 
is central to the initiation of TcR signaling pathways, and their regulation is tightly 
controlled by conformational changes arising from binding of ligands to the SH3 and/or 
SH2 domains of the kinases (da Silva et al., 1997; Holdorf et al., 1999; Xu et al., 1999), and 
by the phosphorylation and dephosphorylation of two critical tyrosine residues (Palacios 
and Weiss, 2004). 
 A second intracellular signaling component, the LAT, was also found to co-
immunoprecipitate with CD4 and CD8 (Bosselut et al., 1999; Kim et al., 2003). 
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1.1.2 Co-stimulation governing the activation of T cells 
T-cell activation is mediated by antigen-specific signals from the TcRζ/CD3 and 
CD4-CD8-p56lck complexes in combination with additional co-signals provided by 
coreceptors such as CD28, inducible costimulator (ICOS), cytotoxic T-lymphocyte antigen-
4 (CTLA-4), programmed death (PD-1), and others. In general terms, CD28 and ICOS 
provide positive signals that promote and sustain T-cell responses, while CTLA-4 and PD-1 
limit responses. The balance between stimulatory and inhibitory co-signals determines the 
ultimate nature of T-cell responses where response to foreign pathogen is achieved without 
excessive inflammation or autoimmunity. 
 
1.1.2.1 CD28 
CD28 is the most characterized of the Ig family of coreceptors possessing an 
intracellular domain with several residues, which are critical for its effective signalling. In 
particular, the YMNM motif beginning at tyrosine 170 is critical for the recruitment of 
SH2-domain containing proteins, especially PI3K, GRB2 and Gads. CD28 is a 44 kDa 
homodimer expressed on both, naïve and activated T cells and binds the ligands B7-1 
(CD80) and B7-2 (CD86), using a signature MYPPPY binding motif (Balzano et al., 1992). 
Its gene is located on human chromosome 2q33 (Naluai et al., 2000) and mouse 
chromosome 1 (Howard et al., 1991). 
T-cell activation can occur with a potent TcR signal alone (i.e. high avidity TcR-
pMHC interaction and/or high ligand density), however CD28 coligation is required in most 
responses to peptide antigens (Bluestone, 1995; Linsley, 1995; Noel et al., 1996). Without 
CD28 coligation, TcR-engagement often induces a non-responsive, anergic state or cell 
death (Linsley and Ledbetter, 1993). T cells from CD28-deficient mice show reduced 
proliferation in response to peptide antigens (Shahinian et al., 1993), although repeated 
antigen stimulation or long-term viral infection can bypass the requirement of CD28 
(Kundig et al., 1996). CD28 co-signals can stabilize the mRNA of cytokines and amplify 
the activation of nuclear factor of activated T cells (NFAT) and nuclear factor kappa B (NF-
κB) (Kalli et al., 1998; Karin and Ben-Neriah, 2000; Rincon and Flavell, 1994). 
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CD28 engagement enhances the production of various cytokines, including IL-1, IL-
2, IL-4, IL-5, TNF, and IFN-γ (Linsley and Ledbetter, 1993; McArthur and Raulet, 1993; 
Thompson et al., 1989). In addition it has been shown, that CD28 engagement plays a vital 
role in the early development and differentiation of both, Th1 and Th2 T cell subsets (King 
et al., 1995; Seder et al., 1994; Van der Pouw-Kraan et al., 1992). In the absence of CD28 
signaling, naive T cells are biased towards a Th1 phenotype and no IL-4 is observed when 
CD28/B7 interactions are blocked with hCTLA4-Ig (Seder et al., 1994). Recently, it has 
been shown that CD28 costimulation downregulate Th17 development in-vitro 
(Bouguermouh et al., 2009). Furthermore, CD28 is also important in the homeostasis and 
function of regulatory T cells (Tregs), the importance of CD28 signaling in Treg 
proliferation is suggested by the effectiveness of anti-CD3 and anti-CD28 treatment to 
expand Tregs in-vitro. Accordingly, both mouse and human Tregs can be expanded using 
CD3 and CD28 antibodies in the presence of high concentrations of IL-2 (Earle et al., 2005; 
Tang et al., 2004). It is also established that mice lacking CD28 or its ligands have 
decreased numbers of CD4+CD25+ regulatory T cells (Lohr et al., 2003; Salomon et al., 
2000). In addition CD80/86-blockade experiments have suggested that continual expression 
of CD28 ligand in the periphery is necessary to maintain the peripheral Treg compartment 
(Salomon et al., 2000). 
 
1.1.2.2 Cytotoxic T lymphocyte-associated antigen-4  (CTLA-4) 
CTLA-4, also known as CD152, is an activation-induced type 1 transmembrane 
glycoprotein of the Ig superfamily (Brunet et al., 1987). The CTLA-4 gene is located on 
chromosome 2 in humans and on chromosome 1 in mice (Dariavach et al., 1988; Ling et al., 
1999). The CTLA-4 gene product contains 223 amino acids, with a 35 amino acid signal 
peptide (Brunet et al., 1987; Dariavach et al., 1988), and is found as a covalent homodimer 
of 41–43 kDa (Lindsten et al., 1993; Linsley et al., 1995). 
The extracellular architecture of CTLA-4 is characterized by a single Ig V-like 
domain containing the CD80/CD86 binding site (Brunet et al., 1987; Dariavach et al., 1988; 
Linsley et al., 1995; Metzler et al., 1997; Ostrov et al., 2000). Homodimerization of CTLA-
4 is mediated by cysteine-dependent binding at position 122 in the stalk region and by N-
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glycosylation at positions 78 and 110 (Darlington et al., 2005; Linsley et al., 1995). The 
simplicity of its structure disguises its critical function as a major negative regulator of T 
cell–mediated immune responses (Alegre et al., 2001; Chambers et al., 2001; Rudd et al., 
2002; Salomon and Bluestone, 2001).  
The structural similarities and sequence homology between CTLA-4 and CD28 
extend to share natural ligands: the B7 molecules CD80 and CD86 (Freeman et al., 1993a; 
Freeman et al., 1993b; Linsley et al., 1990). However, a key feature that may explain 
CTLA-4's mechanism of action is that CTLA-4 binds CD80 and CD86 with greater affinity 
and avidity compared to CD28 (Linsley et al., 1991; Linsley et al., 1994). In general, 
CTLA-4 is thought to raise the threshold for TCR signaling, thereby preventing responses 
to self-antigens (Chambers et al., 2001; Greenwald et al., 2005). Furthermore, cell extrinsic 
and intrinsic mechanisms influence the CTLA-4 function. Cell extrinsic mechanisms 
include the secretion of soluble CTLA-4 (sCTLA-4), the production of indoleamine 2,3-
dioxygenase (IDO) and the involvement of Tregs (Rudd, 2008). Cell intrinsic mechanisms 
include CTLA-4 ectodomain competition with CD28 for the binding to CD80/86 (Masteller 
et al., 2000), the presence of associated phosphatases (Chuang et al., 2000; Lee et al., 1998; 
Marengere et al., 1996), blockade of lipid-raft expression (Chikuma et al., 2003; Martin et 
al., 2001) and microcluster formation (Schneider et al., 2008). It is likely that most of these 
factors contribute to the overall function of CTLA-4 in different contexts. 
When engaged to B7, CTLA-4 plays a key role as a negative regulator of T cell 
activation (Krummel and Allison, 1995; Walunas et al., 1994), leading to downregulation of 
T cell responses and to the preservation of T cell homeostasis and peripheral tolerance 
(Tivol and Gorski, 2002). The mechanism of T cell inactivation by CTLA-4 involves 
antagonism of CD28-dependent costimulation and direct negative signaling through its 
cytoplasmic tail (Carreno et al., 2000). CTLA-4 can exert its inhibitory effects in both, 
CD80/CD86 dependent and independent fashions (Grohmann et al., 2002; Ise et al., 2010; 
Vijayakrishnan et al., 2004).  
CTLA-4 has an intrinsic plasticity for signaling. It refers to the ability of CTLA-4 to 
actively deliver, by itself, a negative signal or a positive signal to a T cell, depending on the 
ligand it engages and its association/dissociation to protein phosphatase-2A (PP2A). When 
engaged to B7, it dissociates from PP2A and acts as an inactivator of T cells (Baroja et al., 
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2002). In contrast, when CTLA-4 is engaged to recombinant ligands 24 and 26 Abs, its 
association to PP2A is stabilized and it acts as an activator of T cells (Madrenas et al., 
2004).  
 
1.1.2.3 B7-1 (CD80) and B7-2 (CD86) 
Co-signalling molecules are that, whose functions are entirely dependent on TcR 
signals (Schwartz, 2003), and they control the TcR signals itself. In the absence of 
sufficient TcR signalling, co-signalling molecules lose their function (Chen, 1998). 
The two B7 family members, CD80 and CD86, bind to the same two receptors, 
CD28 and CTLA-4 (Chikuma and Bluestone, 2003; Coyle and Gutierrez-Ramos, 2001; 
Sharpe and Freeman, 2002). These receptors have distinct kinetics of expression and 
affinities for CD80 and CD86 (van der Merwe and Davis, 2003). Two additional B7 
homologs, B7-H3 (Chapoval et al., 2001) and B7-H4 (Sica et al., 2003) [B7x (Zang et al., 
2003), B7S1 (Prasad et al., 2003)], and another CD28 homolog, BTLA (B and T 
lymphocyte attenuator) (Watanabe et al., 2003), have been identified. 
CD80 and CD86 have a restricted expression pattern, being expressed mainly by 
professional APCs and haematopoietic cells (Chen, 2004). CD80 and CD86 on APCs have 
well-recognized roles as T cell costimulatory molecules, but the functional significance of 
their expression on T cells is not well understood. CD86 is constitutively expressed on 
some resting T cells, whereas CD80 is not present on resting T cells (Taylor et al., 2004). 
CD80 and CD86 may influence immune responses through reverse signaling into B7-
expressing APCs (Fallarino et al., 2003; Grohmann et al., 2002; Munn et al., 2004). CD86 
on B cells can signal bidirectionally, it stimulates CD28 on T cells and transduces positive 
signals into B cells that increase IgG1 and IgE production (Podojil et al., 2004; Podojil and 
Sanders, 2003). Basal or constitutive expression of B7 appears to be key for maintaining 
regulatory T cell homeostasis and preventing immune responses against self-antigens.  
In brief, CD28 first functions by costimulating T cells and preventing the induction 
of either anergy or apoptosis (Linsley and Ledbetter, 1993). Second, a CD28 homologue, 
CTLA-4, counterbalances CD28 by downregulating the immune response either by 
inducing apoptosis or competing with CD28 for its ligands, as both form homodimers and 
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bind the ligands CD80 and CD86, using a signature MYPPPY binding motif. CD80 binds 
CTLA-4 with much lower affinity than CD28 (van der Merwe et al., 1997) . Third, two 
distinct molecules, CD80 and CD86, function as costimulatory ligands for CD28 and 
CTLA-4 (Linsley and Ledbetter, 1993). While CD86 dominates in primary responses, the 
roles of CD80 and CD86 during an ongoing response depends on the relative expression of 
CD28/CTLA-4, the nature and concentration of cytokines in the surrounding milieu, and the 
characteristics of the APCs that are encountered. Finally, manipulation of the CD28/B7 
pathway can alter the balance of the immune response by influencing the nature of the 
cytokines produced in response to antigen exposure.  
 
1.1.2.4 Inducible co-stimulatory molecule (ICOS) and its ligand (ICOSL) 
ICOS is a glycosylated disulfide-linked homodimer (Rudd and Schneider, 2003) like 
CD28 and CTLA-4. The ICOS cytoplasmic tail contains a YMFM motif that binds the p85 
subunit of PI3K, similar to the YMNM motif of CD28 (Coyle et al., 2000), and stimulates 
greater PI3K activity than CD28 costimulation (Okamoto et al., 2003; Parry et al., 2003). 
However, in contrast to CD28, the ICOS YMFM motif does not allow the binding of 
GRB2, which is critical for IL-2 production (Harada et al., 2001; Okamoto et al., 2003). 
ICOS signals lead to effector cytokine production and can be inhibited by CTLA-4 
engagement (Riley et al., 2001). 
ICOS is upregulated on CD4+ and CD8+ T cells following activation and is 
expressed on effector and memory T cells (Coyle et al., 2000; Yoshinaga et al., 1999). It is 
also upregulated on activated NK cells, and promotes NK cell function (Ogasawara et al., 
2002). ICOS expression is stimulated on T cells by TcR and CD28 signals (Beier et al., 
2000; Coyle et al., 2000; Mages et al., 2000; McAdam et al., 2000). ICOS engagement was 
shown initially to selectively produce high levels of IL-10 and IL-4, but in-vivo studies in 
several different model systems have demonstrated that ICOS can stimulate production of 
both, Th1 and Th2 cytokines during initial priming and during effector T cell responses 
(Hutloff et al., 1999; McAdam et al., 2000). 
ICOSL has been detected on the surface of T cells, B cells, macrophages, DCs and 
other cell types including endothelial cells and some epithelial cells, and its mRNA is 
expressed constitutively in lymphoid and nonlymphoid tissues including kidney, liver, lung, 
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and testis (Richter et al., 2001; Swallow et al., 1999; Wang et al., 2000; Yoshinaga et al., 
2000). Costimulatory signals through ICOS provide critical T cell help to B cells (Hutloff et 
al., 1999; McAdam et al., 2001; Tafuri et al., 2001). 
ICOS and CD28 have unique and overlapping functions that synergize to regulate 
CD4+ T cell differentiation. Like CD28, ICOS augments T cell differentiation and cytokine 
production and provides signals for Ig production (Sharpe and Freeman, 2002; Sperling and 
Bluestone, 2001). It also regulates the outcome of autoimmunity in the murine model of 
multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE) but plays 
distinct roles at different times during the pathogenesis of EAE (Chapoval et al., 2001; 
Rottman et al., 2001; Sporici et al., 2001). Blocking of ICOS during induction of EAE 
exacerbates disease, whereas ICOS blocking during the effector phase of EAE ameliorates 
disease (Dong and Nurieva, 2003; Rottman et al., 2001).  
 Both CD28 and ICOS signaling upregulate Th1 as well as Th2 cytokines; however, 
ICOS does not upregulate IL-2 production. Thus, ICOS stimulates T cell effector function 
but not T cell expansion. The role of ICOS in stimulating IL-10 production may contribute 
to its role in regulating Treg, T cell tolerance, and autoimmunity. The function of ICOS 
during in-vivo immune responses appears to depend on timing/stage of immune response as 
well as microenvironment, because ICOSL can be expressed on endothelial and epithelial 
cells as well as professional APCs. 
 
1.1.2.5 Programmed death-1 (PD-1) molecule 
PD-1 is a monomeric member (Freeman et al., 2000; Latchman et al., 2001; Zhang 
et al., 2004) of the Ig superfamily (Ishida et al., 1992; Shinohara et al., 1994; Vibhakar et 
al., 1997) related to CD28 and CTLA-4, but it lacks the membrane proximal cysteine that 
allows these molecules to homodimerize. The PD-1 cytoplasmic domain has two tyrosines, 
one that constitutes an immunoreceptor tyrosine-based inhibition motif (ITIM), and the 
other an immunoreceptor tyrosine-based switch motif (ITSM) (Shlapatska et al., 2001). PD-
1 is expressed during thymic development primarily on CD4-CD8- cells and double 
negative γδ thymocytes (Nishimura et al., 2000) and is induced on peripheral CD4+ and 
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CD8+ T cells, B cells, and monocytes upon activation (Agata et al., 1996). NK-T cells also 
express low levels of PD-1 (Nishimura et al., 2000).  
PD-L1 is a 290 amino acid type I transmembrane protein encoded by the Cd274 
gene on mouse chromosome 19 and human chromosome 9. The PD-1 ligands exhibit 
distinct patterns of expression; PD-L1 is expressed more broadly than PD-L2 (Dong et al., 
1999; Freeman et al., 2000; Latchman et al., 2001; Tseng et al., 2001). PD-L1 is expressed 
on resting cells and upregulated on activated B, T, myeloid, and DCs (Liang et al., 2003). In 
contrast to CD80 and CD86, PD-L1 is expressed in nonhematopoietic cells including 
microvascular endothelial cells and in nonlymphoid organs including heart, lung, pancreas, 
muscle, and placenta (Ishida et al., 2002; Liang et al., 2003; Petroff et al., 2003; Rodig et 
al., 2003; Wiendl et al., 2003). The expression of PD-L1 within nonlymphoid tissues 
suggests, that PD-L1 may regulate self-reactive T or B cells in peripheral tissues and/or 
may regulate inflammatory responses in the target organs. 
PD-L2 is a type I transmembrane protein encoded by the Pdcd1lg2 gene adjacent to 
Cd274 and separated by only 23 kb of intervening genomic DNA in mouse and 42 kb in 
human. There are three PD-L2 splice variants identified from activated human PBMCs (He 
et al., 2004; Latchman et al., 2001). PD-L2 is rarely expressed on resting cells and hardly 
induced on B cells and T cells. PD-L2 can be induced on macrophages by IL-4 and IFNγ 
and on DCs by anti-CD40 antibody, GM-CSF, IL-4, IFNγ and IL-12. It has been reported 
that IL-4 induces PD-L2 more strongly than IFNγ, while IFNγ induce PD-L1 more strongly 
than IL-4 on macrophages, suggesting that Th1 and Th2 responses mobilize PD-L1 and PD-
L2 differentially (Loke and Allison, 2003).  
The lupus-like phenotype of PD-1-/- C57BL/6 mice first suggested a role for PD-1 in 
the regulation T cell tolerance and autoimmunity, as these mice exhibit hyperactivation of 
the immune system such as splenomegaly and in-vitro augmented proliferation of B cells 
(Nishimura et al., 1999; Nishimura et al., 2001). Administration of anti-PD-1 or anti-PD-L1 
mAb to one to ten-weeks old prediabetic NOD female mice led to the rapid onset of 
diabetes, and it was associated with increased IFN-γ producing glutamate acid 
decarboxylase (GAD) reactive splenocytes (Ansari et al., 2003). The expression of PD-L1 
on islet cells suggests that it may critically control the responses of self-reactive T cells in 
the target organ (Ansari et al., 2003; Liang et al., 2003). PD-1 and its ligands have a 
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negative regulatory role in EAE (Latchman et al., 2004; Salama et al., 2003). PD-1, PD-L1, 
and PD-L2 are expressed on brain infiltrating inflammatory cells in mice with EAE (Liang 
et al., 2003; Salama et al., 2003). PD-L1 is also expressed on vascular endothelial cells, 
astrocytes, and microglia. A role for PD-L1 in controlling the responses of self-reactive T 
cells is further indicated by the severe clinical EAE that develops following immunization 
of PD-L1-/- mice with the myelin oligodendrocyte glycoprotein 35-55 peptide (MOG35-55) or 
following the adoptive transfer of MOG35-55 specific T cells into PD-L1-/- recipients 
(Latchman et al., 2004).  
The PD-1: PD-L1/PD-L2 pathway has critical roles in regulating T cell activation 
and tolerance. CTLA-4 and PD-1 have important nonredundant inhibitory functions. 
CTLA-4 appears to have a more central role in the lymphoid organs, whereas PD-1 has an 
important role in regulating inflammatory responses in peripheral tissues. 
 
1.1.2.6 Adhesion molecules  
The continuous recirculation of naïve T cells and their subsequent migration to 
tissues following activation is crucial for maintaining protective immunity against invading 
pathogens. The preferential targeting of effector and memory T cells to tissues is instructed 
during priming and mediated by cell surface expressed adhesion receptors such as integrins.  
Integrins are αβ heterodimeric cell surface adhesion molecules that mediate cell-
extracellular matrix (ECM) and cell-cell interactions (Pribila et al., 2004), which are 
essential for T cell recirculation, migration into inflammatory sites and for a specific and 
effective immune response against foreign pathogens (Hynes, 2002; Shimizu et al., 1999). 
Integrin-dependent interactions of lymphocytes and APCs to endothelium regulate the 
efficiency and specificity of trafficking into secondary lymphoid organs and peripheral 
tissue.  
Naïve T cells express a homogeneous array of cell surface molecules that promotes 
recirculation through the secondary lymphoid organs of the body, including the spleen, 
peripheral lymph nodes (pLN), mesenteric lymph nodes (mLN) and Peyer’s patches (PP) of 
the small intestine. Naïve T cells express low levels of the αLβ2 (LFA-1), α4β1 (VLA-4) 
and α4β7 (LPAM) integrins, which bind ICAM-1, VCAM-1, and MAdCAM-1, 
29
Introduction 
 
respectively (Springer, 1995). The interaction of αLβ2 with ICAM-1 is important for T cell 
entry into pLN and for T cell interactions with APCs. The α4β1 ligand VCAM-1 is 
expressed at low levels throughout the vasculature, but becomes upregulated on a wide 
array of tissue during inflammation (Henninger et al., 1997). MAdCAM-1, the major ligand 
for α4β7 is preferentially expressed at steady state in the mLN and Peyer’s patches, where 
it promotes entry of naïve T cells into these sites through a high affinity interaction (Berlin 
et al., 1993; Erle et al., 1994; von Andrian and Mackay, 2000). Both VCAM-1 and ICAM-1 
are also expressed on the vasculature of the inflamed brain. In particular, VCAM-1 is 
known to promotes T cell entry through its interaction with α4β1 expressed on activated T 
cells (Engelhardt and Ransohoff, 2005).  
In addition to mediating adhesion to cell surface and extracellular matrix ligands, 
integrins generate a diverse array of intracellular signals. In T cells, LFA-1 and several β1 
integrins can provide costimulatory signals for TcR-induced T cell activation (Shiow et al., 
2006; Sprent et al., 1971). Differences in the regulation of IL-2 production by integrins and 
CD28 following TcR stimulation demonstrate the unique costimulatory properties of these 
molecules. In CD4 T cells, LFA-1-mediated costimulation enhanced IL-2 transcription, 
which is not mediated by stabilization of IL-2 mRNA (Abraham and Miller, 2001), in 
contrast, CD28 costimulation alters IL-2 levels by stabilizing IL-2 mRNA (Arnold et al., 
2004). Furthermore, LFA-1 and CD28 induce the activation of PI3-K in CD8 T cells 
however; PI3-K activity is required only for LFA-1-meditated costimulation (Ni et al., 
2001). 
In addition, osteopontin, also known as secreted phosphoprotein1 (SPP1), is a 
member of SIBLING (small integrin-binding ligand, N-linked glycoproteins) family of 
proteins (Fisher et al., 2001). It is highly expressed in MS lesions (Chabas et al., 2001). 
Studies in MS tissue and in models of relapsing-remitting (RR) and progressive EAE 
showed that osteopontin might have a role in the progression from RR disease to the more 
chronic form (Chabas et al., 2001). Osteopontin expression is induced on inflamed 
endothelium in the ECM of the perivascular cuff, and it serves as a ligand for two classes of 
adhesion molecules, CD44 and various integrins including VLA-4 (Ashkar et al., 2000). 
Furthermore, chemokine receptors served as adhesion molecules especially during 
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leukocyte migration, by acting on firm adhesion, locomotion, diapedesis, and chemotaxis 
(Cartier et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31
Introduction 
 
1.1.3 T cells activation 
1.1.3.1 Immunological synapse 
Activation of T cells by APCs requires the formation of a specific and long-lasting 
interface between the two cells, known as the immunological synapse (IS). TcR interaction 
with pMHC complexes in the IS between the T cell and APC is required for T cell 
activation (Norcross, 1984; Paul and Seder, 1994; Valitutti et al., 1995). The required 
duration of signaling is on the order of hours, while the activating and inhibitory molecular 
interactions in the IS have half-lives on the order of seconds (Iezzi et al., 1998; Matsui et 
al., 1994). The mature IS has been defined by arrangement of supramolecular activation 
clusters (SMACs) that form within a few minutes of T cell–APC contact (Grakoui et al., 
1999; Monks et al., 1998; Wulfing and Davis, 1998). Physiological T cell activation can be 
divided into a series of temporal stages: T cell polarization, initial adhesion, IS formation, 
and IS maturation (Grakoui et al., 1999) (Fig.4).  
Circulating T cells are rounded and nonpolarized, with a uniform radial distribution 
of membrane domains, receptors, and microvilli on the cell surface (Kucik et al., 1996; 
Sanchez-Madrid and del Pozo, 1999). These cells are relatively nonmotile and integrin 
adhesion molecules are maintained in a low-activity state (Kucik et al., 1996). In order to 
extravasate into lymph nodes and inflamed tissues, these T cells must encounter chemokine 
gradients before they encounter APC, leading to the rapid polarization of the T lymphocyte. 
The close contact areas of IS between polarized T lymphocytes and APCs are established 
by adhesion molecules. These close contact areas are achieved indirectly through 
cytoskeletal protrusions anchored to larger adhesion mechanisms like LFA-1 and ICAM-1 
(Grakoui et al., 1999) or more directly by smaller adhesion receptor pairs like CD2 and 
CD58 that would work beside the TcR. CD2 and its ligand CD48 are associated with rafts 
in the same fashion like TcR (Yashiro-Ohtani et al., 2000).  
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Figure 4: Dynamic processes of antigen recognition and T-cell activation by formation 
of microclusters and immunological synapse (Saito et.al. 2006) 
 
Upon T-cell attachment, LFA-1/ICAM-1 complexes cluster in the center and the 
MHC complexes are located at the periphery of the synapse. Later, TcR/MHC complexes 
become clustered in the center, whereas the LFA-1/ICAM-1 complexes are segregated to 
the periphery to form a ring around the TcR/MHC clusters (Grakoui et al., 1999), which is 
facilitated by the CD2-CD48 interaction that provides the correct membrane alignment 
(Dustin et al., 1996; Dustin et al., 1997; Wild et al., 1999). The formation of the central 
cluster gives rise to the immunological synapse that will remain stable for over an hour. 
Furthermore it has been shown by intravital two-photon laser scanning microscopy 
that T cells undergo rapid, random amoeboid locomotion in secondary lymphoid tissues 
(Miller et al., 2003; Miller et al., 2002b). This has been most intensively observed in mouse 
lymph nodes, which are subjected to either explanted or in-vivo imaging by two-photon 
laser scanning microscopy, which led to the model of stochastic repertoire scanning, in 
which T cells, in the T-cell zones move rapidly with average speeds of 10–15 µm/min and 
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peak speeds of over 30 µm/min. In another study, it has been shown by two-photon 
imaging, that T-cell priming by DCs occurs in three successive stages: transient serial 
encounters during the first activation phase are followed by a second phase of stable 
contacts culminating in cytokine production, which makes a transition into a third phase of 
high motility and rapid proliferation (Mempel et al., 2004). 
 
1.1.3.2 TcR sensitivity 
The sensitivity of the TcR for the pMHC complex plays a crucial role in T cell 
activation. The TcR discriminates between peptides by as little as a single amino acid, as 
was shown when a single amino acid mutation turned an agonistic peptide into an 
antagonistic peptide (Allen et al., 1987). The spectrum of peptides presented by the MHC is 
generally classified as full agonist, partial agonist APL, non-stimulatory, and antagonist 
peptides. Full agonist peptides induce full activation of the peripheral T cells or negative 
selection of thymocytes, partial agonist peptides induce incomplete peripheral T cell 
activation and positive selection of thymocytes (Kersh and Allen, 1996), and antagonistic 
peptides prevent activation of  peripheral T cells though they do induce positive selection of 
thymocytes (Hogquist et al., 1994). 
It has been shown that T cells are sensitive to minute amounts of stimulatory 
(agonist) pMHC complexes in a sea of endogenous ligands (Irvine et al., 2002; Krogsgaard 
et al., 2005; Purbhoo et al., 2004). T helper cells can stop rolling and transiently increase 
cytosolic calcium levels in response to even one agonist-pMHC complex. Ten agonist 
complexes appear to be sufficient for sustained calcium release and the formation of the 
immunological synapse (Grakoui et al., 1999; Huppa and Davis, 2003; Monks et al., 1998). 
Cytotoxic (CD8+) T cells also seem to be very sensitive (Brower et al., 1994; Purbhoo et 
al., 2004; Sykulev et al., 1996) and as few as three agonist-pMHC complexes have been 
demonstrated to be sufficient for the killing of target cells (Purbhoo et al., 2004). Signalling 
induced by agonist ligands can be severely impaired if antagonist-pMHC molecules are 
present. Antagonists can be obtained by mutating TcR contact residues of agonistic peptides 
(Madrenas et al., 1995; Sloan-Lancaster et al., 1994; Stefanova et al., 2003). 
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Because of thymic selection, endogenous ligands bind TcRs much more weakly than 
pathogen-derived pMHC molecules. The extraordinary sensitivity of T cells to agonists, and 
the weak binding of TcRs to endogenous ligands, has led to the suggestion that these 
agonist ligands may be implicated in T cell activation (Irvine et al., 2002; Janeway, 2001; 
Krogsgaard et al., 2005; Li et al., 2004; Stefanova et al., 2003; Wulfing et al., 2002). For 
CD4+ T cells, a basic model is emerging in which agonist and endogenous ligands act 
cooperatively, to trigger TcRs, thereby amplifying signalling when agonists are limiting 
(Irvine et al., 2002; Krogsgaard et al., 2005; Li et al., 2004). Spatial localization of a kinase, 
Lck, in a signalling complex nucleated by agonist binding to TcRs has been considered to 
play a key role in enabling certain endogenous ligands, that associate with such complexes, 
to trigger TcRs (Krogsgaard et al., 2005). Recent advancement has also provided evidence 
for cooperative interactions between agonist and endogenous ligands in triggering CD8+ T 
cells (Anikeeva et al., 2006; Yachi et al., 2005). 
 
1.1.4 Heterogeneity of T cell phenotype: Cytokines & T cell differentiation  
There is extensive plasticity in the T-cell response to antigen. Helper CD4+ T cells, 
cytotoxic CD8+ T cells, the progression from naïve to effector and memory T cells, and 
differentiation into Th1, Tc1, Th2 and Tc2 subsets have long been recognized. However, 
the recent identification of multiple distinct subsets of CD4+ cells, like Th17, Th9, and 
Th22 and even Treg lineage, highlights a surprising degree of developmental convergence 
and late-stage plasticity with particular relevance for autoimmune diseases. More recently it 
has become apparent, that T-cell populations display additional diversity in terms of 
phenotype, anatomical distribution and effector function. The underlying mechanisms 
regulating these processes are poorly understood, although co-stimulatory molecules, 
cytokines, chemokines, regulatory cells and the local environment almost certainly play a 
role. 
Upon interaction with cognate antigen presented by APCs such as DCs, CD4+ T 
cells can differentiate into a variety of effector subsets, including classical Th1 cells and 
Th2 cells, the more recently defined Th9, Th17, Th22, follicular helper T (Tfh) cells, or   
induced regulatory T (iTreg) cells. The differentiation decision is governed predominantly 
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by the cytokines in the microenvironment and, to some extent, by the strength of the 
interaction of the TCR with pMHC complexes (Boyton and Altmann, 2002). 
Th1 cells are characterized by their production of IFN-γ and are involved in cellular 
immunity against intracellular microorganisms. IL-12 produced by innate immune cells as 
well as IFN-γ produced by both NK cells and T cells polarize naïve T cells toward the Th1 
cell differentiation program through action of the signal transducer and activator of 
transcription 4 (Stat4), Stat1, and T box transcription factor T-bet (Thieu et al., 2008). Th2 
cells produce IL-4, IL-5, and IL-13 and are required for humoral immunity to control 
helminths and other extracellular pathogens. Th2 cell differentiation requires the action of 
GATA3 downstream of Stat6, and IL-4R (Ansel et al., 2006) (Fig. 5). 
Th17 cells produce IL-17A, IL-17F, and IL-22 and play important roles in clearance 
of extracellular bacteria and fungi, especially at mucosal surfaces. Th17 cell differentiation 
requires retinoid-related orphan receptor (ROR)γt, a transcription factor that is induced by 
TGF-β in combination with the proinflammatory cytokines IL-6, IL-21, and IL-23, all of 
which activate Stat3 phosphorylation (Chen et al., 2007). Furthermore, T cells producing 
IL-22 but not IL-17 are designated as Th22 cells (Duhen et al., 2009). Th17 cells also 
produce IL-22, but IL-17 is not obligatorily co-expressed with IL-22, and the fact that some 
cells may make only IL-22 does not necessarily qualify them as Th22 cells (Duhen et al., 
2009) (Fig. 5). 
TcR stimulation of naïve CD4 T cells in the presence of TGF-β and IL-4 can induce 
cells to production IL-9 (Dardalhon et al., 2008; Veldhoen et al., 2008). IL-9 was first 
recognized as a Th2 cytokine (Temann et al., 1998). It has been proposed that such IL-9-
producing cells be designated as Th9 cells. TGF-β reprograms the differentiation of Th2 
cells towards Th9 cells. T cells producing IL-9 do not produce IL-4, but are nevertheless 
associated with Th2-type responses such as helminth-specific immune responses or allergy 
(Fig. 5).   
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Figure 5: The cytokine milieu determines CD4+ T cell differentiation and conversion 
Upon encountering foreign antigens presented by APCs, naive CD4+ T cells can 
differentiate into Th1, Th2, Th17, iTreg, and Tfh cells. These differentiation programs are 
controlled by cytokines produced by innate immune cells, such as IL-12 and IFN-γ, which 
are important for Th1 cell differentiation, and IL-4, which is crucial for Th2 cell 
differentiation. TGF-β together with IL-6 induces Th17 cell differentiation, whereas iTreg 
differentiation is induced by TGF-β, retinoic acid (RA), and IL-2. Tfh cell differentiation 
requires IL-21. (Zhou et.al. 2009)  
 
Given the finding that circulating resting T cells in humans show constitutive TGF-β 
signaling (Classen et al., 2007), one can ask if TGF-β is a rate limiting factor for human 
Th17 responses. Differences in the requirements for exogenous TGF-β between mice and 
humans may apply also to iTreg. Indeed, while TGF-β in the absence of IL-6 readily 
induces iTreg differentiation in mice (Bettelli et al., 2006b; Chen et al., 2003), there is no 
evidence that TGF-β may do the same in humans (Tran et al., 2007). The iTreg are 
functionally similar to thymus derived natural Treg as they are anergic, suppressive, and 
capable of inhibiting disease in-vivo. Differentiation of iTreg is under the control of the 
transcription factor FoxP3 in both mice and humans (Chen et al., 2003). 
Follicular T cells are a subset of helper T cells that regulate the maturation of B cell 
responses. These follicular helper T (Tfh) cells are characterized by the expression of 
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CXCR5, that mediates their homing and long-term residence in the B-cell follicles 
(Breitfeld et al., 2000; Fazilleau et al., 2009a; Schaerli et al., 2000) In addition, Tfh cells 
produce IL-21 and express ICOS and PD-1 (King et al., 2008) molecules. Differentiation of 
these Tfh cells requires the cytokine IL-21 (Nurieva et al., 2008; Vogelzang et al., 2008), 
and may be dependent on the transcription factor Bcl-6 (Fazilleau et al., 2009b). 
T helper cells are heterogeneous and somewhat plastic. Many Tregs, just like naïve 
CD4 T cells, can be differentiated into various types of T helper cells. Th17 cells are more 
plastic than Th1/Th2 cells, suggesting that Th17 cells may represent cells that are not 
terminally differentiated. Alternatively, Th17 cells may continue to express important 
molecule(s) in determining cell plasticity, which presumably have been repressed in fully 
differentiated Th1/Th2 cells. At early stages of T helper cell differentiation or within certain 
subsets that are partially differentiated, CD4 T cells can be reprogrammed into different 
lineages on receiving appropriate stimulus. 
The notion that Th17 cells are derived from the Th1 cell lineage was invalidated by 
the findings that these cells express RORγt and can develop in the absence of T-bet or Stat4 
(Ivanov et al., 2006; Weaver et al., 2007). However, under homeostatic or inflammatory 
conditions, IL-17+IFN-γ+ double-producer cells are easily detected, suggesting that there 
may be some intricate relationship between the Th1 and Th17 cell differentiation programs. 
Indeed, several recent findings highlight the plasticity of Th17 cells. In-vitro generated 
Th17 cells lose IL-17A and IL-17F expression without constant exposure to IL-6 and TGF-
β (Lexberg et al., 2008). Cells polarized in Th17-polarizing conditions for as long as 3 
weeks still failed to maintain IL-17A and IL-17F expression and can convert to Th1 or Th2 
cells in the presence of IL-12 or IL-4, respectively (Lee et al., 2009; Lexberg et al., 2008). 
However, Th17 cells secrete IL-21, which may function together with TGF-β for 
maintenance of IL-17 expression in an autocrine manner. In contrast to in-vitro-
differentiated Th17 cells, in-vivo memory CD4+CD62Llo Th17 cells appear more resistant 
to conversion (Lexberg et al., 2008). Thus, these findings suggest that there may be 
epigenetic differences between in-vitro and in-vivo generated Th17 cells. 
TGF-β is profoundly important for establishment of immunological tolerance, at 
least in part, because it is required for the differentiation of iTreg cells and for maintenance 
of natural Treg (nTreg) cells after they emigrate from the thymus (Chen et al., 2003; Li et 
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al., 2006; Marie et al., 2005). Therefore it was surprising to discover that TGF-β is also 
essential for the differentiation of proinflammatory Th17 cells (Bettelli et al., 2006b; 
Mangan et al., 2006; Veldhoen et al., 2006). Mice deficient in TGF-β lack both FoxP3+ 
Treg and Th17 cells and have overwhelming autoimmunity largely caused by uncontrolled 
Th1 cell activity (Li et al., 2006; Veldhoen et al., 2006). These findings suggest an intimate 
link between the Treg and Th17 cell programs of differentiation, and indeed there is 
evidence for such a relationship from both in-vitro and in-vivo studies (Beriou et al., 2009; 
Bettelli et al., 2006b; Koenen et al., 2008; Yang et al., 2008; Zhou et al., 2008). Therefore, 
Th17 cells are reciprocally related to FoxP3+ Tregs given that TGF-β induces FoxP3 in 
naive T cells, whereas IL-6 suppresses the TGF-β-driven induction of FoxP3, and TGF-β 
plus IL-6 together induce RORγt and the Th17 transcriptional program. At the molecular 
level, the balance between Th17 cells and FoxP3+ Tregs is mediated by the antagonistic 
interaction of the transcription factors FoxP3 and RORγt.  
The proximal signals required for commitment of type 1 and type 2 subsets in CD8+ 
T cell compartment are similar to their CD4 counterparts (Sad et al., 1995), recently it has 
been shown that the IL-17 producing subset of CD8+ T cells follows the same 
differentiation program as Th17 cells (Ciric et al., 2009; Hamada et al., 2009; Huber et al., 
2009). However, the importance and function of this subset of CD8 T cells need to be 
studied in more depth to better understand its significance. Taken together, the recent 
findings suggest that the local microenvironment, through provision of specific cytokines 
directs multiple possible alternate fates that T cells can adopt. 
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1.2 T cell development and immune tolerance: 
1.2.1 The development of the T cell repertoire 
The immune system includes a functionally competent T-cell repertoire that is 
reactive to foreign antigens but is tolerant to self-antigens. The repertoire of T cells is 
primarily formed in the thymus through positive and negative selection of developing 
thymocytes.  
 
1.2.1.1  T cells ontogeny 
The thymus is an organ that supports the development and repertoire formation of T 
cells (Bevan, 1977; Miller, 1961; Zinkernagel et al., 1978). Thymic parenchyma consists of 
leukocytic cells called thymocytes, the majority of which belongs to T-cell lineage, and 
various stromal cells including thymic epithelial cells (TEC) (Le Douarin and Jotereau, 
1975; Sainte-Marie and Leblond, 1964). Thymic stromal cells provide multiple signals to 
support manifold processes of thymocyte development that are essential for the supply of 
circulating T cells (Kingston et al., 1985; Williams et al., 1986). In response to these 
signals, developing thymocytes undergo proliferation, differentiation, and relocation to 
generate mature T cells that carry a diverse yet self-tolerant repertoire of T-cell antigen 
receptors (Marrack and Kappler, 1988; Scollay et al., 1988; von Boehmer, 1988). These 
steps of T-cell development take place in anatomically discrete regions of the thymus where 
a variety of specialized stromal cells are localized (Bhan et al., 1980; Jenkinson et al., 1980; 
von Boehmer, 2004; von Boehmer et al., 2003). 
The extensive diversity of the TcR αβ and γδ heterodimers is required to recognize 
the endless variety of pathogen-derived peptides and is achieved by a process of random 
gene arrangements. The genes encoding each chain comprise various segments that form 
the foundation of the TcR diversity. Analogous to the Ig genes, the loci of the α and γ 
chains contain variable (V) joining (J) and constant (C) gene segments, whereas the β 
chains and δ chain loci include additional diversity (D) segments. Recombination of these 
segments is performed by V(D)J-recombinase, an enzymatic complex comprising RAG-1 
and RAG-2 (recombinase activating genes) proteins and DNA double strand repair proteins 
(Li et al., 1995; Schatz et al., 1992). 
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 The recent discovery of thymoproteasomes, a molecular complex specifically 
expressed in cortical TEC (cTEC), has revealed a unique role of cTEC in cuing the further 
development of immature thymocytes in thymic cortex, possibly by displaying unique self-
peptides that induce positive selection (Murata et al., 2007). Cortical thymocytes that 
receive TcR-mediated positive selection signals are destined to survive for further 
differentiation and are induced to express CCR7. Being attracted to CCR7 ligands 
expressed by medullary TEC (mTEC), they relocate to thymic medulla (Liu et al., 2006a; 
Liu et al., 2005). The medullary microenvironment displays another set of unique self-
peptides for trimming the positively selected T-cell repertoire to establish self-tolerance, via 
promiscuous expression of tissue-specific antigens (TSAs) by mTEC and efficient antigen 
presentation by dendritic cells. 
T cells arise from hematopoietic stem cell derived T-lymphoid progenitor cells that 
migrate to the thymus (Le Douarin and Jotereau, 1975). T-cell differentiation is most 
commonly characterized by the combination of temporally coordinated expressions of cell 
surface proteins, including CD4, CD8, CD25, and CD44 (Ceredig et al., 1985; Pearse et al., 
1989; Penit, 1988; Petrie et al., 1990; Scollay et al., 1988). Most immature hematopoietic 
cells that have just entered the thymus are defined as early T-lineage progenitors (Benz et 
al., 2008; Bhandoola et al., 2003). These cells lack the expression of CD4 and CD8 and 
therefore belong to CD4/CD8 double-negative (DN) thymocytes (Scollay et al., 1984; 
Scollay et al., 1988). The survival and development of DN thymocytes are supported by 
delta-like ligands (Anderson et al., 2001; Besseyrias et al., 2007; Manilay et al., 2005; 
Mohtashami and Zuniga-Pflucker, 2006; Sambandam et al., 2005; Schmitt and Zuniga-
Pflucker, 2002) and cytokines such as IL-7 (Moore et al., 1996; Murray et al., 1989; 
Peschon et al., 1994; Suda et al., 1990; von Freeden-Jeffry et al., 1995), both of which are 
produced by cTEC (Faas et al., 1993; Schmitt et al., 2004). At the DN stage, thymocytes 
undergo developmental programs through DN1 (CD44+CD25-), DN2 (CD44+CD25+), and 
DN3 (CD44-CD25+), during which V(D)J rearrangement at TcR γ, δ, and β loci occurs 
(Garman et al., 1986; Habu et al., 1987). In order to pass the β-selection point, the β-chain 
of the rearranged TcR at the DN3 stage must retain structural properties allowing it to be 
presented on the surface of the thymocyte with pre-TcRα. Two lineages of T cells 
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expressing either TcR αβ or TcR γδ diverge at DN stage (Raulet et al., 1991; von Boehmer, 
1988) (Fig.6). 
 
 
   
Figure 6: Different stages of thymocyte development (Sebzda et al. 1999) 
 
The assembly of successfully rearranged TcR β and invariant pre-TcRα together 
with CD3 chains leads to commitment to the TcR αβ lineage and further differentiation 
beyond DN3 stage, including proliferation, TcRα-VJ rearrangement, CD25 downregulation, 
and expression of CD4 and CD8 coreceptors (Saint-Ruf et al., 1994; Shinkai et al., 1993; 
Yamasaki et al., 2006). Thymocytes migrate toward the capsular region of the thymus 
during the differentiation of DN2 and DN3. Most DN3 thymocytes are localized in the 
subcapsular region of the cortex (Benz et al., 2004; Li et al., 2007) where they further 
develop to pre-DP stage, or DN4 thymocytes, which show low expression of CD4, CD8, 
CD25, and CD44 and are immediate precursor cells of CD4/CD8 double-positive (DP) 
thymocytes (Saint-Ruf et al., 1994; Shinkai et al., 1993; Wilson et al., 1989) (Fig. 6). 
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1.2.1.2  Positive selection of thymocytes 
DP thymocytes express TcR αβ at low levels on the cell surface and move actively 
within the cortical microenvironment (Li et al., 2005a; Witt et al., 2005) apparently to 
scrutinize for TcR interactions with pMHC molecules. These DP thymocytes are selected 
for survival or demise depending on the avidity of the interaction of TcRs with the self-
pMHC complex (Allen, 1994; von Boehmer, 1994). When expressing a TCR that cannot 
interact with self-peptide–MHC complexes, they die as a consequence of neglection 
referred as death by neglect (Williams and Brady, 2001). DP thymocytes that receive TcR 
signals with ligand interactions of weak avidity and confined aggregation are induced to 
survive and differentiate into mature thymocytes, the process referred as positive selection 
(Ashton-Rickardt et al., 1993; Takahama et al., 1994) (Fig.7).  
 
 
 
Figure 7: The affinity model of thymocyte selection (Klein et.al. 2009) 
 
During positive selection, the differential kinetics of TcR–ligand interactions 
determines cell lineage to become either CD4+CD8- or CD4-CD8+ single-positive (SP) 
thymocytes (Singer, 2002; Singer and Bosselut, 2004). Positively selected thymocytes 
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relocate to thymic medulla where they further interact with self-peptides displayed in the 
medullary microenvironment (Takahama, 2006; Ueno et al., 2004). Initial αβ TcR signals 
in DP thymocytes upregulate CD5 and CD69 surface expression and terminate RAG 
expression, which precludes further TCRα gene rearrangements and fixes αβ TCR 
specificity. Importantly, since positive selection of DP thymocytes involves differentiation 
into either CD4 or CD8 SP T cells, the CD4/CD8 lineage decision is an intrinsic feature of 
the positive selection process (Janeway, 1988). 
 
1.2.1.3  CD4 & CD8 lineage differentiation  
Synchronized with positive selection, thymocytes undergo alternate commitment to 
either the cytotoxic or the helper T cell lineages, generating MHC-class I-restricted SP 
CD8+ and MHC class II-restricted SP CD4+ thymocytes. The mechanism by which this 
correlation between MHC restriction and functional phenotype is achieved remains elusive, 
however recent advancement starting to delineate the process. 
Initially it was suggested, that lineage commitment might either be directed by 
qualitatively distinct signals initiated upon TcR and coreceptor engagement by class I- or II 
MHC ligands (instructive model) (Robey et al., 1991), or occurred randomly and was 
followed by a selection step that eliminates thymocytes that express the inappropriate 
coreceptor (stochastic-selective model) (Chan et al., 1993; Davis et al., 1993). However, 
these models gave inconsistent outcomes, suggesting that they needed to be refined 
(Borgulya et al., 1991; Matechak et al., 1996; Robey et al., 1994). A quantitative-instructive 
model proposes, that stronger and weaker TcR signals, respectively, promote CD4 and CD8 
commitment (Matechak et al., 1996). This is based on the fact that the cytoplasmic tail of 
CD4 binds Lck with substantially higher affinity than that of CD8α (Ravichandran and 
Burakoff, 1994).  
It has been suggested, that lineage commitment is not completed until the transition 
from DP to SP,  with an intermediate CD4+8lo stage, because many of these cells are not 
yet irreversibly committed to a particular lineage (Bosselut et al., 2003; Brugnera et al., 
2000). Indeed, the distinct kinetic-signaling model postulates that lineage commitment is 
determined at the CD4+8lo stage, on the basis of the relative ability of coreceptors to 
contribute to TcR signaling (Singer and Bosselut, 2004) (Fig. 8).  
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Figure 8: Environmental cues and nuclear factors that influence CD4/CD8 lineage 
choice (Singer et. al. 2008) 
 
However, the intracellular control of lineage commitment remained elusive before 
the discovery of helper T cell-deficient (HD) mice, which carry a spontaneous mutation that 
causes MHC class II-restricted thymocytes to mature into SP CD8 rather than CD4 T cells 
(Dave et al., 1998; Keefe et al., 1999). The HD mutation has been mapped to the locus 
encoding the Zinc-finger transcription factor ThPOK (He et al., 2005; Kappes and He, 
2006). The expression pattern of ThPOK during thymic development is tightly regulated in 
a manner that indicates a specific role in CD4 commitment. Thus, ThPOK RNA is first 
detected at the CD4+8lo stage, and ThPOK mRNA expression is substantially higher in 
MHC class II than MHC class I-restricted cells at this stage, consistent with preferential 
induction by class II ligands (He et al., 2005). Constitutive expression of ThPOK during 
thymic development causes redirection of class I-restricted thymocytes to the CD4 lineage. 
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Therefore, ThPOK expression is both necessary and sufficient for CD4 commitment (Fig. 
8). 
Two properties of ThPOK need to be underlined, first although ThPOK is expressed 
in a wide variety of cells, its expression in the thymus is highly lineage specific (He et al., 
2005; Sun et al., 2005), CD4 SP thymocytes express ThPOK, whereas DP and CD8 SP 
thymocytes do not. In addition, during MHC-II-induced selection, ThPOK is up regulated 
progressively as thymocytes down-regulate CD8.  Second, it has been shown, that ThPOK 
affects lineage choice but not positive selection, i.e. ThPOK-deficient, MHC-II-restricted 
thymocytes becomes CD8 instead of CD4 T cells (Keefe et al., 1999). 
Several additional transcription factors also play selective roles in CD4 or CD8 
development and might therefore be involved in lineage commitment, notably GATA-3 and 
Runx3. Constitutive expression of GATA-3 specifically blocks CD8 development, whereas 
its conditional deletion blocks CD4 development (Hernandez-Hoyos et al., 2003; Nawijn et 
al., 2001; Pai et al., 2003). However, in neither case affected thymocytes redirected to the 
opposite lineage. Hence, GATA-3 is necessary, but not sufficient for CD4 development. 
Runx factors clearly play an important role in regulating the CD8 development program, 
including the CD8 lineage-specific suppression of CD4 (Sato et al., 2005; Sawada et al., 
1994; Siu et al., 1994; Taniuchi et al., 2002). However, a direct role of Runx factors in 
initiating lineage commitment appears unlikely on the basis of results from constitutive 
Runx3 transgenic mice. Thus, although development of SP CD4 thymocytes is impaired in 
Runx3 transgenic mice, this is corrected by constitutive CD4 expression (Grueter et al., 
2005). CD4 deficiency is known to cause redirection of MHC class II-restricted thymocytes 
to the CD8 lineage, presumably by weakening or interrupting TcR signaling (Matechak et 
al., 1996; Tyznik et al., 2004). The CD8 population in CD4-deficient mice is heavily 
contaminated with MHC class II-restricted T cells; hence the primary effect of Runx factors 
on lineage commitment appears to lie on controlling the CD4 expression. 
Recent identification of the negative feedback loop between ThPOK and Runx acts 
as the keystone of lineage choice in our understanding of CD4 & CD8 differentiation, 
preventing the co-expression of both factors in mature thymocytes (Egawa and Littman, 
2008; Setoguchi et al., 2008). First, Runx activity is not sufficient for ThPOK repression; 
Runx binds the ThPOK silencer not only in DP thymocytes and in CD8 cells but also in 
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CD4 cells that express ThPOK (Setoguchi et al., 2008), and there is evidence that additional 
segments of the silencer are required for its function (He et al., 2008). Therefore Runx 
activity is not sufficient to prevent CD4 differentiation, because enforcing Runx1 or Runx3 
expression in thymocytes does not impair CD4 lineage differentiation (Grueter et al., 2005; 
Hayashi et al., 2001; Kohu et al., 2005).  
In addition to above mentioned lineage specific transcription factors, recent reports 
suggested that a previously unknown T cell–specific protein, called 'Themis' (thymus-
expressed molecule involved in selection), is critical for the positive selection of developing 
T cells. Themis-/- mice showed a late block in thymocyte selection characterized by fewer 
CD4+CD8int, CD4SP and CD8SP thymocytes. Although Themis-/- thymocytes showed no 
defect in proximal TcR signaling, but CD4 lineage commitment and maturation was 
compromised in a way consistent with signal attenuation, which suggests, that Themis is 
involved at a distal point in the TcR signaling cascade. These findings indicate, that Themis 
functions to integrate or sustain TcR signaling in CD4+CD8int thymocytes and demonstrate 
that this ability is critical for appropriate lineage commitment as well as the development of 
CD4SP and CD8SP thymocytes (Fu et al., 2009; Johnson et al., 2009; Lesourne et al., 
2009). 
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1.2.2 Central tolerance 
Central tolerance is regulated at several levels. First, only those self-antigens that are 
presented by thymic APCs can influence central tolerance. So, molecules that regulate the 
presentation of self-antigens have a crucial influence on tolerance. Second, when 
progenitors encounter such self-antigens, they can undergo apoptosis or acquire regulatory 
properties. 
 
 1.2.2.1 Role of autoimmune regulator (AIRE) 
Most self-reactive T cells are deleted in the thymus, resulting in central tolerance. 
This is further supported by regulatory mechanisms outside of primary lymphoid organs, 
which are collectively known as peripheral tolerance. The main mechanism of central 
tolerance, the negative selection of self-reactive thymocytes, occurs mainly in the medullary 
compartment of the thymus (Anderson et al., 2007b; Takahama, 2006). The mTECs express 
a large number of genes, including TSAs that are normally present only in specialized 
peripheral organs and are apparently not required for the direct function of mTECs 
(Derbinski et al., 2005; Kyewski and Klein, 2006). During negative selection, these 
encoded TSAs are presented by mTECs or DCs to thymocytes as self-antigens 
(Aschenbrenner et al., 2007; Gallegos and Bevan, 2004), leading to the induction of 
tolerance by clonal deletion, functional inactivation or clonal deviation of self-reactive T 
cells (Hogquist et al., 2005; Palmer, 2003; Yamagata et al., 2004). 
The autoimmune regulator (AIRE) protein has been found to be important for the 
maintenance of self-tolerance (Nagamine et al., 1997). Mutations in the human AIRE gene 
cause autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED), a 
syndrome that is characterized by the presence of autoimmunity including autoantibodies 
that are specific for multiple self-antigens. This leads to lymphocytic infiltration of 
endocrine glands (such as parathyroid, adrenals, endocrine pancreas, ovaries/testes) and 
autoimmune disorders localized in these organs (Perheentupa, 2006; Peterson and Peltonen, 
2005). Mice with mutations in the AIRE gene have pathological autoimmune features that 
are similar to those of patients with APECED, including multiorgan lymphocytic infiltration 
and autoantibody production. In recent years, many studies have shown, that AIRE is a 
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crucial factor for the promiscuous expression of TSAs in the thymus, and that mutations in 
this gene lead to the escape of self-reactive T cells from the thymus, which results in 
autoimmunity (Jiang et al., 2005; Kuroda et al., 2005; Niki et al., 2006; Ramsey et al., 
2002). It has been shown, that T cells, in particular Th1 cells, are crucial mediators of the 
autoimmune tissue damage in AIRE-deficient mice, whereas B cells have more limited 
functions but are still required for early and severe autoimmunity (Devoss et al., 2008; 
Gavanescu et al., 2008). Recently, candidiasis in APECED patients was attributed to the 
presence of neutralizing autoantibodies to IL-17A, IL-17-F and IL-22 (Puel et al., 2010) 
(Fig.9).  
 
 
 
 
Figure 9: Aspects of the thymic medulla that are involved in central tolerance (Kristin 
et.al. 2005) 
Importantly, mTECs from AIRE-deficient mice have a marked decrease in the 
expression of multiple transcripts encoding peripheral TSAs (Anderson et al., 2002; 
Derbinski et al., 2005), including the insulin 2 and salivary protein 1 genes, which seem to 
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be under the direct control of AIRE (Kont et al., 2008). However, not all transcripts 
encoding peripherally expressed antigens are down regulated in the thymus of AIRE-
deficient mice, which indicates that other factors are necessary for the efficient expression 
of these genes. 
Experimental evidence for the function of AIRE in negative selection was obtained 
using mice expressing transgenic TcRs that are specific for neo-self antigens. AIRE-
dependent negative selection of specific TcR-transgenic T cells was observed in transgenic 
mice expressing hen egg lysozyme (Kont et al., 2008; Liston et al., 2004a) or ovalbumin 
(Anderson et al., 2005) as neo-self antigens under the control of the rat insulin promoter, 
which drives the expression of these antigens in mTECs as well as pancreatic β-cells. These 
data provided compelling evidence that AIRE is essential for efficient thymic T-cell 
deletion of at least some clones reactive to TSAs. Importantly, AIRE-deficient, double-
transgenic mice expressing hen egg lysozyme or ovalbumin antigens under the control of 
the rat insulin promoter together with the respective transgenic TcR developed aggressive 
diabetes at birth. This suggests that T cells that escape negative selection are capable of 
inducing autoimmunity. So, the consequence of AIRE deficiency is thought to be disturb 
negative selection of T cells that are specific for self antigens, which could be caused by 
defective expression of self antigens by TECs (Villasenor et al., 2005). In support of this 
idea, AIRE-deficient mice spontaneously develop autoimmune uveitis and autoimmune 
gastritis as a result of self-reactivity against interphotoreceptor retinoid-binding protein 
(DeVoss et al., 2006) and mucin 6 antigens (Gavanescu et al., 2007), respectively, the 
expression of which is regulated by AIRE in mTECs. In humans, differences in the 
expression level of AIRE, together with genetic variances in the insulin and acetylcholine 
receptor genes, influence the expression levels of these two established self-antigens of 
type-1 diabetes (T1D) and autoimmune myasthenia gravis, respectively (Giraud et al., 2007; 
Sabater et al., 2005). 
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1.2.2.2  Negative selection of thymocytes  
During development, autoreactive thymocytes are eliminated through apoptosis in a 
process termed negative selection, which is important to prevent autoimmunity. 
Experimental evidence demonstrates, that self-reactive T cells are indeed purged from the 
repertoire in the thymus (Kappler et al., 1987). Further studies have demonstrated that 
negative selection occurs primarily in the thymic medulla, via presentation of self-antigen-
MHC complexes on DCs, forcing any thymocytes with strong reactivity to undergo 
apoptosis (Ashton-Rickardt and Tonegawa, 1994; Sebzda et al., 1994).  
The removal of strongly self-reactive T cells has long been considered the sole 
purpose of negative selection, however negative selection may play a fundamental role in 
moulding the T cell repertoire (Huseby et al., 2005). It has been shown that by limiting 
negative selection but leaving positive selection intact, a repertoire of T cells develops that 
is highly cross-reactive for many different peptide-MHC complexes. After TcR 
rearrangement, most T cells display a very high affinity for MHC, validating the high basal 
affinity hypothesis (Huseby et al., 2005). 
In the context of negative selection, Cbl proteins may influence signaling pathways 
involving Bim, a pro-apoptotic member of the Bcl-2 family, Nur77 family of orphan steroid 
nuclear receptors as well as the regulators of the MAPK cascades. Role of Bim and Nur77 
have been implicated in apoptosis of autoreactive T cells during negative selection (Bouillet 
et al., 2002; Calnan et al., 1995). In NOD mouse strain, Bim and Nur77 among genes that 
are upregulated in stimulated wild type but not NOD CD4+CD8+ thymocytes, which is 
consistent with their role in negative selection (Liston et al., 2004b; Zucchelli et al., 2005).  
In general, thymic selection appears to have two roles: the first one is to bias the 
repertoire towards TcRs that are specific for a single complex, and the second to eliminate 
undesirable clones with the potential to drive autoimmunity. The rigours of negative 
selection are encountered by positively selected thymocytes upon further migration from 
the thymic cortex into the thymic medulla (Surh and Sprent, 1994). Negative selection is 
most prominent at the cortico-medullary junction removing two thirds of positively selected 
thymocytes (Murphy et al., 1990; van Meerwijk et al., 1997).  
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Overall the rigorous procedure of neglect and negative selection allow only 3-5% of 
double positive thymocytes to survive the transition to end stage single positive cells 
committed to either CD4 or CD8 lineage (Huesmann et al., 1991) . 
 
1.2.3 Peripheral tolerance: 
Evidence suggests that thymic negative selection most effectively deletes those T 
cell precursors that express TcRs with high avidity for self-pMHC complexes expressed on 
medullary DCs and mTECs. This implies that peripheral immune tolerance mechanisms are 
most important for controlling mature T cells that carry a TcR of relatively low avidity for 
self pMHC and that escape to the periphery. The mechanisms responsible for peripheral 
tolerance is divided into T-cell intrinsic mechanisms, which act directly on the responding T 
cell and T cell extrinsic mechanisms, which evoke additional subsets of cells, including 
DCs and Tregs. 
 
1.2.3.1  T cell ignorance  
The simplest mechanism of peripheral ‘tolerance’ involves T-cell ignorance of self-
antigens, as the simplest mechanism to avoid an unwanted self-antigen-specific immune 
response is to impede the penetration of an immune response in well-defined areas, 
designated as immune privileged sites. Several such sites have been identified, including the 
brain, the anterior chamber of the eye, and the testis. These sites all seem to be privileged in 
their capacity to readily accept allografts / xenografts (Barker and Billingham, 1977). 
Ignorance and sequestration are not the direct mechanisms of peripheral tolerance as 
neither of the two actively induces unresponsiveness. In the case of ignorance, T cells 
bearing a self-reactive TcR may persist without being anergic because they proliferate 
normally when challenged ex-vivo with their specific antigen. Nevertheless, these cells do 
not mediate a destructive immune response in-vivo except when challenged by the same 
antigen presented by different APCs (Ohashi et al., 1991), which suggests that the site and 
nature of antigen presentation plays a critical role in how T cells respond to their antigen. In 
addition, to mount an immune response a threshold level of antigen is required, which plays 
a vital role in T cells ignorance (Kurts et al., 1998).  
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Immune privileged sites were originally thought to insulate tissue antigens from 
patrolling lymphocytes, however, T cells have been identified to migrate into the brain 
(Brabb et al., 2000; Yednock et al., 1992). T cells are not actively excluded, but immune 
privilege is maintained by other passive mechanisms, as the brain has very few local APCs 
and also lacks lymphatic drainage, which facilitates APC and lymphocyte migration (Barker 
and Billingham, 1977; Hart and Fabre, 1981; Wong et al., 1984). In addition to passive 
mechanisms, active mechanisms have been identified to maintain the immune privilege by 
eliminating or silencing infiltrating lymphocytes. In the anterior chamber of the eye and the 
testis, the active mechanism is conferred by expression of Fas-ligand (Fas-L), which 
mediates programmed cell death to recruited activated lymphocytes (Griffith et al., 1995). 
This suggests that limiting accessibility of the antigen to the immune system by anatomical 
sequestration (Alferink et al., 1998; Zinkernagel, 1996) is important for T cell ignorance. 
However, ignorance is a reversible state, therefore there is always the risk of 
autoimmunity if the self-Ag leaks out of the tissue (Voehringer et al., 2000).   
 
1.2.3.2  T cell anergy 
T-cell encounters with self-antigen under certain circumstances and might lead to 
functional inactivation, a cell-intrinsic state of unresponsiveness, subsequently termed 
anergy, this was shown to be long-lived, associated with defects in cell-cycle progression 
and some effector functions, and reversible with strong stimuli.  
Clonal T-cell anergy was initially characterized in Th1-cell clones by stimulation 
through the TcR without co-stimulation through CD28 (Jenkins et al., 1990; Jenkins et al., 
1987; Quill and Schwartz, 1987). Anergized T-cell clones produced negligible amounts of 
IL-2, which was initially thought to be crucial for clonal expansion following T-cell 
activation. However, IL-2 receptor knockout mice showed, that IL-2 is mainly implicated in 
promoting Tregs to control T cell expansion of activated T cells (Malek, 2003). 
Interestingly, clonal T-cell anergy was found not to be a terminal fate, as the addition of 
exogenous IL-2 during restimulation could reverse the phenotype (Beverly et al., 1992). 
The reduction in IL-2 production by restimulated anergic T cells was found to reside 
at the level of IL-2 transcription. In anergic T cells, DNA binding of the activator protein 1 
(AP1) heterodimer, comprised of the transcription factors FOS and JUN, was reduced in 
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reporter assays, and subsequent studies of signalling pathways in anergic T cells found 
defects in the activation of the immediate upstream molecules of the mitogen-activated 
protein kinase (MAPK) families (DeSilva et al., 1996; Fields et al., 1996; Kang et al., 1992; 
Li et al., 1996). Importantly, anergic T cells had no defects in the activation and nuclear 
translocation of nuclear factor of activated T cells (NFAT), which is activated following 
calcium flux, principally downstream of TcR cross-linking (Lyakh et al., 1997). 
Furthermore, E3 ubiquitin ligases have been described as important mediators of T cell 
tolerance (Fathman and Lineberry, 2007; Lin and Mak, 2007). The transmembrane E3 
ligase, gene related to anergy in lymphocytes (GRAIL) has been reported to be highly up-
regulated during anergy induction compared with resting/activated T cell clones 
(Anandasabapathy et al., 2003), and was subsequently shown to be involved in anergy 
induction (Seroogy et al., 2004). 
Most studies on the induction of anergy in-vivo utilize T cells bearing a transgenic 
TcR. Administration of soluble cognate peptide antigen for the transgenic TcR can induce 
an unresponsive state, in cells bearing these transgenic TcR (Kearney et al., 1994). The 
signaling pathways responsible for this anergic state are believed to be similar to those 
engaged in-vitro. Mice deficient for many of the molecules identified as important for 
imposing anergy in-vitro, such as Cbl-b (Bachmaier et al., 2000), Egr-3 (Safford et al., 
2005) as well as mice expressing a dominant negative GRAIL molecule (Seroogy et al., 
2004), are resistant to the induction of peptide-induced anergy in-vivo (Heissmeyer et al., 
2004).  
Another model of in-vivo anergy induction, however, involves the transfer of TcR 
transgenic T cells into a T cell-depleted host that ubiquitously expresses cognate antigen for 
the transferred cells. These transferred T cells also enter into an unresponsive state, called 
‘adaptive tolerance’ (Schwartz, 2003). ‘Adaptively tolerant’ T cells are functionally anergic 
but differ from clonally anergized cells in their requirements for antigen persistence to 
maintain unresponsiveness and by the effect that IL-2 has on unresponsiveness (Rocha et 
al., 1993). Later on it has been observed, that the signaling defects between these two 
unresponsive states were indeed different, as cells made anergic in-vitro had impaired 
activation of the Ras signaling pathway (Chiodetti et al., 2006). In adaptively tolerant cells, 
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however, the signal defect was more proximal to the TcR, as these cells displayed impaired 
activation of Zap70 kinase activity.  
Additionally, a role of PD-L1 molecule has been implicated in maintaining T cell 
anergy. Blocking antibodies to PD-L1 or genetic ablation of PD-L1 was sufficient to 
reverse established anergy and promote autoimmunity in two different models of 
autoimmune diabetes (Fife et al., 2006; Tsushima et al., 2007). Moreover, it was mentioned 
that PD-L1 plays a role in the lymphoid organs in the establishment of T cell anergy as well 
as in the periphery in the maintenance of the unresponsive state (Tsushima et al., 2007). 
This suggests a role of PD-L1 in the establishment of the anergic state in models of both 
CD4+ and CD8+ T cell anergy.  
Recently it has been shown, that PD-L1 can bind to CD80. In-vitro ligation of PD-
L1 expressed on T cells lacking CD28 and CTLA-4 by a CD80 fusion protein was able to 
deliver an inhibitory signal to T cells and inhibit proliferation (Butte et al., 2007). 
Interestingly, ligation of CD80 on T cells lacking PD-1 by PD-L1 fusion protein was also 
able to inhibit proliferation. Thus, it appeared that the PD-L1:CD80 interaction signaled bi-
directionally, and that expression of either CD80 or PD-L1 on T cells was sufficient to 
deliver an inhibitory signal when the B7-1:PD-L1 interaction was engaged (Butte et al., 
2007). 
1.2.3.3  Apoptosis/Deletion 
Deletion of potential auto-reactive lymphocytes is a vital mechanism in maintaining 
self-tolerance. Exterminating self-specific cells from the peripheral lymphocyte repertoire is 
an integral part of the negative selection process applied during thymic development. 
Both functional unresponsiveness and deletion are effects of incomplete activation 
of T cells in the absence of appropriate signals. However, deletion of autoreactive T cells is 
the most permanent and irrevocable form of peripheral tolerance. The factors, which 
distinguish between these two cell fate decisions, are not completely understood. Antigenic 
persistence has been found to be an important variable in determination of either deletion or 
survival. To examine the role of antigen persistence, recent adoptive transfer studies of 
clone 4 TcR (CL4) transgenic T cells which recognizes the influenza hemagglutinin (HA) 
peptide, into Ins-HA mice, constitutively expressing the HA antigen in the pancreatic islet β 
cells, showed that after 4 days of initial priming, cells transferred alone proliferated much 
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less than cells that were transferred along with an additional activating signal, but still 
persisted as a stable pool of surviving T cells (Redmond et al., 2003). These experiments 
suggested that the initial priming by a self-antigenic stimulus was not sufficient to result in 
complete deletion of the T cell pool. Transferring the transgenic T cells from the original 
recipient into a new Ins-HA host resulted in complete deletion of the CL4 T cells, whereas 
transfer into an wild type secondary host allowed recovery of a stable population of CL4 T 
cells (Redmond et al., 2003). These data proved, that sustained antigenic stimulation in 
tolerogenic environments could lead to tolerance by deletion. Furthermore, to assess the 
role of the initial tolerogenic antigenic stimulus in either deletion or anergy, they found that 
multiple exposures of high doses of antigen resulted in a stable population of antigen-
specific T cells, similar to the effect of a single exposure of antigen, implying that complete 
deletion did not take place. Instead these cells appeared to have become refractory to further 
stimulation. However, multiple exposures to low doses led to complete deletion of the CL4 
donor T cells (Redmond et al., 2005). Later it has been observed, that when T cells are 
exposed to a low level of antigenic stimulus under tolerogenic conditions, they are unable to 
maintain expression of the anti-apoptotic genes through TcR signaling, and therefore are 
steered into a path of death by deletion (Redmond and Sherman, 2005). 
 Furthermore, the most effective way to prevent autoimmune destruction by a given 
T-cell clone is to delete that specificity from the repertoire by activation induced cell death 
(AICD). As self-antigens cannot be easily cleared, repetitive TcR engagement might be a 
feature of T-cell encounters with self-proteins, which perhaps serves as a trigger for AICD. 
A key mechanism underlying AICD in CD4+ T cells is the ligation of the Fas death 
receptor by its ligand (Sobel et al., 1993; Suda et al., 1993; Watanabe-Fukunaga et al., 
1992).  The physiological importance of Fas signalling was underscored by the finding, that 
defects in the Fas pathway in humans are associated with the autoimmune 
lymphoproliferative syndrome (ALPS) (Fisher et al., 1995). Recent advancements in the 
signalling for AICD include a role for Pten (phosphatase and tensin homolog) (Suzuki et al., 
2001) and potential negative regulation by TGF-β, which has recently been suggested to 
inhibit T-cell apoptosis by acting in an intracellular manner. 
The apoptosis of mature T cells comprises at least two major forms, antigen driven 
apoptosis and apoptosis due to lymphokine withdrawal (Lenardo et al., 1999). Apoptosis 
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due to lymphokine withdrawal is a consequence of T cell deprivation of growth factors, a 
scenario relevant at the conclusion of an immune response when there is no further antigen 
stimulation resulting in the abrogation of cytokine release (Lenardo et al., 1999; Lenardo, 
1991). In contrast, the apoptosis of antigen activated mature T cells is mediated by either 
Fas-L or TNF (Dhein et al., 1995; Zheng et al., 1995). The selective cytotoxicity towards 
mature T cells is predominantly achieved as a result of two interactions. Firstly, contrary to 
resting T cells, only IL-2 activated mature T cell express Fas-L and TNF (Zheng et al., 
1998), and second only those T cells whose TcR is actively engaged are susceptible to 
autocrine or paracrine Fas mediated apoptosis (Hornung et al., 1997; Lenardo et al., 1999; 
Wong et al., 1997). 
Consistent with a role for IL-2 in peripheral tolerance, mice deficient in IL-2 
production or signalling show autoimmunity (Sadlack et al., 1995; Suzuki et al., 1995; 
Willerford et al., 1995). However, it is unclear, if defective AICD is the only abnormality in 
these mice, as the absence of IL-2 might lead to abnormalities in thymic selection (Malek et 
al., 2000) or production of Tregs. Later studies have shown, that thymus-specific transgenic 
expression of IL-2Rβ in IL-2Rβ-/- mice prevented lethal autoimmunity while the peripheral 
T cells remained unresponsive to IL-2 which strongly favors a mechanism other than 
peripheral AICD for tolerance (Malek et al., 2000; Malek et al., 2002). Importantly, more 
studies with mixtures of bone marrow or T cells from either IL-2Rβ-/- or IL-2-/- cells with 
wild-type cells showed, that the autoimmunity in these deficient mice was not due to 
intrinsic defects but rather lack of a regulatory population (Suzuki et al., 1999; Wolf et al., 
2001). This was further highlighted in experiments, where IL-2Rβ-/- T cells in mice 
reconstituted with a mixture of IL-2Rβ-/- T cells and IL-2Rβ+/- bone marrow T cells did not 
develop into an abnormally activated phenotype, and already activated IL-2Rβ-/- T cells 
were effectively eliminated by IL-2Rβ+/- T cells when both cells were co-transferred to T 
cell-deficient host mice (Suzuki et al., 1999). 
Importantly, peripheral deletion is rarely complete, and in many models the 
remaining cells are anergic, which indicates that removal of a T-cell clone from the 
peripheral repertoire is perhaps an overrepresentation of events. Instead, deletion might 
simply serve to decrease the precursor frequency to a level at which anergy can be 
effectively induced. 
57
Introduction 
 
1.2.4. Regulatory T cells 
1.2.4.1  FoxP3+CD4+CD25+ naturally occurring regulatory T (Treg) cells 
Tregs play an indispensable role in maintaining immunological unresponsiveness to 
self-antigens and in suppressing excessive immune responses deleterious to the host. There 
are two types of Tregs; natural Tregs (nTreg), which develop in the thymus, and induced 
Tregs (iTreg), which are derived from naive CD4+ T cells in the periphery. Tregs utilize a 
variety of mechanisms to suppress the immune response. While Tregs are critical for the 
peripheral maintenance of potential autoreactive T cells, they can also be detrimental by 
preventing effective anti-tumor responses (Kretschmer et al., 2006) and sterilizing 
immunity against pathogens (Belkaid, 2007; Rouse et al., 2006). 
nTreg cells are generated in the thymus through MHC class II-dependent TcR 
interactions resulting in high-avidity selection (Apostolou et al., 2002; Bensinger et al., 
2001; Fontenot et al., 2005; Jordan et al., 2001; Larkin et al., 2008; Modigliani et al., 1996; 
Sakaguchi, 2001), however additional selection may take place (van Santen et al., 2004). 
They are characterized by the expression of CD25 and the forkhead-family transcription 
factor FoxP3, and they have the capacity to suppress in-vitro the activation of other T cells 
in a contact-dependent manner (Bluestone and Abbas, 2003; Fontenot and Rudensky, 2005; 
Sakaguchi, 2000; Shevach, 2000). 
The importance of this T-cell subset, and the role of FoxP3 in its development and 
function, is highlighted by experiments of nature in which mutations in FoxP3 result in fatal 
autoimmune lymphoproliferative disease. The spontaneous scurfy (sf) mutation in mice is a   
loss of function in the FoxP3 gene, which results in a complete loss of Treg cells and death 
of the mice at 3-4 weeks of age (Brunkow et al., 2001; Godfrey et al., 1991). Similarly, 
humans with IPEX (immunodysregulation, polyendocrinopathy and enteropathy, X-linked 
syndrome) also have mutations in the FoxP3 gene and have a range of symptoms that are 
consistent with a lack of functional Treg cells (Bennett et al., 2001; Gambineri et al., 2003). 
Although nTreg cells develop in a highly controlled thymic microenvironment 
(Josefowicz and Rudensky, 2009), FoxP3+ iTreg cells differentiate under more varied 
conditions; as an example iTreg cells appear in the mesenteric LNs during induction of oral 
tolerance (Coombes et al., 2007; Mucida et al., 2005) and they may continuously 
differentiate in the lamina propria of the gut in response to microbiota and food antigens 
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(Sun et al., 2007). They are also attracted to mucosa in chronically inflamed tissues 
(Curotto de Lafaille et al., 2008), in tumors (Liu et al., 2007), and in transplanted tissues 
(Cobbold et al., 2004). Recent finding reveal that FoxP3+ iTreg cell development requires 
TcR stimulation and the cytokines TGF-β and IL-2, for both in-vitro and in-vivo 
generation. Addition of TGF-β to TcR-stimulated naive CD4+ T cells induced transcription 
of FoxP3, acquisition of anergic and suppressive activity in-vitro, and the ability to suppress 
inflammation in an experimental asthma model (Chen et al., 2003). TGF-β induced FoxP3 
expression in cultures of plate-bound anti-CD3 and CD28-stimulated naive T cells (Chen et 
al., 2003) thus, APCs were not required for in-vitro conversion. The mechanism by which 
TGF-β induces transcription of FoxP3 involves cooperation of the transcription factors 
Stat3 and NFAT at a FoxP3 gene enhancer element (Fantini et al., 2004; Josefowicz and 
Rudensky, 2009). Consistent with the in-vitro findings, in-vivo neutralization of TGF-β 
impaired oral tolerance (Faria and Weiner, 2005; Miller et al., 1992) and inhibited the 
differentiation of antigen-specific FoxP3+ iTreg cells (Mucida et al., 2005).  
 
Phenotype 
Naturally occurring Tregs are a heterogeneous population of cells that express 
FoxP3 and high levels of CD25, which is considered to be a useful marker for 
distinguishing the CD4+ Tregs cells (Asano et al., 1996; Sakaguchi et al., 1995). However, 
all T cells express CD25 upon activation, therefore CD25 is hardly a good marker for 
unambiguous identification of nTregs. In addition, similar to CD25 expression, CTLA-4 
and glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR) 
are highly expressed on nTreg cells, however CTLA-4 and GITR are also expressed by 
activated T cells. Nevertheless, several molecules have recently been identified that can 
help to distinguish Tregs from other activated T cells (Fig. 10). 
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Figure 10 : Cell surface markers for naturally arising CD4+ Treg cells. The most 
specific and reliable marker for naturally occurring CD4+ Treg cells is the transcription 
factor FoxP3, which is expressed by the majority of CD25+CD4+ T cells and a fraction of 
CD25−CD4 T cells. CD45RBlow T cells, GITRhigh T cells, and CTLA-4+ T cells in the 
CD4+ T cell population include FoxP3-expressing T cells in normal naive mice. (Sakaguchi 
et.al. 2004) 
 
Latency associated peptide (LAP) forms a latent complex with TGF-β1, one of the 
most important cytokines involved in Treg cell development and function (Nakamura et al., 
2004). LAP is useful for distinguishing between Tregs and activated FoxP3- or FoxP3+ 
non-Tregs (Tran et al., 2009).  The expression of LAP characterizes a Treg subset with high 
levels of FoxP3, CTLA-4, and GITR (Chen et al., 2008). LAP can be used as a marker for 
TGF-β expressing Tregs, which exhibit greater suppression of EAE in-vivo than 
CD4+CD25+LAP- cells. In the LAP+ subpopulation, suppression is TGF-β dependent and 
is mediated by both cell-to-cell contact and soluble factors. In contrast, the less potent 
suppressive function of LAP- cells is mainly cell contact dependent. 
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In rats, the folate receptor 4 (FR4) is expressed at high levels by Tregs and is 
essential for their maintenance (Yamaguchi et al., 2007). This is in contrast to other naive or 
activated T cells. Tregs can thus be distinguished from other activated CD4+ T-cell 
subpopulations using a combination of FR4 and CD25 expression. 
CD39 (ENTPD1 [ectonucleoside triphosphate diphosphohydrolase-1]; EC 3.6.1.5), 
an ectoenzyme that degrades ATP to AMP, represents another surface marker of Tregs 
(Borsellino et al., 2007; Deaglio et al., 2007). In mice, it is present on virtually all 
CD4+CD25+FoxP3+ Tregs. In humans, CD39 expression is limited to a subset of FoxP3+ 
regulatory effector/memory-like T cells. These cells have been demonstrated to be present 
in dramatically reduced numbers during flares of relapsing/remitting MS (Fletcher et al., 
2009). In addition Tregs also express CD73, an ecto-5'-nucleotidase that converts AMP into 
adenosine (Zimmermann, 1992), these suppressor cells are therefore able to catalyze 
ATP/ADP eventually into immunosuppressive nucleoside adenosine (Borsellino et al., 
2007; Deaglio et al., 2007; Kobie et al., 2006). Thus, dual expression of CD39 and CD73, 
serves as a phenotypic marker for Tregs, and also contributes to their functional suppressive 
activity by catalyzing the generation of pericellular adenosine. 
Recently, CD127 (IL-7R) expression for discriminating between CD25+ regulatory 
and CD25+ activated T cells has been described, because many non-regulatory T-cell 
subsets are IL-2-independent and IL-7-dependent (Seddiki et al., 2006). However, Tregs 
which require IL-2 for survival, might not require IL-7 or the IL-7R. Eventually, CD127 
downregulation on Treg cells was confirmed by using microarray gene-expression-profiling 
studies of CD4+CD25hi and CD4+CD25- T cells, and by using quantitative polymerase 
chain reaction (qPCR) to confirm the reduction in CD127 mRNA expression (Liu et al., 
2006b). In addition, functional suppressive activity of the CD127low/- population and its 
absence in the CD127+ population has been demonstrated (Seddiki et al., 2006). Therefore 
CD127low/- also serves a good phenotypic marker for Tregs. 
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Mechanism of suppression:   
The various potential suppression mechanisms used by Treg cells can be grouped 
into four basic 'modes of action': suppression by inhibitory cytokines, suppression by 
cytolysis, suppression by metabolic disruption and suppression by modulation of DC 
maturation or function. 
 
Suppression by inhibitory cytokines 
TGF-β is a cytokine with immunoregulatory activity that is present in a latent form 
that must be activated in order to be biologically active. The role TGF-β plays in Treg 
activity is controversial, as there are conflicting reports in the literature depending on the 
experimental model that was used. Recent work has demonstrated the importance of      
TGF-β not in the suppressive activity of Tregs, but in their de-novo generation (Shevach et 
al., 2008). Thymus-derived Tregs, in the presence of DCs, induced additional Treg 
formation from naive precursors in a process termed infectious tolerance. It was proposed 
that LAP expressed on the surface of Tregs in combination with TGF-β interact with naive 
T cells and transform them into Tregs. Interestingly, DCs lacking the TGF-β-activating 
integrin αVβ8 were unable to induce Tregs (Travis et al., 2007). Thus, TGF-β appears 
important for Treg expansion and conversion. Additionally, TGF-β has been reported to 
play a role in the suppressive function of Tregs. Neuropilin-1 (Nrp1), a suggested marker of 
Tregs, has been reported to act as a TGF-β receptor in mice that can bind and activate latent 
TGF-β, leading to promotion of suppressive function (Glinka and Prud'homme, 2008). 
TGF-β may not necessarily function as a soluble mediator but may bind to surface 
molecules, such as LAP and Nrp1, and function as a membrane-bound mediator in a cell-to-
cell contact-dependent manner (Fig. 11). 
In addition to TGF-β, IL-10 production by Treg cells has been shown to be essential 
for the prevention of colitis in mouse models of IBD (Asseman et al., 1999; Menager-
Marcq et al., 2006). Moreover, it appears that the tumour microenvironment promotes the 
generation of FoxP3+ Treg cells that mediate IL-10 dependent, cell-contact independent 
suppression (Bergmann et al., 2007). Similarly, IL-10 produced by Treg cells also appears 
to be important for IL-10-mediated tolerance in a model of hepatitis induced by 
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concanavalin A (Erhardt et al., 2007). In addition, Treg-cell-derived IL-10 is also 
implicated in the induction of B-cell-enhanced recovery from EAE (Mann et al., 2007). 
Interestingly, the Treg cell-specific deletion of IL-10 did not result in the development of 
spontaneous systemic autoimmunity, but did result in enhanced pathology in the colon of 
older mice and in the lungs of mice with induced airway hypersensitivity, suggesting that 
the function of Treg cell-derived IL-10 may be restricted to the control of inflammatory 
responses that are induced by pathogens or environmental insults (Rubtsov et al., 2008). 
Recently, a new inhibitory cytokine, IL-35, a member of the IL-12 heterodimeric 
cytokine family formed by the pairing of Epstein–Barr virus-induced gene 3 (Ebi3) and p35 
(IL-12a), has been described to be preferentially expressed by Treg cells and required for 
maximal suppressive activity (Collison et al., 2007). Both Ebi3 and IL-12a are 
preferentially expressed by mouse FoxP3+ Treg cells (Collison et al., 2007; Gavin et al., 
2007), but not resting or activated effector T cells, and are significantly upregulated in Treg 
cells that are actively suppressing (Collison et al., 2007). As predicted for a heterodimeric 
cytokine, both Ebi3-/- and IL-2a-/- Treg cells had significantly reduced regulatory activity 
in-vitro and failed to control homeostatic proliferation of effector T cells and resolve IBD 
in-vivo. This precise phenotype suggested, that IL-35 is required for the maximal 
suppressive activity of Treg cells. Importantly, IL-35 was sufficient for Treg-cell activity, 
as ectopic expression of IL-35 conferred regulatory activity to naive T cells and 
recombinant IL-35 suppressed T-cell proliferation in-vitro (Collison et al., 2007). All these 
findings confirm that three inhibitory cytokines, IL-10, IL-35 and TGF-β, are key mediators 
of Treg-cell function (Fig. 11).  
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Figure 11: Basic mechanisms of suppression used by Treg cells (Vignali et.al. 2008) 
 
Suppression by cytolysis 
CD8+ T cells and natural killer (NK) cells are known to kill target cells through the 
secretion of granzyme molecules (Lieberman, 2003). However, many human CD4+ T cells 
also exhibit cytotoxic activity. Consistent with this, activated human Treg cells have been 
shown to express granzyme A. Furthermore, Treg cell-mediated target-cell killing was 
mediated by granzyme A and perforin through the adhesion of CD18 (McHugh et al., 
2002). 
By contrast, as mouse CD4+ T cells are not cytolytic, it was surprising that early 
gene expression arrays showed that the expression of granzyme B was upregulated in 
mouse Treg cells (Herman et al., 2004; McHugh et al., 2002). It has been shown, that 
granzyme B-deficient mouse Treg cells had reduced suppressive activity in-vitro, and that 
this granzyme B-dependent suppression appeared to be a perforin-independent one, as 
shown by the result of Treg cell-induced apoptosis of effector T cells (Gondek et al., 2005). 
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The notion that Treg cells might possess cytolytic activity was supported by studies 
showing that Treg cells can kill B cells in a granzyme B-dependent and partially perforin-
dependent manner that results in the suppression of B-cell function (Zhao et al., 2006). 
More recently, Treg cells were shown to suppress the ability of NK cells and CTLs to clear 
tumors by killing these cells in a granzyme B-dependent and perforin-dependent manner 
(Cao et al., 2007). Furthermore, Treg cells induce perforin-dependent DC death in tumor-
draining lymph nodes, which limits the onset of CD8+ response in-vivo (Boissonnas et al., 
2010) (Fig.11). 
Recently it has been shown, that activated Treg cells induce apoptosis of effector T 
cells through a TRAIL–DR5 (tumour-necrosis-factor-related apoptosis-inducing ligand–
death receptor 5) pathway (Ren et al., 2007). Furthermore, galectin-1, which can induce T-
cell apoptosis, has been shown to be upregulated by mouse and human Treg cells and 
galectin-1-deficient Treg cells have reduced regulatory activity in-vitro (Garin et al., 2007). 
In addition to these findings, more work is required to define the cytolytic mechanisms that 
Treg cells use to mediate suppression. 
 
Suppression by metabolic disruption 
Several fascinating suppressive mechanisms have been described that could 
collectively be referred to a 'metabolic disruption' of the effector T-cell target. There are 
some speculative thoughts whether high expression levels of CD25 privilege Treg cells to 
consume local IL-2 and therefore starve actively dividing effector T cells by depleting the 
IL-2 they need to survive (de la Rosa et al., 2004; Thornton and Shevach, 1998). In 
contrast, recent reports from human Treg cells suggested, that IL-2 depletion alone is not 
enough for Treg cells to suppress effector T cells (Oberle et al., 2007), therefore more 
definitive evidence is still needed. 
Recently two new Treg-cell mechanisms have been proposed, that induce the 
intracellular or extracellular release of adenosine nucleosides. Concordant expression of the 
ectoenzymes CD39 and CD73 on Tregs was shown to generate pericellular adenosine, 
which suppressed effector T-cell function through activation of the adenosine receptor 2A 
(A2AR) (Borsellino et al., 2007; Deaglio et al., 2007; Kobie et al., 2006). Interestingly, 
binding of adenosine to A2AR appears to not only inhibit effector T-cell functions, but also 
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to enhance the generation of induced Treg cells by inhibiting IL-6 expression while 
promoting TGF-β secretion (Zarek et al., 2008). Both actions favor Treg generation and 
expansion over Th17. Recently it has been shown, that nucleus-localized Foxo3 functions in 
DCs to inhibit the production of inflammatory cytokines like IL-6, which induced T cell 
survival in Foxo3-/- mice resulted from an inability of Foxo3-/- DCs to shut down cytokine 
production in response to CTLA-4 signals (Dejean et al., 2009). Treg cells were also shown 
to suppress effector T-cell function directly by transferring the potent inhibitory second 
messenger cyclic AMP (cAMP) into effector T cells through membrane gap junctions 
(Bopp et al., 2007) (Fig.11).  
 
Suppression by targeting dendritic cells 
In addition to the direct effect of Treg cells on T-cell function, Treg cells might also 
modulate the maturation and/or function of DCs, which are required for the activation of 
effector T cells (Bluestone and Tang, 2005). Interestingly, studies using intravital 
microscopy have revealed direct interactions between Treg cells and DCs in-vivo. These 
interactions were proposed to function in attenuating the effector T-cell activation by DCs 
(Tadokoro et al., 2006; Tang et al., 2006) in a process involving the CTLA4, which is 
constitutively expressed by Treg cells (Read et al., 2000; Takahashi et al., 1998). More 
specifically, the use of CTLA4-specific blocking antibodies or CTLA4-deficient Treg cells 
showed, that in the absence of functional CTLA4, Treg-cell-mediated suppression of 
effector T cells via DCs was reduced (Oderup et al., 2006; Serra et al., 2003). Importantly, 
it was also shown, that Treg cells could condition DCs to express IDO, an enzyme inducing 
the production of pro-apoptotic metabolites from the catabolism of tryptophan, resulting in 
the suppression of effector T cells. This mechanism is dependent on interactions between 
CTLA4 and CD80 and/or CD86 (Fallarino et al., 2003; Mellor and Munn, 2004). 
In addition to inducing DCs to produce immunosuppressive molecules, several 
studies have suggested, that Treg cells may also downmodulate the capacity of DCs to 
activate effector T cells (Houot et al., 2006; Kryczek et al., 2006; Lewkowich et al., 2005; 
Serra et al., 2003). Recent reports have also suggested that lymphocyte-activation gene 3 
(LAG3) may block DC maturation. LAG3, a CD4 homologue that binds MHC class II 
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molecules with very high affinity, has a negative regulatory T-cell intrinsic function and is 
required for maximal Treg-cell suppression (Huang et al., 2004; Workman et al., 2004). 
Finally, Treg cells can also influence immune responses by modulating the 
recruitment and function of other cell types. For instance, Treg cell-derived IL-9 has been 
shown to recruit and activate mast cells, which are essential regulatory intermediaries in the 
establishment of peripheral allograft tolerance (Lu et al., 2006) (Fig.11). 
 
1.2.4.2  Tr1 cells or IL-10-producing cells 
Initially, IL-10 was recognized as a Th2 cytokine (Mosmann et al., 1986). Later on, 
it was reported, that some cells with regulatory functions express IL-10 and were designated 
as Tr1 cells (Groux et al., 1997). However, some conventional Tregs also produce IL-10, 
and IL-10 production by these cells is important for controlling inflammation in the gut 
(Rubtsov et al., 2008). Nevertheless, it appears that Tr1 cells are different from FoxP3+ IL-
10-producing cells (Roncarolo et al., 2006). 
Recently it has been documented, that IL-10 production is also found in the subsets 
of Th17 and Th1 cells (Anderson et al., 2007a; Jankovic et al., 2007; McGeachy et al., 
2007), and that IL-10 production by these cells negatively regulates their function. Indeed, 
strong TcR stimulation, which leads to sustained Erk activation, results in IL-10 production 
in Th17 and Th1 cells (Saraiva et al., 2009), suggesting that IL-10 serves as a critical 
negative feedback regulator to control the magnitude of many types of immune responses 
and to prevent tissue damage. Therefore, Tr1 cells may very well not be a separate lineage, 
but include both IL-10-producing Tregs, as well as those subsets of Th1, Th2 and Th17 
cells that are capable of expressing IL-10. 
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1.3 CNS inflammation and Autoimmunity 
1.3.1. Triggering auto-aggressive immune response  
Intrathymic deletion of T cells with high avidity for self-antigens restricts the 
repertoire of peripheral autoreactive T cells, but this process is incomplete (Ashton-Rickardt 
et al., 1994). Lymphocytes with lower avidity for self-antigens or with high avidity for 
determinants that are not expressed in the thymus can be found in the periphery (Klein et 
al., 2000). The presence of peripheral T cells that react with self-antigens in healthy 
individuals (Arnold et al., 1993; Burns et al., 1983) indicates the existence of physiological 
regulatory mechanisms that prevents pathological autoimmunity. Autoimmune disease 
occurs, when the adaptive immune response is released to mount a response to self-
antigens. The induction of an autoimmune response requires autoantigens to rupture self-
tolerance. Recently it has been shown in different animal models of autoimmunity, how 
tolerance can be broken. 
 
1.3.1.1  Exposure of tissue specific antigen 
The fact that TSAs are expressed in the thymus makes implausible the hypothesis 
that autoimmunity results from a failure to impose central tolerance on the developing T 
cell except if gene polymorphisms affect the central tolerance mechanisms or provided if 
not all the TSAs are expressed in the thymus. But how genetic polymorphisms in the 
regulatory regions of TSA genes might modulate the intrathymic expression levels of the 
respective gene remains unclear. One possibility is that these polymorphisms might affect 
the access to the TSAs or the DNA binding of transcription co-factors such as AIRE. This 
in turn shifts the threshold of self-tolerance to an extent that translates into significant 
alterations of disease susceptibility on the appropriate genetic background. However, the 
exquisite sensitivity of the central tolerance process to moderate quantitative variations in 
TSA expression in this context is quite surprising. Thus, subtle differences in the range of 2 
- 4 fold in intrathymic expression of auto-antigens as, obtained in mice with defined copy 
numbers of pancreatic or CNS-specific antigens can modulate the susceptibility to 
autoimmunity (Chentoufi and Polychronakos, 2002; Miyamoto et al., 2003; Thebault-
Baumont et al., 2003). The threshold range for self-antigens in humans is not well defined. 
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Carriers of a single allele of an AIRE mutation do not develop autoimmune polyglandular 
syndrome type-1 (Vogel et al., 2002). Considering a direct gene-dosage effect between 
AIRE and target gene expression levels, as suggested by findings in the AIRE knockout 
mouse model (Liston et al., 2004a), minor variations apparently do not predispose to 
disease in a polygenic setting in humans. Nevertheless, in type-1 diabetes mellitus, the 
IDDM2 (insulin-dependent diabetes mellitus 2) locus shows the highest correlation with 
disease susceptibility of all identified disease-associated non-MHC loci. This trait reflects a 
polymorphism in variable number of tandem repeats (VNTRs) upstream of the promotor 
region of the insulin gene. These VNTR alleles correlate with the level of insulin 
transcription in the thymus (Pugliese et al., 1997; Sabater et al., 2005; Vafiadis et al., 1997). 
This suggests that there is only limited buffering of the tolerance threshold in humans on a 
susceptible background. 
Self-antigens expressed in the thymus delete high affinity self-reactive T cells, 
whereas low affinity T cells can seed to the periphery (Daniels et al., 2006). This has been 
illustrated in studies of the T cell repertoire specific for myelin basic protein (MBP). MBP-
deficient, C3H (H-2k) mice immunized with whole MBP exhibit a strong T cell response to 
MBP 79–87, whereas wild type mice exhibit a response that is at least 3 logs lower in 
avidity, suggesting that endogenous MBP inactivates the high avidity T cell repertoire 
(Huseby et al., 2001b; Targoni and Lehmann, 1998). However, this effect of MBP 
expression is not necessarily restricted to the thymus. 
Self-reactive cells can escape thymic deletion because the isoform of the antigen 
expressed in the thymus differs from that expressed in the target organ. This was 
demonstrated in studies of the T cell repertoire specific for myelin proteolipid protein 
(PLP), another target antigen in EAE. The predominant form of PLP expressed in the 
thymus is a splice variant, DM20, which lacks residues 116–150 of the full-length protein 
(Anderson et al., 2000; Klein et al., 2000). Thus, only T cells that react with epitopes within 
DM20 would be expected to undergo central tolerance. Indeed, this is to be the case in 
studies of the T cell repertoire to PLP in wild type versus PLP-deficient C57BL/6 mice. The 
authors described, that expression of DM20 by thymic epithelium was sufficient to confer 
T-cell tolerance to PLP in EAE-resistant C57BL/6 mice, whereas PLP-deficient mice 
maintained a brisk T cell response upon PLP immunization. They analyzed the PLP-
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specific response in thymectomized PLP-deficient mice. They transplanted them with a 
wild-type thymus, irradiated them to ablate their immune system and reconstituted them 
with PLP-deficient bone marrow cells. They showed in these mice that intrathymic 
expression of PLP, presumably by radio-resistant epithelial cells, was sufficient to confer 
tolerance on the T-cell repertoire in C57BL/6 mice. In contrast, the major T-cell epitope in 
SJL/J mice is only encoded by the CNS-specific exon of PLP, but not by thymic DM20. 
Thus, lack of tolerance to this epitope offers an explanation for the exquisite susceptibility 
of SJL/J mice to EAE induced by PLP (Klein et al., 2000). 
Alternatively, thymically expressed self-antigens may not mediate central tolerance 
due to inefficient antigen presentation by MHC alleles present in the individual. This 
mechanism has been proposed to explain the escape from tolerance of MBP 1–11 reactive T 
cells in H-2k- expressing mice. MBP 1-11, which is expressed in the thymus (Mathisen et 
al., 1993), has been shown to bind weakly to I-Au (Kumar et al., 1995) and to form unstable 
peptide–MHC complexes (Harrington et al., 1998), resulting in the escape of self-reactive T 
cells from the thymus. 
Studies based on the transgenic expression of a neo-self antigen have allowed to 
clearly delineate the impact of thymic expression of the neo-self antigen at the development 
of tolerance. As an example, transgenic mice were raised by crossing mice expressing a 
tissue specific transgene encoding hen egg lysozyme (HEL), with mice expressing a 
transgenic TcR specific for HEL. The double transgenic mice expressed HEL specifically 
on thyroid epithelium, pancreatic islets or systemically (including the thymus). The mice 
expressing HEL on thyroid epithelium and pancreatic islets did not express HEL in the 
thymus, allowing HEL specific T cells to escape thymic deletion resulting in subclinical 
lymphocytic thyroiditis or insulitis (Akkaraju et al., 1997). In contrast, systemic HEL 
expression allowed thymic deletion of HEL specific thymocytes, establishing tolerance to 
HEL (Akkaraju et al., 1997). 
Collectively these examples demonstrate, that the expression of self-antigen in the 
thymus shapes the self-reactive repertoire, but in some cases deletion may not be complete 
or may not occur at all due to the limited affinity of the MHC molecule for the self-antigen 
or due to expression of a splice variant or isoform of the self-antigen. 
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1.3.1.2 Cryptic epitope hypothesis 
This theory is based on epitope sequestration within protein, in that immunogenic 
self-epitopes can arise from peptides not usually presented by APCs. Although typical 
protein antigens possess numerous immunogenic peptide sequences, only a few of these, the 
dominant epitopes, contribute to the development of the T-cell response against the whole 
protein. Epitopes that are immunogenic in peptide form, but do not participate in the 
immune response against the whole protein, are termed cryptic epitopes (Sercarz et al., 
1993). 
Cryptic epitopes have proven important in understanding self–non-self 
discrimination and autoimmunity (Lanzavecchia, 1995; Warnock and Goodacre, 1997).  
Several studies using transgene-derived neo-self antigens have shown, that immune 
tolerance extends only to dominant epitopes, and that T cells specific for cryptic epitopes 
may be immune competent (Cabaniols et al., 1994; Cibotti et al., 1992; Moudgil and 
Sercarz, 1993; Shih et al., 1997). Some autoimmune diseases are characterized by 
determinant spreading, in which the early stages of the disease are characterized by T cells 
reactive against one or a few dominant epitopes, while T-cell populations reactive against 
cryptic epitopes appear in the later stages of disease (Tuohy et al., 1998).  
This potential of cryptic epitopes to unfold an autoimmune disease was indeed 
demonstrated in MBP-induced EAE. Significantly, epitope spreading during the chronic 
stages of EAE resulted in the activation of T cells responding to various MBP peptides 
(Lehmann et al., 1992). Furthermore, the concept of epitope spreading has been 
documented in the Theiler murine encephalomyelitis virus-induce demyelinating disease 
(TMEV-IDD) mouse model. TMEV, a natural mouse pathogen, is a picornavirus, which 
induces a chronic CD4+ T cell-mediated demyelinating disease with a clinical course and 
histopathology similar to that of chronic progressive MS (McMahon et al., 2005; Miller et 
al., 1990). Demyelination in TMEV-infected mice is initiated by a mononuclear 
inflammatory response mediated by CD4+ T cells targeting virus, which chronically 
persists in the CNS (Pope et al., 1996). In addition, kinetic and functional studies show, that 
T-cell responses to the immunodominant myelin PLP epitope (PLP139-151) did not arise 
because of cross-reactivity between TMEV and self-epitopes (Miller et al., 1997), but 
because of de-novo priming of self-reactive T cells to sequestered autoantigens released 
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secondary to virus-specific T cell-mediated demyelination (Lehmann et al., 1992). 
Therefore epitope spreading is an important alternate mechanism to explain the etiology of 
virus-induced organ-specific autoimmune diseases. 
 
1.3.1.3 Molecular mimicry 
The concept of molecular mimicry is based on a structural similarity between a 
pathogen and self-antigens. The similarity could be expressed as shared amino acid 
sequences or similar conformational structure between the antigens (Fig.12). In molecular 
mimicry, the exogenous antigen needs not to be present or to infect the target tissue of the 
autoimmune process. Molecular mimicry is characterized by an immune response to an 
environmental agent that cross-reacts with a host antigen, resulting in disease (Albert and 
Inman, 1999; Oldstone, 1998). This hypothesis has been implicated in the pathogenesis of 
diabetes, lupus and MS (Albert and Inman, 1999; Fujinami and Oldstone, 1985; Gran et al., 
1999; Oldstone, 1998). In addition, implication of molecular mimicry has been described in 
some forms of Guillain-Barré syndrome (GBS), an example of damage to the peripheral 
nervous system (PNS) mediated by an immune reaction after infection with bacteria 
Camyllabacter jejuni due to share expression of the ganglioside GM1 (Ang et al., 2004; 
Yuki and Odaka, 2005). 
Providing support to this hypothesis is the observation that a given TcR can cross-
react with different pMHC complexes and therefore a single T cell can respond to different 
peptides (Gregersen et al., 2006; Lang et al., 2002; Marrack et al., 2008; Wucherpfennig 
and Strominger, 1995). This implies, that responses to microbial antigens could result in the 
activation of T cells, which are cross-reactive with self-antigens. Similarly, monoclonal 
antibodies have also been found to recognize both microbial and self-antigens (Fujinami et 
al., 1983).  
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Figure 12: The evolution of the molecular mimicry concept and activation of 
autoreactive T cells via cross-reactivity with foreign antigens (Sospedra et.al. 2005) 
 
The potential for molecular mimicry has been documented in many animal models 
of autoimmune disease, such as herpes simplex virus (HSV)-associated stromal keratitis, 
(Zhao et al., 1998) and models of type I diabetes (Christen et al., 2004). This mechanism of 
molecular mimicry is also involved in the TMEV-IDD model of MS, a severe rapid-onset 
demyelinating disease of the CNS induced by intracerebral or peripheral infection with 
TMEV that has been engineered to express the immunodominant self epitope from myelin 
PLP 139–151 (Olson et al., 2001). Several bacterial and viral peptides that mimic PLP 139–
151 or MBP 1-11 have been identified and have been used in models that directly address 
the possibility that autoimmune diseases could be induced by molecular mimicry (Carrizosa 
et al., 1998; Gautam et al., 1998) (Fig. 12). 
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Possibly relevant to human disease, bacterial peptides mimic the MBP epitope 85–
99 and induce demyelinating disease in mice that transgenically express a human MBP 85-
99 specific TcR and the appropriate HLA class II molecule that can present the peptide 
(Greene et al., 2008). 
This mechanism of molecular mimicry has been indirectly implicated in MS. 
Indeed, high viral loads that occur during symptomatic primary infection of EBV and result 
in infectious mononucleosis, are associated with an increased risk of developing MS 
(Nielsen et al., 2009; Thacker et al., 2006), and could prime these polyspecific T-cell 
responses. Accordingly, patients with MS have predominant clonal expansions of T cells 
that are specific for EBV nuclear antigen 1 (EBNA1), the EBV antigen that is most 
commonly targeted by CD4+ T cells in healthy virus carriers, and EBNA1-specific T cells 
recognize myelin antigens more frequently than autoantigens that are not associated with 
MS (Lunemann et al., 2008).  
Although all these findings demonstrate, that molecular mimicry is a plausible 
hypothesis that can explain the link between infection and autoimmunity, evidence for this 
phenomenon in human autoimmune diseases is still need to be established, except for some 
forms of GBS. 
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1.3.1.4  Dual TcR expression 
During T cell ontogeny successful rearrangement of the TcR β chain VDJ regions 
results in the allelic exclusion of the alternative TcR β locus (Fenton et al., 1988; 
Krimpenfort et al., 1989; Uematsu et al., 1988). Conversely, TcR α chain rearrangement 
occurs simultaneously on both chromosomes and successful rearrangement does not 
abrogate expression of the alternative allele, though α chain rearrangement is abrogated due 
to down-regulation of RAG expression after positive selection of the expressed αβ TcR 
(Borgulya et al., 1992; Petrie et al., 1993). This allows thymocytes to develop into T cell 
clones expressing one TcR β chain complexed with either of two TcR α chains, effectively 
estabilishing dual TcR expression. Some of these clones can express two functional MHC-
restricted TcRs (Hardardottir et al., 1995; Morris and Allen, 2009). If the initially expressed 
αβ TcR is not selected, T cells can be rescued from apoptosis by coexpression of a second 
TcR that can mediate positive selection and appear in the periphery as dual TcR expressing 
T cells (Borgulya et al., 1992; Brandle et al., 1992; Padovan et al., 1995; Petrie et al., 1993). 
These dual TcR expressing T cells could be activated by engagement of either TcR; this 
dual-specific T cell activation could potentially provide T cells with a mechanism to evade 
tolerance (Padovan et al., 1993; Simpson et al., 1995). In-vivo observations indicated that 
thymocytes expressing low levels of an auto-reactive TcR could escape negative selection 
provided they express a second non-self specific TcR (Zal et al., 1996) (Fig.13). 
Interestingly, an alternative approach has indicated a function for the expression of 
dual TcRs in autoimmune induction in-vivo. Mice expressing a transgenic HA-specific TcR 
in combination with systemic expression of transgenic HA fail to develop autoimmunity 
due to central tolerance and anergy. However, this state of tolerance can be by-passed if 
high levels of an irrelevant TcR are expressed on the HA-specific T cells, permitting 
insulitis and mild diabetes (Sarukhan et al., 1998). 
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Figure 13: Different scenarios for dual TcR T cells. 
(a) Tourist visa. Thymocytes express one TcR (1), which is incapable of interacting with 
peptide-self-MHC ligands presented on thymic epithelium. Thus, due to ongoing TcR α 
rearrangement, a second TcR (2) is expressed, composed of the original TcR β chain and a 
new TcRα. This second TcR mediates positive selection, and, in the periphery, it can 
recognize foreign peptides presented by the selecting MHC. The first TcR (1) does not 
contribute to the useful TcR repertoire, however, it may infrequently detect foreign antigen. 
(b) Illegal emigrant. During thymocyte selection, the first TcR (1) exhibits high affinity for 
an MHC-peptide ligand expressed in the thymus. Consequently, this TcR is down regulated 
(shown as an orange TcR-1 α-chain), and RAG expression re-induced. Subsequent TcRα 
rearrangement produces TcR (2), which rescues the thymocyte from deletion. In the 
periphery, low expression of the first TcR will result in autoimmunity if it is not excised 
from the TcRα locus. (c) Dual citizenship. During thymocyte selection, both TcRs (1 and 2) 
may contribute synergistically to positive selection. Neither TcR is capable of efficiently 
selecting the thymocyte by itself however; both are self-restricted and are equally capable 
of detecting nonself peptides presented by the selecting MHC molecule(s) in the periphery. 
Thus, the repertoire of useful TcRs is expanded (He et.al. 2002)  
 
Most discussion has focused on the dangers of dual TcR expression because one of 
the TcRs on dual TcR cells does not go through thymic selection. This may allow 
autoreactive TcRs to sneak into the mature T cell repertoire under the cover of a original 
TcR that drives positive selection of a given thymocyte. However, it has been shown that 
the dual TcR cells can extend the TcR repertoire for foreign antigens by rescuing functional 
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TcRs that cannot be selected on single TcR cells and can, therefore, benefit the immune 
system (He et al., 2002). 
Recently it has been shown in a dual-TcR transgenic murine model, that tolerization 
of the self-reactive TcR does not disrupt signaling or function mediated via the second 
receptor, suggesting that tolerance can be maintained proximally at the level of the self-
reactive TcR (Teague et al., 2008). 
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1.3.2. Multiple Sclerosis 
1.3.2.1 Generalities 
MS is a chronic demyelinating inflammatory disease that affects the CNS and 
usually begins in young adulthood (McFarlin and McFarland, 1982a, b). The disease affects 
0.05–0.15% of Caucasians and women more frequently than men. MS leads to substantial 
disability through deficits of sensation and of motor, autonomic, and neurocognitive 
function (Noseworthy et al., 2000). In 80–90% of cases, MS starts with a relapsing–
remitting course (RR-MS). Over time, the number of relapses decreases, but most patients 
develop progressive neurological deficits that occur independently of relapses (the so-called 
secondary progressive phase). In 10–20% of patients, MS begins with a primary progressive 
course (PP-MS) without acute relapses. In general, the progression rate in RR-MS is 
comparable to that of PP-MS as soon as the patients enter the secondary progressive phase 
(Kremenchutzky et al., 1999). Imaging studies have revealed differences between RR-MS 
and PP-MS. In patients who suffer from RR-MS, acute CNS lesions with spontaneous 
resolution are frequently detected, even in the absence of clinical attacks (Miller et al., 
1998). These lesions are usually located in the white matter, and are often characterized by 
a disturbance of the BBB and local oedema that are compatible with an inflammatory 
process. By contrast, when progressing to the secondary phase and in patients with PP-MS, 
such inflammatory activity is much less conspicuous (Miller et al., 1998). Global brain 
atrophy, however, is more dominant in the progressive stage and seems to correlate with 
disability (Fox et al., 2000; Losseff et al., 1996). These findings indicate, that early in the 
disease, ongoing inflammatory activity is present in most patients and is responsible for the 
relapsing–remitting course, whereas a distinct process might be operative in the progressive 
phase of the disease, when inflammatory activity diminishes despite faster evolution of 
disability. 
The prevalence of MS varies significantly depending on the genetic background of 
the population considered (Compston and Coles, 2008). MS is highly prevalent in 
Caucasians, but only rarely observed in Asians or Africans. Even in areas with high MS 
prevalence, these ethnic groups are at much lower risk than Caucasians. Moreover, the risk 
of developing the disease is significantly higher for family members of patients with MS 
(Ebers et al., 1995). By contrast, the prevalence in MS-patient’s spouses and adopted family 
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members does not differ from that of the general population (Fig.14). These findings argue 
for a strong genetic predisposition to MS, and have prompted a large number of linkage and 
association studies to identify disease loci and alleles. The results of genomic screens in MS 
indicate that a number of different genes (estimated to date 30-100), each having a 
relatively small contribution, in different potential combination are involved in the 
susceptibility to MS (Fugger et al., 2009). The large variations in susceptibility loci between 
the studies also indicate heterogeneity in disease alleles, even in Caucasian populations. The 
role of genetic factors is even more complex, as they seem to be involved not only in 
disease manifestation, but also in the clinical course of MS (Chapman et al., 2001; Fazekas 
et al., 2001) . 
 
 
 
Figure 14 Geographical distributions of MS and migrations (Compston et.al. 2008) 
The five continents are depicted to show medium prevalence of MS (orange), areas of 
exceptionally high frequency (red), and those with low rates (grey-blue). Some regions are 
fairly uncharted and these colors are only intended to provide an impression of the 
geographical trends. Major routes of migration from the high-risk zone of northern Europe, 
especially including small but informative studies, are shown as dotted arrows. Studies 
involving migrants from low-risk to high-risk zones are shown as solid arrows. 
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However, genome-wide association studies and candidate gene association studies 
revealed, that MS is associated with many common genetic variants including mostly 
immunologically relevant genes (Fig. 15). 
HLA controls immune responses and its association with MS indicates the primary 
involvement of the immune system in this disease. MS was one of the first conditions 
proven to be HLA associated involving primarily HLA class II loci. HLA-class II alleles of 
the HLA-DR2 haplotype are more strongly associated to MS (Jersild et al., 1973; Madsen et 
al., 1999). Three candidate risk genes of this haplotype, HLA-DRB1*1501 (HLA-DR2b), 
HLA-DRB5*0101 (HLA-DR2a) and HLA-DQB1*0602 (HLA-DQ6), are tightly associated 
with MS susceptibility. Recently, HLA-DRB1*1501 allele has been implicated as the main 
susceptibility allele in MS as conditioning on either HLA-DRB1 or the most significant 
HLA class II haplotype block found no additional block or SNP association independent of 
the HLA class II genomic region (Lincoln et al., 2005; Oksenberg et al., 2004). In addition 
it has been shown, that carriers of HLA-DRB1*1501 had a median of 4 spinal cord lesions 
compared with 2 lesions for noncarriers (P < .001)(Sombekke et al., 2009).  
Furthermore, more genetic studies have identified additional susceptibility loci 
within the HLA class I region. The HLA-A and HLA-C are candidate susceptibility loci, 
and the disease-associated alleles at these loci are HLA-A*0301, which predisposes to 
disease (Fogdell-Hahn et al., 2000; Harbo et al., 2004) and HLA-A*0201 and HLA-C*05 
which have a protective effect (Brynedal et al., 2007; Yeo et al., 2007) (Fig.15). 
Although the MHC region certainly plays a dominant role in the development of 
MS, non-MHC genetic variants contribute to disease susceptibility. At least 16 non-MHC 
genes have been identified so far to be associated with MS including the immunological 
genes (Fig.15), with the possible exception of the C-type lectin (CLEC16A) and the killer 
cell lectin-like receptor subfamily B, member 1 (KLRB1), all genes encode protein which 
are known to be important for T cell responses, cytokine receptors for IL-7 and IL-2 (Hafler 
et al., 2007; Lundmark et al., 2007), signal transducers tyrosine kinase-2 (TYK2) for 
cytokines, such as interferons, IL-10, IL-12 (Ban et al., 2009) and cell adhesion molecules   
(like CD58) (Reich et al., 2005) and CD226 (Hafler et al., 2009), . The neurological genes 
include amiloride-sensitive cation channel 1, neuronal (ACCN1; also known as ASIC2) 
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(Bernardinelli et al., 2007) and kinesin family member 1B (KIF1B) (Aulchenko et al., 
2008) (Fig. 15). This latter gene has yet to be confirmed (De Jager et al., 2009).  
 
 
 
Figure 15: Genes associated with risk of development of MS (Fugger et.al. 2009) 
 
Epidemiological studies have provided evidence for an additional, environmental 
component in the disease process. Migration from high to low-risk areas before adolescence 
reduces the risk of developing MS (Gale and Martyn, 1995). In areas with homogeneous 
ethnic populations, MS prevalence varies, being higher in areas with moderate climate 
(Lauer, 1994). One proposed causative factor is the decrease in sunlight exposure 
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depending on the latitude. UV radiation may exert its effects either by influencing 
immunoregulatory cells or by the biosynthesis of vitamin D (Hayes, 2000). EAE data and 
the association of a vitamin D receptor polymorphism support the latter notion with MS in 
Japan (Simon et al., 2010). The underlying factors are not completely understood, moreover 
environmental factors can influence disease course, as MS relapses are often associated 
with common viral infections (Sibley et al., 1985). 
Overall, clinical studies indicate at least two distinct phases to characterize MS, one 
that is dominated by acute relapses and one by steady progression. Both genetic and 
environmental factors seem to contribute synergistically to the manifestation and 
progression of the disease. 
 
1.3.2.2 Animal Model: Experimental autoimmune encephalomyelitis 
EAE represents a useful animal model for MS (Rivers et al., 1933; Whitehouse et 
al., 1969), as it mimics some of its key clinical and histological features and also served to 
develop several new therapeutic strategies, now implemented in patients (Copaxone, 
Natalizumab, FTY720). 
The minimal requirement for inducing CNS inflammation in the various EAE 
models is activation of myelin-reactive T cells in the peripheral immune system (Goverman 
et al., 1993; Zamvil and Steinman, 1990). EAE can be induced by several ways in 
susceptible experimental animals, as follows: 
Actively induced EAE 
Immunization of susceptible inbred strains of rats or mice with CNS protein extract 
(purified myelin proteins or myelin derived peptides), in CFA causes paralytic disease in 
most strains, often starting with limp tail and hind legs and paralysis progressing towards 
the upper limbs. The rapidly unfolding neurological defects are accompanied by a dramatic 
loss of weight. 
Not all animal strains and species respond in the same way to encephalitogenic 
immunization. For example, MOG is a strong encephalitogen, especially in C57BL/6 mice, 
but also DA rats and marmosets (Mendel et al., 1995), but not in PL/J mice or Lewis rats.  
 
82
Introduction 
 
Passive transfer of EAE 
EAE can be transferred to naïve hosts by myelin-specific T-cell clones isolated from 
actively primed syngenic donors. The encephalitogenic T cells are classically CD4+ T 
lymphocytes producing IFN-γ and TNFα, recognizing autoantigenic peptide epitopes in the 
context of MHC class II determinants (Liblau et al., 1995). Recent evidence, however, 
suggests that these populations include a subset of CD4+ T cells that preferentially secrete 
IL17 rather than IFN-γ, the Th17 cells (Bettelli and Kuchroo, 2005; Haak et al., 2009). It 
currently appears that both Th1 and Th17 have pathogenic potentials, and that they 
complement each other as the ratio between Th1:Th17 dictate T cell infiltration and 
inflammation in the brain parenchyma (Jager et al., 2009; Stromnes et al., 2008). 
Although the most common models of transferred EAE involve CD4+ T cells, some 
reports describe the role of MBP-specific CD8 T cells in EAE (Huseby et al., 2001a). 
Alternatively, MOG-reactive CD8 T cells were isolated from wild-type C57BL/6 mice 
immunized with MOG. The T cells were primed by conventional active immunization, but 
upon culturing with antigen the CD8 T cells overgrew their CD4 counterparts. Enriched 
CD8 cell populations transferred EAE, which was characterized by a particularly high 
proportion of CD8 T cells in the CNS infiltrates (Sun et al., 2001). 
Spontaneous EAE 
Untill recently there were no naturally occurring animal models of spontaneous EAE 
comparable to the NOD mouse model of autoimmune diabetes. However, a number of 
recent transgenic mouse strains have been generated that spontaneously develop a variety of 
EAE phenotypes. The first transgenic mice harbouring the genes for MBP-specific TcRs 
showed spontaneous EAE at variable rates, depending on the microbial status of their 
breeding facility (Goverman et al., 1993). Spontaneous EAE development with severe 
outcome and complete penetrance was also demonstrated in PLP139-151 TcR transgenic mice 
(Waldner et al., 2000). 
Furthermore, 2D2 TcR transgenic mice that possess CD4 T cells specific for the 
MOG35–55 peptide on the C57Bl/6 background develop spontaneous optic neuritis, the first 
signs of disease in a large proportion of MS patients. In addition, some transgenic mice 
(4%) also develop bonafide EAE (Bettelli et al., 2003). 
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Recently, two groups described double transgenic mice that developed a 
spontaneous EAE syndrome strikingly resembling human neuro-myelitis optica (Devic’s 
disease), an autoimmune disease related to MS (Bettelli et al., 2006a; Krishnamoorthy et al., 
2006). The animals possess T cells with receptors specific for a MOG epitope, at the same 
time, 30% of their B cells bind a conformational MOG epitope and secrete autoantibodies 
of the same specificity. The mice develop optico-spinal EAE as a result of cooperation 
between T and B cells recognizing the same encephalitogenic autoantigen. This is 
important, since evidence is emerging, that in a substantial proportion of patients with MS, 
autoimmune T and B cells contribute to the pathogenesis, as B cells are efficient APCs for 
processing intact myelin antigen and subsequent activation and pro-inflammatory 
differentiation of T cells (Weber and Hemmer, 2009). 
 
1.3.2.3 Pathophyisology of MS 
CNS demyelination in MS is mediated by an inflammatory response characterized 
by the recruitment of CD4 and CD8 T cells as well as macrophages in the white matter.  The 
antigenic targets of this immune response is currently unknown but may include myelin 
self-antigens resulting in myelin destruction (Sospedra and Martin, 2005). While 
considering the pathogenesis of MS, the disease process mainly comprises of an initial 
phase of inflammation, which leads to demyelination, and this results in axon loss. The loss 
of axons is considered to be the ultimate cause of the permanent clinical disability that 
occurs during the disease.  
 
Glial cells and myelin composition 
Glial cells are non-neuronal cells that maintain homeostasis, form myelin, and 
provide support and protection to the neurons and axons. In the human brain, there is 
roughly one glial cell for every neuron with a ratio of about two neurons for every three 
glial cell in the cerebral gray matter (Azevedo et al., 2009). The three types of CNS glial 
cells are astrocytes, microglia, and oligodendrocytes. 
Astrocytes are star-shaped glial cells that provide physical support to neurons and 
clean up debris within the brain.  They also provide neurons with some of the chemicals 
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needed for proper functioning and help control the chemical composition of the fluid 
surrounding neurons.  Finally, astrocytes play a role in providing nourishment to neurons. 
Microglia are the smallest of the glial cells, which act as phagocytes to clean up 
CNS debris. Microglia protect the brain from invading microorganisms and are thought to 
be similar in nature to macrophages. 
Oligodendrocytes are the myelin producing cells; arise during development from 
oligodendrocyte precursor cells, which can be identified by their expression of a number of 
antigens, such as ganglioside GD3, the NG2 chondroitin sulfate proteoglycan (Dawson et 
al., 2000), and platelet-derived growth factor-α receptor subunit (Scolding et al., 1998). The 
myelin sheath provides insulation to the axon that allows electrical signals to propagate 
more efficiently. Myelin is mainly composed of 80% lipid and 20% protein.  
The most abundant CNS myelin protein (about 50%) is PLP. It is highly 
hydrophobic and evolutionarily conserved across species. PLP is a four transmembrane 
domain myelin protein, which binds strongly to other copies of itself on the extracellular 
side of the membrane. In a myelin sheath, as the layers of myelin wraps come together, PLP 
will bind itself and tightly hold the cellular membranes together.  
In mice, there are two main transcripts, one encoding the full-length 276 amino acid 
isoform, and one encoding DM-20, an isoform that lacks 35 amino acids and is mainly 
expressed in brain and spinal cord prior to myelination but also in lymphoid organs, where 
full-length PLP is barely found as previously discussed in (section 1.3.1.1) (Bruno et al., 
2002; Seamons et al., 2003).  
MBP is the second most abundant myelin protein (30%–40%) after PLP. It contains 
170 amino acids and is relatively easy to isolate owing to its physicochemical 
characteristics, and was the first to be used extensively in EAE. The highly basic MBP is 
positioned at the intracellular face of myelin membranes, and via interactions with acidic 
lipid moieties it is involved in maintaining the structure of compact myelin. MBP is found 
in significant quantities in both central and peripheral myelin, and MBP transcripts have 
also been detected in the thymus and in peripheral lymphoid organs (Bruno et al., 2002). 
EAE can be induced with MBP in several mouse and rat strains, guinea pigs, and nonhuman 
primates (Wekerle et al., 1994). 
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MOG, a 218 amino acid transmembrane glycoprotein of the Ig superfamily, is much 
less abundant (0.01%–0.05%). It is located at the outermost lamellae of compact myelin and 
on the outer surface of the oligodendrocyte membrane, therefore it is directly accessible to 
antibodies and believed to be relevant as a target for both cellular and humoral immune 
responses in MS. MOG is expressed late in myelination and is only found in the 
brain/spinal cord and the optic nerve, not in peripheral nerves. Furthermore, MOG is either 
absent or weekly expressed in lymphoid organs (Bruno et al., 2002; Seamons et al., 2003). 
MOG-induced EAE is best examined in C57/BL6 mice, in which the MOG(35–55) peptide 
induces a chronic, nonrelapsing EAE (Mendel et al., 1995). The recent 2D2 MOG TcR 
transgenic mouse model showed spontaneous EAE with inflammation, demyelination, and 
axonal damage in brain and spinal cord in a small fraction of animals, while 35% developed 
spontaneous optic neuritis (Bettelli et al., 2003). The relatively higher expression of MOG 
in the optic nerve has been proposed as one explanation for the involvement of the optic 
nerve. 
Myelin associated glycoprotein (MAG) is a 626 amino acid large myelin 
glycoprotein located at the inner surface of the myelin sheath opposing the axon surface. It 
accounts for less than 1% of total myelin protein in the CNS and is even less abundant in 
the peripheral nervous system (PNS). Anti-MAG IgM response in polyneuropathies 
revealed the pathogenic significance of this protein (Steck et al., 1983). 
2’, 3’-Cyclic nucleotide 3’phosphodieserase (CNPase) exists in two splice variants 
(CNPase I and II, 46 kDa and 48 kDa) and makes up 3%–4% of total myelin protein. 
 
Demyelination 
The pathology of MS is defined as an inflammatory process, associated with focal 
plaques of primary demyelination in the white matter of the brain and spinal cord. 
Inflammatory infiltrating cells mainly consist of T cells, activated macrophages and 
microglia. In active lesions this inflammatory process is accompanied by a profound 
disturbance of the BBB (Hochmeister et al., 2006; Kirk et al., 2003), the local expression of 
proinflammatory cytokines and chemokines as well as of their cognate receptors (Cannella 
and Raine, 1995; Huang et al., 2000). Complete demyelination is associated by a variable 
degree of acute axonal injury and axonal loss (Ferguson et al., 1997; Trapp et al., 1998). 
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Furthermore, demyelination-associated axon degeneration was increased when 
remyelination was inhibited (Irvine and Blakemore, 2008).  
Although axon degeneration is accepted as a major cause of persistent disability in 
MS (De Stefano et al., 1998; Griffiths et al., 1998), little is known about the mechanisms of 
how inflammatory demyelination leads to neuronal damage. Evidence based from animal 
models suggested, that myelin-specific T cells are activated outside the CNS, followed by 
upregulation of adhesion molecules and chemokine receptors, allowing them to adhere, role 
along and finally transmigrate through the endothelium (Charo and Ransohoff, 2006; 
Engelhardt and Ransohoff, 2005). Once in the perivascular space, autoreactive T cells get 
reactivated by local APCs, such as DCs (Greter et al., 2005), and thereby gain access to 
CNS parenchyma. Proinflammatory cytokines released by activated T cells and activated 
microglia lead to further inflammatory cell recruitment, finally resulting in an aggressive 
immune attack against the myelin sheath. (Fig.16) 
Antibodies to various myelin proteins and lipids of the myelin sheath are secreted by 
B cells that have migrated to the brain or from serum that has extravasated across the BBB 
(Steinman, 2001). Activated T cells are targeted to CNS proteins and their distribution 
throughout the lesion is reflected in the expression pattern of MHC molecules. MHC class 
II is sufficiently displayed only on professional APCs (e.g. DCs, B cells, macrophages), 
whereas MHC class I can be expressed by all cells in the inflammatory milieu of the CNS 
(Dandekar et al., 2001; Neumann et al., 1995). Accordingly, CD4+ T cells are 
predominantly found in perivascular cuffs and the meninges, whereas CD8+ T cells also 
seem to invade the parenchyma of the inflamed lesion. On contact with their cognate 
antigen, the T cells arrest and locally mediates their effector functions (Kawakami et al., 
2005). CD4+ T cells recruit macrophages, which release proinflammatory cytokines and 
toxic molecules, such as nitric oxide (NO), IL-1, IL-6, TNF-α, TNF-β and matrix 
metalloproteinases (MMPs) which is involved in the killing of oligodendroglial cells. CD8+ 
T cells also directly attack MHC class I-expressing cells such as oligodendrocytes (Saxena 
et al., 2008)  and neurons (Fig.16). 
The combined effect of antibodies and inflammatory milieu damages myelin and 
induces the macrophages to phagocytose large fragments of the myelin sheath. In addition, 
macrophages and T cells produce osteopontin, which further induces Th1 cytokines IFN-γ 
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and IL-12, while downregulating Th2 cytokines like IL-10. Th1 cytokines may induce 
exacerbations of MS (Bielekova et al., 2000; Chabas et al., 2001; Kappos et al., 2000; 
Steinman, 2001). Overall, this attack of immune cells and inflammatory mediators 
including cytokines, osteopontin, and NO produce areas of demyelination, impairing 
electrical conduction along the axon and producing the pathophysiologic defect. 
Histological analysis of MS tissue has demonstrated deposition of antibodies and 
complement on the myelin sheath of a substantial fraction of lesions, but also indicated 
significant heterogeneity in the composition of demyelinating lesions. These lesions have 
been classified in four categories based on inflammatory features and on myelin 
oligodendrocyte pathology (Lassmann et al., 2001). The first two patterns (P1 and P2) are 
characterized by demarcated regions of infiltrating T cells (P1) and activated macrophages 
(P2), centered on small veins, however, areas of demyelination were observed in both 
patterns (P1 & P2). The presence (P2) or absence (P1) of antibody and complement 
deposition distinguishes these two types of lesions, suggesting a different level of B cell 
involvement. Infiltrating T cells and macrophages were also found in other two patterns (P3 
& P4) of lesions, but these two patterns are characterized by an oligodendrocyte defect with 
a preferential loss of MAG (P3) or nearly complete loss of oligodendrocytes and complete 
lack of remyelination (P4). The IgG found in P2 lesions may directly contribute to disease 
progression, as patients with P2 lesions respond to therapeutic plasma exchange (Keegan et 
al., 2005). 
However, in contrast to the role of T cells in demyelination, recently it has been 
shown, that myelin phagocytosis is not due to CD4 T-cell-mediated macrophage activation. 
It is an innate scavenging response of macrophages to the presence of degenerate and dead 
myelin, with T and B cell activity largely restricted to recently demyelinated tissue. In 
detail, the sequence of changes that occurs in tissue bordering actively expanding MS 
lesions starts with a loss of oligodendrocytes in the presence of activated microglia with few 
other inflammatory cells. Macrophages then appear and scavenge the degenerate and dead 
myelin, again with relatively few other inflammatory cells present. Following the removal 
of all myelin from axons, and while the tissue remains packed with lipid-filled macrophages 
and steeped in IgG, activated T cells, B cells, and IgG-positive plasma cells accumulate in 
large numbers, together with increasing numbers of differentiated oligodendrocytes. 
88
Introduction 
 
Although adaptive immune activity is easily seen in recently demyelinated tissue, there are 
early cases of MS in which large MS lesions expand rapidly in the absence of IgG-positive 
plasma cells within the lesions and with relatively few lymphocytes present in perivascular 
spaces or in the parenchyma (Henderson et al., 2009). 
 
 
Figure 16: Immunopathogenesis of MS (Hemmer et.al. 2005) 
 
 The acute neurologic dysfunction that occurs during a relapse is speculated to be due 
to a depolarization-induced conduction block at demyelinated regions of axons (Kornek and 
Lassmann, 2003). One way to reduce long-term disability in patients with MS would be to 
promote remyelination of axons (Stangel and Hartung, 2002). Some remyelination does 
occur in MS lesions, but the myelin is usually thinner than before, with shorter internodes 
(Stangel and Hartung, 2002). Moreover, several features are predicted to inhibit 
remyelination in MS: the loss of oligodendrocytes and oligodendrocyte precursors as a 
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consequence of attack by immune cells; inhibitory signals produced by inflammation; the 
obstruction of oligodendrocytes by astrocytic scarring; and the reduced receptiveness of 
injured axons to remyelination (Hohlfeld, 2002). 
Axonal loss 
Loss of axons is a key anatomic determinant of disability in MS, but its mechanisms 
still remain elusive. Axonal injury is believed to occur as a consequence of demyelination 
and was recently shown to be a feature even of the early disease stages (Kuhlmann et al., 
2002). Initially, the MS lesion was considered to be an area of demyelination with 
preservation of axons. However, it has been observed, that destruction of axons does occur, 
with axon loss being reported in normal-appearing white matter (Neumann, 2003). Axon 
damage and transection occur in both acute and chronic inflammatory plaques and have 
been observed in inactive and chronic lesions from patients with clinical disease durations 
ranging from 2 weeks to 27 years (Trapp et al., 1998). Axon transection is irreversible and 
is most abundant in areas of inflammation. Later axon damage may result from changes in 
the microenvironment in the CNS or from sublethal injury during acute inflammatory 
events, resulting in decreased long-term survival. Therefore, the following mechanisms 
have been proposed for demyelination-induced axon loss: a direct effect through the loss of 
trophic influences from oligodendrocytes; a consequence of sustained demyelination-
induced conduction block; and indirectly through the increased vulnerability of the exposed 
axon (Halfpenny et al., 2002). The progressive disability that occurs in MS is believed to 
result from cumulative axon damage and degeneration, along with neuron loss due to 
Wallerian degeneration. Dropout of damaged axons over time may result in premature 
stress and damage to surviving axons within the same pathways, thereby producing further 
loss and functional impairment. Brain white matter contains, by volume, 46% axons, 24% 
myelin, 17% glia, and 13% blood vessel, blood, and tissue fluid (Miller et al., 2002a). 
Given the large amount of myelin in brain tissue, demyelination is of course also a factor to 
consider in atrophy. Therefore, brain atrophy can be explained by axonal loss, that may be 
caused either by tissue loss within the lesion or by Wallerian degeneration which may 
especially be expected in spinal cord atrophy (Lovas et al., 2000). Atrophy is most evident 
in progressive forms of MS and may be a predictor for the conversion from RR-MS to SP-
MS, once a threshold of axon transection is exceeded.  
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1.3.2.3 Effector mechanisms of multiple sclerosis 
The immune responses in MS are mainly targeting the cellular components of the 
CNS that are normally inaccessible to the immune system because of their location behind 
the BBB. Entry of immune cells into the CNS depends on their state of activation and their 
ability to respond to adhesion molecules and chemokine signals that induce them to cross 
the BBB. The inflammatory infiltrates in active MS lesions consist of a mostly perivascular 
accumulation of CD4 and CD8 T cells, monocytes, and B cells. 
Penetration of the BBB by activated lymphocytes take place in a synchronized way. 
First, the endothelial cells in the CNS, which are nonfenestrated and connected through 
tight junctions, are induced to express vascular cellular adhesion molecule (VCAM) and 
MHC class II molecules by IFN-γ and TNF-α, which are released in the inflammatory 
response (Allavena et al., 2010; Cannella and Raine, 1995). In inflammatory conditions of 
the CNS, the expression of adhesion molecules and chemokines is induced on BBB 
endothelium and the choroid plexus epithelium, providing additional traffic signals for 
circulating leukocytes. In inflamed murine vessels, CD8+ T lymphocytes from MS patients 
preferentially roll via P-selectin glycoprotein ligand-1 (PSGL-1), whereas CD4+ T 
lymphocytes roll via α4-integrin (Battistini et al., 2003). During EAE, both α4-integrin and 
PSGL-1-mediated leukocyte rolling occur in brain vessels (Kerfoot and Kubes, 2002). 
After chemokine activation, cell surface integrins on leukocytes undergo 
conformational changes and engage in interactions of higher affinity with endothelial cell 
adhesion molecules. Integrin activation, mediated by signalling through G-protein-coupled 
receptors, is essential for leukocyte arrest under flow conditions. Chemokines and their 
receptors deliver such signals (Piccio et al., 2002; Vajkoczy et al., 2001). Chemokines 
produced by BBB endothelium during EAE include the lymphoid ‘homeostatic’ 
chemokines CCL19 and CCL21 (Alt et al., 2002; Columba-Cabezas et al., 2003). 
Numerous other chemokines are produced in the inflamed brain, both in EAE and in MS, 
and encephalitogenic lymphocytes express a substantial number of chemokine receptors. 
It has been described, that the adhesion molecules ICAM-1 and VCAM-1 were 
upregulated on CNS microvascular endothelial cells during EAE (Baron et al., 1993; 
Steffen et al., 1994). Perivascular inflammatory cells surrounding ICAM-1 and VCAM-1-
positive murine venules stain positive for LFA-1 (αLβ2-integrin) and α4β1-integrin, but 
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not for L-selectin or α4β7-integrin. Furthermore, adhesion of encephalitogenic T 
lymphocytes to brain endothelial cells in vitro is mediated by α4–VCAM-1 and LFA-1–
ICAM-1 interactions (Laschinger and Engelhardt, 2000). Overall, these observations clearly 
implicate α4β1–VCAM-1 and probably also LFA-1–ICAM-1 in CNS inflammation during 
EAE. 
However, recently it has been shown, that activated leukocyte cell adhesion 
molecule (ALCAM also known as CD166) is upregulated substantially during 
inflammatory stimuli, along with ICAM-1. More notably, the upregulation of VCAM-1 
after inflammatory stimulus is marginal relative to that of ALCAM. During the 
transmigration of lymphocytes across BBB endothelial cells, the ALCAM ligand CD6 
localizes together with ALCAM and forms a transmigratory cup. Furthermore, post-mortem 
sections from patients with MS and mice with EAE have higher expression of ALCAM, 
and antibody blockade of ALCAM significantly lowers the accumulation of CD4+ T cells 
and decreases the severity and delays the onset of disease in EAE models (Cayrol et al., 
2008). All these novel findings suggest, that ALCAM-CD6 interactions seem to replace 
VCAM-1–VLA-4 interactions in mediating the transmigration of CD4+ T cells across the 
BBB.  
During diapedesis across the inflamed BBB, leukocytes migrate by a transcellular 
pathway through endothelial cells, leaving tight junctions intact (Engelhardt and Wolburg, 
2004). Recently, CD99, a unique highly O-glycosylated protein expressed on leukocytes, 
was localized in endothelial cell-to-cell-contacts (Schenkel et al., 2002). CD99 antibodies 
inhibit the migration of encephalitogenic T lymphocytes across brain endothelial 
monolayers in vitro, suggesting the involvement of CD99 in T-lymphocyte recruitment 
across the BBB in vivo (Bixel et al., 2004). 
Once the activated lymphocytes have extravasated, they must still pass through a 
barrier of extracellular matrix comprised of type IV collagen before entering into the CNS. 
α-1-integrin may play a role in binding to collagen type IV (Steinman et al., 2002). 
Following contact with collagen, immune cells secrete enzymes such as MMPs, which 
allow the activated lymphocytes to gain access to the white matter surrounding axons of the 
CNS. The MMPs are a family of structurally and functionally related enzymes involved in 
the degradation of the extracellular matrix as well as the proteolysis of myelin components 
in MS (Hartung, 1995; Rosenberg, 2002).  
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CD4 + T cell function in MS 
The role of CD4+ T cells in MS is supported indirectly by the fact that certain HLA 
class II alleles represent the strongest genetic risk factor for MS (Oksenberg and Hauser, 
2005), presumably via their role as antigen-presenting molecules to pathogenic CD4+ T 
cells. Initially, MS was mainly considered as a CD4+ Th1-mediated autoimmune disease 
(Hafler, 2004; Martin et al., 1992), which is further evident by the cellular composition of 
brain and cerebrospinal fluid (CSF)-infiltrating cells and findings from the EAE model 
(Zamvil and Steinman, 1990). Recently it has been shown that Th17 cells also play a 
pivotal role in the pathogenesis of EAE (Becher et al., 2003; Jager et al., 2009; Langrish et 
al., 2005; Reboldi et al., 2009), further emphasizing the importance of CD4+ T cells. In MS, 
the role of Th17 cells is more difficult to explore, but there are some evidence implicating 
IL-17 producing cells in the pathogenesis. Indeed, IL-17 and IL-6 are among the most 
highly expressed genes in MS lesions (Lock et al., 2002), and elevated levels of IL-17 has 
been reported in the serum and CSF of MS patients (Matusevicius et al., 1999). 
Furthermore, it has been shown both in-vitro and in-vivo, that human Th17 cells might be 
well competent to breach the BBB and infiltrate the CNS parenchyma (Kebir et al., 2007; 
Tzartos et al., 2008). Altogether these findings suggest, that Th17 cells may play an 
important role in MS pathogenesis. 
Recent studies have suggested that Foxp3+ Tregs are capable of migrating into the 
CNS under inflammatory conditions and may actively modulate the function of effector 
cells within the target organ itself. During EAE, peripherally expanded Tregs are found to 
accumulate within the CNS (Korn et al., 2007), and Foxp3+ Tregs were found enriched in 
the CSF of MS patients (Feger et al., 2007a; Venken et al., 2006). Although there is no 
difference in the number of Tregs between MS and control patients, Tregs play a likely role 
in MS pathogenesis, since patients with MS demonstrates reduced Treg function (Haas et 
al., 2005). 
Recently a novel population of nTreg cells has been identified in human peripheral 
blood. These cells can be either CD4+ or CD8+, they lack FoxP3 expression, and they are 
distinguished from other nTreg cells by the expression of human leukocyte antigen G 
(HLA-G) (Feger et al., 2007b; Wiendl et al., 2005). They exhibit potent suppressive 
properties that are partially mediated by HLA-G and Ig-like transcript 2. 
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HLA-G-expressing Treg cells accumulate at sites of inflammation in acute relapses   
of MS. Indeed, those patients uniformly show higher frequencies of HLA-G-expressing 
cells in the CSF than in peripheral blood (Feger et al., 2007b; Wiendl et al., 2005). 
 
CD8 + T cell function in MS 
Although evidence for the importance of CD4+ T cells exists in MS, the involvement 
of CD8+ T cells cannot be neglected as CD8+ T cells are easily demonstrated in 
inflammatory lesions (Traugott et al., 1983). CD8+ T cells are present at the lesion edge as 
well as perivascular regions. In addition, a higher frequency of CD8+ T cells recognizing 
myelin proteins in patients with MS than in healthy controls has been reported (Crawford et 
al., 2004), although these data are controversial (Berthelot et al., 2008). TcR analysis of 
brain tissue from patients with MS has shown oligoclonal expansion of CD8+ T cells in 
lesions based on TcR analysis (Babbe et al., 2000; Junker et al., 2007), and more strikingly 
in the CSF (Jacobsen et al., 2002). This suggests antigen-driven activation of CD8+ T cells 
during the course of MS. 
Furthermore, CD8+ T cells have been shown to mediate EAE (Ji and Goverman, 
2007), and transgenic mice over-expressing the costimulatory molecule CD86 on microglia 
develop disease mediated mainly by CD8+ T cells (Brisebois et al., 2006). Conversely, mice 
lacking CD8+ T cells develop a less severe encephalomyelitis (Koh et al., 1992). 
Interestingly, oligodendrocyte do express detectable levels of MHC class I molecules in MS 
lesions (Hoftberger et al., 2004), and this may be functionally relevant as myelin-specific 
CD8+ T cells induce lysis of HLA-matched oligodendrocyte in-vitro (Jurewicz et al., 1998). 
Altogether these findings further strengthened the observations for an active role of CD8+ T 
cells in CNS autoimmunity. 
CD8+ T cells found in MS lesions might also have a regulatory function on disease 
progression. These cells demonstrate both immune suppressive and pathogenic 
characteristics (Babbe et al., 2000; Correale and Villa, 2008; Johnson et al., 2007). CD8+ T 
cells can mediate suppression on CD4+ T cells proliferation through the secretion of 
perforin (Johnson et al., 2007). Although it appears plausible that CD8+ T cells are 
important players in MS pathogenesis, the precise subset of CD8+ T cells that infiltrates the 
CNS in MS remains to be defined. However, a recent report suggested a significant increase 
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in the number of IL-17+ T cells in the active areas of the lesions (Tzartos et al., 2008). 
Importantly, these included CD8+ and CD4+ T cells, which expressed IL-17 at similar 
frequencies (Tzartos et al., 2008). It might have been overlooked in EAE, where the antigen 
and/or adjuvant used in the immunization procedure introduces a bias toward CD4+ T cell 
priming, and possibly toward pathogenic Th17 responses (Bettelli et al., 2008; Gold et al., 
2006). Interestingly, CD8+ T cells from mice deficient in the transcription factors T-bet and 
eomesodermin differentiate excessively into IL-17-secreting cells. On viral infection, these 
mice experience development of a overwhelming CD8+ IL-17+ T-cell mediated 
autoinflammatory syndrome (Intlekofer et al., 2008). However, the importance of CD8+ IL-
17+ T cells in MS pathogenesis remains to be established. 
It can be speculated that the MS lesion is initiated by CD4+ T cells but the 
amplification and damage could be mediated by CD8+ T cells, which is supported by data 
showing that CD8+ T cells can directly attach to and damage axons (Medana et al., 2001). 
 
B-cell function in MS 
The elimination or reprogramming of self-reactive B cells through B-cell receptor 
(BCR) editing takes place in bone marrow during the B-cell development and in spleen and 
lymph nodes during the B-cell maturation (Hardy and Hayakawa, 2001). During the 
establishment of tolerance, cytokines such as IL-7 and B-cell activating factor (BAFF) play 
a significant role (Goodnow et al., 2005).  
B cells and antibodies also play a role in MS pathogenesis. There is a very consistent 
presence of oligoclonal IgG bands in CSF but not in the serum of patients with MS, 
indicating an intrathecal Ig production (Cross et al., 2001; Obermeier et al., 2008). These 
high concentrations are caused by a local IgG response that mainly involves the IgG1 and 
IgG3 isotypes (Archelos et al., 2000; Losy et al., 1990; Walsh and Tourtellotte, 1986). 
Indeed, the occurrence of an oligoclonal intrathecal antibody response is still an important 
marker for chronic CNS inflammation in MS and bears a diagnostic value. Interestingly, the 
antibody response seems to be stable over long periods and to involve a limited number of 
clonotypes (Walsh and Tourtellotte, 1986). It has been further complemented by 
investigations of antibody-secreting B cells in the CNS and CSF of patients with MS, which 
suggest that there may be an intense antigenic stimulation, possibly by a relatively restricted 
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number of antigens leading to compartmentalized clonal expansion (Baranzini et al., 1999; 
Colombo et al., 2000; Qin et al., 1998). Furthermore, recently a novel method, coupling the 
Ig proteomes with the B cell transcriptome in the CSF of MS patients showed that the 
oligoclonal Ig bands correspond to the clonally expanded B cells, have been described as 
diagnostic hallmarks of MS (Obermeier et al., 2008). However the antigenic target(s) of 
these oligoclonal IgG are still unknown. 
Furthermore, recent evidence implicates a role of BAFF in the pathogenesis of 
autoimmune diseases. Elevated levels of soluble BAFF have been observed in sera and 
target organs of mouse models of SLE (Gross et al., 2000), in collagen-induced arthritis 
(Zhang et al., 2005), or in chemically induced autoimmunity (Zheng et al., 2005). BAFF 
levels were increased in the brains of patients with MS (Krumbholz et al., 2005), and 
correlated with disease activity and titers of pathogenic autoantibodies (Mackay et al., 2007; 
Piazza et al., 2010). 
However, in addition to maturing into antibody producing plasma cells, B cells have 
the robust capacity to present antigen and interact with T cells (Dalakas, 2008). Moreover, 
B cells are abundant producers of both proinflammatory (TNF, IFN-γ) and regulatory (IL-
10) cytokines. In addition, B cells have the capacity to form ectopic lymphoid structures or 
germinal centers, which have been found in patients with MS (Dalakas, 2008; Magliozzi et 
al., 2007; Serafini et al., 2004; Takemura et al., 2001).  
There is increasing evidence that B cells and their products are involved in MS 
pathogenesis and that treatment targeting these cells may provide long-lasting benefits. A 
recent report provides evidence, that follicles rich in CD20+ B cells are found in the brains 
of patients with secondary-progressive MS (Magliozzi et al., 2007). The memory B cells, 
late plasmablasts and long-lived plasma cells migrate not only to the bone marrow, spleen 
and lymphoid tissues, but also to the brain, where they transform into antibody-secreting 
cells after encountering their antigen (Knopf et al., 1998). Interactions between the 
homeostatic chemokines CXCL13, CXCL10 and CXCL12 secreted from the endothelial 
cell wall and their respective receptors on B cells are fundamental for B-cell homeostasis 
not only within the lymphoid follicles but also within the brain (Alter et al., 2003; Dalakas, 
2008). These molecules are upregulated in the brains of patients with MS, allowing the 
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recruitment and transmigration of antibody-producing B cells into the brain (Meinl et al., 
2006; Ritchie et al., 2004). 
Recent advancement of disease modifying therapies including IFN-β, glatiramer 
acetate, and natalizumab, on B-cell function are now coming to be better appreciated as a 
therapeutic target, as no T-cell-specific therapy has shown much clinical efficacy to date in 
either phase II or phase III trials. Treatment with anti-CD20 (rituximab) activates 
complement factors to attack the lipid raft environment on CD20+ B cells and induces 
apoptosis which significantly reduced inflammatory brain lesions and clinical relapses (Bar-
Or et al., 2008; Hauser et al., 2008). In addition to targeting B cells, another approach is to 
target BAFF, which is one of the cytokines responsible for B-cell maturation.  
 
Mast cell function in MS 
Mast cells are derived from CD34+ hematopoietic progenitor cells and initiate their 
differentiation in the bone marrow under the influence of c-kit ligand and IL-3 (Rodewald 
et al., 1996). The mast cells release a number of mediators immediately upon activation, 
such as TNF-α, IL-4, histamine, heparin, serotonin, kinins and proteases. A second class of 
synthesized mediators include the IL-12, IL-13, IL-15 and IL-16, chemokines, and growth 
and angiogenesis factors, such as vasoactive intestinal peptide (VIP), vascular endothelial 
growth factor (VEGF) and platelet-derived growth factor (PDGF), as well as prostaglandins 
and leukotrienes. Together, these molecules have profound effects on inflammatory cell 
activation and recruitment (Galli et al., 2005). 
TNF-α and VIP produced by mast cells can also drive Th17 maturation independent 
of IL-6 (Kimura et al., 2007). Mast cells can play a role in Th17 differentiation via its 
secretion of IL-6, TGF-β, TNF-α and VIP (Kanbe et al., 1999; Kimura et al., 2007; Mekori 
and Metcalfe, 2000). Th2 cells produce IL-4, IL-5, and IL-13, which are associated with 
allergic reactions and maturation of mast cells and have recently suggested to be implicated 
in MS (Pedotti et al., 2003a; Pedotti et al., 2003b). 
Mast cells are found perivascularly surrounding the endothelial cells and the 
pericytes that together form the BBB, at the ventricles (Esposito et al., 2002) and close to 
MS plaques (Ibrahim et al., 1996). They are critical for the regulation of BBB permeability, 
(Ibrahim et al., 1996) disruption of which precedes clinical or pathologic signs of MS 
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(Minagar and Alexander, 2003; Stone et al., 1995). In particular, acute stress can disrupt the 
BBB through secretion of corticotropin-releasing hormone (CRH), which activates human 
umbilical cord blood–derived cultured mast cells (Theoharides and Konstantinidou, 2007). 
In fact, human mast cells express CRH-R1, activation of which leads to selective secretion 
of VEGF (Cao et al., 2006). Release of MBP can stimulate mast cells to secrete VEGF, 
which could increase BBB permeability (Johnson et al., 1988; Theoharides et al., 1993). 
The mast cell proteolytic enzyme, tryptase, is elevated in the CSF of MS patients 
(Rozniecki et al., 1995) and can cause widespread inflammation by stimulating protease-
activated receptors (PARs) (Malamud et al., 2003; Molino et al., 1997). Tryptase can also 
damage myelin directly (Dietsch and Hinrichs, 1991; Johnson et al., 1988). Furthermore, 
tryptase can activate peripheral blood mononuclear cells isolated from MS patients to 
release TNF-α, IL-1β, and IL-6, which are possibly involved in the pathogenesis of MS 
(Martino et al., 2000). Moreover, the genes found to be most upregulated in plaques from 
deceased patients with MS include those for tryptase, for the IgE receptor (FcεRI) and for 
the histamine-1 receptor, all associated with mast cells (Bomprezzi et al., 2003; Lock et al., 
2002).  
Therefore, mast cells could participate in the pathogenesis of MS through multiple 
actions like promoting adhesion molecule expression, BBB disruption, demyelination, 
fibrosis/plaque formation, immune cell chemoattraction, PAR stimulation, T cell 
stimulation and vasodilation. Chemokines produced by mast cells enhance T cell 
recruitment to the site of inflammation, in particular CCL2, CCL3, CCL4, CCL5, and IL-16 
(Salamon et al., 2005) and leukotriene B4 regulates T cell migration (Ott et al., 2003). 
Histamine released from mast cells can promote Th1 and Th2 cell activation (Jutel et al., 
2001). Mast cell-derived IL-4 worsens EAE severity by enhancing the encephalitogenic 
potential of Th1 cells (Gregory et al., 2006).  
Overall, mast cells and their ability to release numerous potent inflammatory 
mediators upon activation, can directly or indirectly activate T cells coming in contact with 
them at the BBB.  
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1.4 General aim of the Thesis 
 
The association of MS with MHC genes, the nature of the inflammatory white 
matter infiltrates, similarities with animal models, and the observation that MS can be 
treated with immunomodulatory and immunosuppressive therapies support the hypothesis 
that autoimmunity plays a major role in the disease pathogenesis. Evidence supports the 
idea, that activated CD4+ T cells are the major mediators of the disease. However, 
increasing evidence suggest that CD8 T cell contribution to the disease process might have 
been underestimated. 
Therefore the main aim of my thesis is to investigate the mechanisms by which 
autoreactive CD4 and CD8 T cells can contribute to the oligodendrocyte loss and   
demyelination, a major pathological feature of MS. During these studies we made the 
surprising observation of spontaneous development of autoimmune EAE, even in the 
absence of the target antigen MOG. Therefore we investigated this paradoxical observation. 
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Oligodendrocyte-specific CD8 T cells in CNS autoimmunity 
 
Summary 
 
 Genetic studies in humans revealed an independent role for HLA class-I genes in 
MS susceptibility. In addition, neuropathologic studies demonstrated that CD8+ T cells are 
the most numerous inflammatory infiltrate in MS lesions at all stages of lesion 
development. CD8+ T cells are also capable of damaging neurons and axons in vitro. To 
assess the pathogenic impact of CD8+ T cells on oligodendrocytes, we generated mice, 
referred as double knock-in (DKI) mice, in which the well-studied model antigen HA is 
selectively expressed on oligodendrocytes. 
 Introduction of HA-specific CD8+ T cells by TcR transgenesis did not result in any 
sign of central or peripheral tolerance, or any CNS pathology in the DKI animals. The 
exclusive expression of HA in oligodendrocytes, and the resulting lack of T-cell silencing, 
is very reminiscent of some natural myelin self-antigens such as MOG. Transfer of pre-
activated HA-specific CD8+ T cells from CL4 TCR transgenic mice in DKI recipients led to 
inflammatory lesions in the optic nerve, spinal cord, and brain. These lesions associating 
CD8+ T-cell infiltration with focal loss of oligodendrocytes, demyelination, and microglia 
activation, were very reminiscent of active MS lesions. In order to trace these HA-specific 
CD8+ T cells in vivo, we labeled them with green florescent protein (GFP). Staining for 
GFP and Granzyme B revealed, that HA-specific Tc1 cells containing Granzyme B 
granules were detected within CNS lesions of DKI mice, some of the Granzyme B+ T cells 
were found in close apposition to carbonic anhydrase II or cyclic nucleotide 3’ 
phosphodiesterase+ oligodendrocytes. We also detected GFP+ Tc1 cells with polarized 
Granzyme B+ granules facing an oligodendrocyte, suggesting directed degranulation. 
These findings can provide important new insights with regard to CNS tissue 
damage mediated by CD8+ T cells specific for a sequestered antigen and in extension for 
the understanding of the role of CD8+ T cells in human MS.  
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Cutting Edge: Multiple Sclerosis-Like Lesions Induced by
Effector CD8 T Cells Recognizing a Sequestered Antigen
on Oligodendrocytes1
Amit Saxena,2*† Jan Bauer,2‡ Tanja Scheikl,*† Jacques Zappulla,*† Marc Audebert,*†
Sabine Desbois,*† Ari Waisman,§ Hans Lassmann,‡ Roland S. Liblau,3*†
and Lennart T. Mars*†
CD8 T cells are emerging as important players in mul-
tiple sclerosis (MS) pathogenesis, although their direct
contribution to tissue damage is still debated. To assess
whether autoreactive CD8 T cells can contribute to the
pronounced loss of oligodendrocytes observed in MS
plaques, we generated mice in which the model Ag in-
fluenza hemagglutinin is selectively expressed in oligo-
dendrocytes. Transfer of preactivated hemagglutinin-
specific CD8 T cells led to inflammatory lesions in the
optic nerve, spinal cord, and brain. These lesions, associ-
ating CD8 T cell infiltration with focal loss of oligoden-
drocytes, demyelination, and microglia activation, were
very reminiscent of active MS lesions. Thus, our study
demonstrates the potential of CD8T cells to induce oligo-
dendrocyte lysis in vivo as a likely consequence of direct
Ag-recognition.These results provide new insightswith re-
gard to CNS tissue damage mediated by CD8 T cells and
for understanding the role of CD8 T cells in MS. The
Journal of Immunology, 2008, 181: 1617–1621.
T he immune effector mechanisms contributing to tissuedamage in multiple sclerosis (MS)4 are only partiallyelucidated. The heterogeneity of MS likely reflects a
varying contribution of humoral factors, T cell subsets, and ac-
tivated macrophages/microglia. Indirect evidence suggests that
the role of CD8 T cells has been largely underestimated to date.
Indeed, CD8T cells accumulate within activeMS lesions where
they often outnumber CD4 T cells (1–3). These CNS-infiltrat-
ing CD8, but not CD4, T cells exhibit oligoclonal expansion, a
likely consequence of their local Ag-driven activation (3).
Moreover, myelin-reactive cytotoxic CD8 T cells have been
identified in MS patients, sometimes more frequently than in
controls (4, 5). Finally, active MS plaques exhibit MHC class-I
expression on CNS oligodendrocytes and neurons/axons (6),
which become potential targets of CD8 T cells. Altogether,
these data suggest that CD8 T cells may be mediators rather
than regulators of CNS inflammation and damage in MS.
Although the loss of oligodendrocytes, the CNS myelin-pro-
ducing cells, is a key feature of MS lesions, the precise contri-
bution of CD8 T cells to oligodendrocyte death and to CNS
demyelination is unknown. It has been shown in vitro that my-
elin-specific CD8 T cells can kill isolated HLA-matched oligo-
dendrocytes (4), but data in vivo are less compelling. Previous
studies have shown that CD8 T cells are necessary for the de-
velopment of a full-blown pathology in animal models of neu-
roinflammation, but their Ag specificity is still unknown (2, 7,
8). Similarly, a role for CD8 T cells in demyelination has been
clearly illustrated in viral models of CNS inflammation, but the
mechanisms involved have remained contentious (9, 10). My-
elin-specific CD8 T cells can adoptively transfer autoimmune
encephalomyelitis but the lesions were reminiscent of ischemic
injury with the demyelination associated with more global tis-
sue damage, and few CD8 T cells actually infiltrated the CNS
parenchyma (11, 12). Therefore, the direct effect of CD8 T
cells on oligodendrocytes and myelin in vivo is not clear.
In this study, to test whether CNS-infiltrating CD8 T cells can
directly induce oligodendrocyte death and demyelination, we de-
veloped amousemodel combining selective expressionof influenza
hemagglutinin (HA) as a neo-self-Ag in oligodendrocytes with
transgenic mice expressing a HA-specific TCR on CD8 T cells.
Materials and Methods
Mice, generation, and characterization of the Rosa-Stop-HA knock-in
mice
The CL4-TCR mouse expresses a TCR specific for the influenza virus
HA512–520 peptide onmost CD8T cells (13). TheMOGi-Cre knock-in mouse
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(where MOG is myelin oligodendrocyte glycoprotein) (14) was backcrossed
10 times on the BALB/c background.
A conditional expression cassette, encompassing the open reading frame of
transmembrane HA placed 3 of a Stop sequence (neoR and a trimer of SV40
polyadenylation sites) flanked by LoxP sites (Fig. 1A), was inserted into the
PacI-AscI sites of the pROSA26PA vector (15). This gene-targeting vector was
then electroporated into 129SV embryonic stem cells. Two embryonic stem cell
clones exhibiting homologous recombination were injected into C57BL/6 blas-
tocysts to generate chimeras that transmitted the Rosa-Stop-HA allele. These
knock-in mice, referred to as Rosa26tm(HA)1Libl, were crossed seven times onto
the BALB/c background.
Cre-mediated recombination of the Rosa26-Stop-HA locus was assessed by
PCR on genomic DNA from different organs. To analyze HA expression, RNA
was extracted using TRIzol, contaminating DNA was removed by DNaseI di-
gestion (Promega), and a quantitative RT-PCR or a nested RT-PCR approach
was followed.
In vitro differentiation, GFP transduction, adoptive transfer of
HA-specific Tc1 cells, and in vivo cytotoxicity
HA-specific Tc1 cells were generated as described and routinely contained
98% pure CD8CD3V8.2 T cells (13). GFP transduction of the HA-
specific Tc1 cells was performed using the pLGFPSN retroviral vector and the
GPE-86 packaging cell line. At day 6, living CD8 T cells were collected by
Ficoll density separation and naive CD8 T cells or Tc1 cells were injected i.v.
into immunocompetent recipient mice. Mice were assessed daily. For in vivo
cytotoxicity, BALB/c mice were injected or not injected with 2  106 HA-
specific Tc1 cells. The next day they all received 20 106HA-pulsed and 20
106 control peptide-pulsed splenocytes stained with a high (CFSEhigh) or low
(CFSElow) concentration of CFSE, respectively. After 24 h, spleens from the
recipient mice were analyzed by flow cytometry.
Histopathology
At the specified time points, mice were perfused with 4% paraformaldehyde in
PBS. Tissues were removed and embedded in paraffin. Five micrometer-thick
sections were stained withH&E and Luxol fast blue/periodic acid Schiff myelin
stain. Immunohistological staining and confocal laser microscope analyses were
performed as described previously (13, 14).
Results and Discussion
Naive HA-specific CD8 T cells are “indifferent” in mice that express
HA as an oligodendroglial neo-self Ag
For this study, we designed amousemodel system ensuring spe-
cific expression of HA in oligodendrocytes by using a double
FIGURE 1. Generation and characterization of DKI mice. A, Schematic
representation of the knock-in mice. Top row, The targeted Rosa26 locus in the
Rosa26tm(HA)1Libl mice contains the LoxP-flanked Stop cassette and the HA
sequence. Filled triangles indicate the LoxP sites.Middle row, The Cre sequence
inserted in the mog gene in MOGi-Cre mice. Bottom row, The Cre-mediated
recombination of the Rosa26 locus inDKImice allows transcription ofHA. P1,
P2, P3, and P4 represent the position of the primers used. B, Cre-mediated re-
combination was assessed by PCR on genomic DNA from different organs using
P1 andP2primers.One representative experiment froma total of three is shown.C,
Transcription of HA in different tissues was assessed by nested RT-PCR using
P1/P2 then P3/P4 primers. Actin was used to evaluate cDNA quality. NoHA sig-
nal was obtained when the reverse-transcription step was omitted. Similar results
were obtained in three different mice per group. Tissue abbreviations: B, brain;
Sc, spinal cord; T, thymus; Sp, spleen; K, kidney; Li, liver. D, Double immu-
nostaining detection of lacZ expression (blue) in oligodendrocytes (CNPase;
red) of a R26R reporter mouse crossed with aMOGi-Cre mouse.White matter
tracts in the corpus callosum (left), spinal cord (middle), and optic nerve (right)
(original magnification: 260) are shown.
FIGURE 2. CD8 T cell indifference in DKI mice and characterization of
effector CD8T cells. A, Gated CD8CD4 lymph node cells fromCL4-TCR
(dotted line) or DKI  CL4-TCR (solid line) mice were stained with Kd:
HA512–520 pentamer (top) or anti-CD62L mAb (bottom). Similar data were ob-
tained for seven mice per group. B, Proliferation of purified CD8T cells from
CL4-TCR (dotted line) or DKICL4-TCRmice (black line) stimulated with
HA512–520 peptide. These results are representative of five independent exper-
iments. C, Following a 6-day culture, the HA-specific CD8 T cells from CL4-
TCR mice differentiated into IFN--producing, granzyme B T cells (left).
Following transduction with a retroviral vector encodingGFP,most of theHA-
specific Tc1 cells were brightly fluorescent at day 6, just before their adoptive
transfer (right).D, The HA-specific Tc1 cells exhibit Ag-specific cytotoxicity in
vivo. The histograms are gated on CFSE-labeled cells; the ratios of CFSEhigh to
CFSElow peaks indicated that the Ag-specific lysis in this experiment was
61.5  2.8% (n  3 mice/group).
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knock-in (DKI) approach. First, we generated mice, referred to
as Rosa26tm(HA)1Libl, in which the HA coding sequence was in-
troduced in the ubiquitously active Rosa26 locus but where HA
transcription was prevented by an upstream LoxP-flanked Stop
cassette (Fig. 1A). The Rosa26tm(HA)1Libl mice were then
crossed with the MOGi-Cre mice (14), which express Cre spe-
cifically in oligodendrocytes (Fig. 1A). The resulting DKI mice
excise the Stop cassette due toMOG-controlled Cre expression,
leading to restricted HA expression to oligodendrocytes. The
DKI mice exhibited no spontaneous phenotype.
PCR analyses of the genomic DNA of DKI and
Rosa26tm(HA)1Libl mice confirmed that Cre-mediated recombi-
nation occurred only in the CNS of DKI mice (Fig. 1B). As a
result, HA transcripts were detected by quantitative RT-PCR
only in the brain, spinal cord, and optic nerve of DKI mice
(data not shown), although HA protein expression in the CNS
was below detection levels using immunohistochemistry.
Moreover, using a sensitive nested RT-PCR approach, HA
RNA was undetectable in extra-neurological tissues (Fig. 1C).
Further indirect evidence of oligodendrocyte specificity of the
transgene expression was provided upon crossing MOGi-Cre
mice with the R26R reporter mice, which are similar in design
to the Rosa26tm(HA)1Libl mice apart from the substitution ofHA
by lacZ. In these mice, LacZ expression was only detected in
oligodendrocytes (Fig. 1D).
Interestingly, we did not observe any neurological signs upon
crossing the DKI mice with CL4-TCR mice (25 CL4-TCR
DKI mice followed for up to 9 mo). Moreover, we did not de-
tect any TCR down-regulation or deletion of HA-specific CD8
T cells, as assessed by Kd:HA512–520 pentamer staining (Fig.
2A). Rather, peripheral CD8 T cells appeared “indifferent” to
HA, as they exhibited mostly a naive phenotype
(CD25CD69CD62LhighCD44intermediate and retained full
proliferative capacity in response to theHA512–520 peptide (Fig.
2, A and B). These data are consistent with a lack of expression
and probably also of cross-presentation of HA in the lymphoid
organs of DKI mice. Therefore, the MOG-driven HA protein
behaves as a sequestered oligodendrocyte Ag in DKI mice.
Transfer of effector HA-specific CD8 T cells into HA-expressing mice
results in CNS inflammation and demyelination
We then decided to test whether effector CD8 T cells can me-
diate oligodendrocyte cell death and demyelination in vivo. Ef-
fector T cells were first generated by in vitro activation of Kd:
HA512–520 pentamer
 CD8 T cells obtained from CL4-TCR
mice using HA peptide, IL-2, and IL-12. The resulting Tc1
cells produce large amounts of granzyme B (GrB) and IFN-
(Fig. 2C, left). These cells exhibit potent cytotoxicity to HA-
loaded target cells in vivo (Fig. 2D).
Next, we transferred these HA-specific Tc1 cells into DKI
and control mice. Following i.v. injection of 3 107 HA-spe-
cific Tc1 cells, but not naive HA-specific CD8 T cells, 40%
of the DKI mice developed an overt monophasic disease peak-
ing at day 8–10 and waning by 4 wk posttransfer. The clinical
manifestations included weight loss and, in the more severe
cases, tremors, reduced mobility, and difficulty to right when
overturned without overt paralysis (Table I). In the littermate
controls, only one animal exhibited weight loss and none devel-
oped any neurological signs (p  0.0004). This Ag-specific,
CD8-mediated disease also provides strong evidence for func-
tional HA protein expression in vivo in DKI mice.
Upon histological analysis, all DKI mice injected with Tc1
cells demonstrated clear CNS pathology from day 5 onwards
(Table I). Parenchymal infiltrates were never observed in con-
trol littermates injected in parallel with HA-specific Tc1 cells.
The pathology of DKI mice was dominant in the optic nerve
(Figs. 3 and 4) and spinal cord (Fig. 4) but also affected fre-
quently the cerebellum, fornix, and periventricular areas of the
brain. Inflammatory lesions were never found in the peripheral
nervous system or in non-nervous tissues. Quantification re-
vealed that T cell infiltration started on day 5 in the spinal cord,
reached its peak on day 9, and declined by day 28 (Fig. 5A). On
Table I. Summary of the clinical and histological signs of Tc1-injected mice
Day of Sacrifice Genotype (No. of Mice) Weight Loss at Day 9a
Spinal Cord Optic Nerve
Inflammation Demyelination Inflammation Demyelination
Day 2.5 DKI (n  3) NAb 0/3 0/3 0/3 0/3
Control micec (n  3) NA 0/3 0/3 0/3 0/3
Day 5 DKI (n  4) NA 4/4 0/4 3/3 1/3
Control mice (n  3) NA 0/3 0/3 0/3 0/3
Day 9 DKI (n  13) 5/13 9/11 0/11 9/9 5/9
Control mice (n  18) 0/18 0/16 0/16 0/16 0/16
Day 18 DKI (n  5) 3/5 5/5 1/5 4/4 4/4
Control mice (n  5) 0/5 0/2 0/2 0/2 0/2
Day 28 DKI (n  5) 2/5 5/5 3/5 4/4 4/4
Control mice (n  9) 1/9 0/9 0/9 0/9 0/9
Day 56 DKI (n  3) 1/3 0/3d 0/3 0/3d 0/3e
Control mice (n  5) 0/5 0/5 0/5 0/5 0/5
a Body weight 95% of the weight before Tc1 injection.
b NA, Not applicable.
c Rosa26tm(HA)1Libl, MOGi-Cre, and nontransgenic littermates.
d Absence of perivascular inflammatory infiltrates but some diffuse tissue infiltration by CD3 cells.
e Focal areas of reduced myelin density with thin myelinated sheaths, suggesting remyelination.
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day 56, there was only mild diffuse infiltration of the CNS by
CD3 T cells. In the optic nerves we found focal areas with
reduced myelin density and thin myelin sheaths, suggesting
remyelination.
We also transferred GFP-transduced Tc1 cells (Fig. 2C,
right), allowing us to trace the CNS-invading, HA-specific
CD8 T cells. Staining for GFP and GrB revealed that HA-spe-
cific Tc1 cells containing GrB granules were detected within
CNS lesions of DKI mice (Fig. 4c). Some of the GrB T cells
were found in close apposition to carbonic anhydrase II (CAII)
or cyclic nucleotide 3-phosphodiesterase (CNPase) oligo-
dendrocytes (Fig. 4, c and d). We also detected Tc1 cells with
polarized GrB granules facing an oligodendrocyte, suggesting
directed degranulation (Fig. 4d). In the inflamed lesions, MHC
class I (2-microglobulin) expression was detected on oligoden-
drocytes (Fig. 5B). The CD8 T cell infiltration was associated
with focal activation of microglia (Fig. 3, h, l, p, and t). Besides
the presence of CD8 T cells and activated microglial cells, le-
sions consisted of CD4 T cells (1–13% of T cells depending on
the time point) and small numbers of B220 B cells (mostly in
the perivascular space).
Oligodendrocyte and myelin pathology was studied on sec-
tions stained for Luxol fast blue, CNPase, andCAII (Figs. 3 and
4). Oligodendrocyte apoptosis, detected by nuclear condensa-
tion (Fig. 3g and Fig. 4, e–h), was present at early time points in
optic nerves and spinal cords of DKI recipients. In the optic
nerve of DKI mice, the number of apoptotic oligodendrocytes
was 6.9  3.5 per section on day 5 and 15.3  4.8 on day 9,
whereas they were virtually absent in control mice. On day 5,
some vacuolization and early demyelination was found in the
optic nerve (Fig. 3e). From day 9 on, most of the animals ex-
hibited extensive demyelination in the optic nerve (Fig. 3, i,m,
and q) and more limited demyelination in the brain and spinal
FIGURE 3. Optic nerve pathology in DKI mice following injection of HA-
specific Tc1 cells. a–d (day 2.5), Staining shows the absence of myelin pathol-
ogy (Luxol fast blue/periodic acid Schiff and CNPase) and of T cell infil-
tration (CD3). e– h (day 5), Large numbers of CD3 cells (f) and activated
microglia (h) have infiltrated the parenchyma. The myelin stain shows some
vacuolization (e) but no demyelination (e and g). Oligodendrocytes with con-
densed nuclei (inset in g) are found, indicating apoptosis. i–l (day 9), Myelin
stains (i and k) reveal vacuolization and some demyelination. The number of T
cells (j) has declined (see Fig. 5A, right), but the MAC-3 staining (l) shows
phagocytic microglia. m–p (day 18), Extensive demyelination is seen in the left
(L) optic nerve (m). Demyelination is ongoing in the right (R) optic nerve, with
myelin degradation products in PAS macrophages. T cells (n) and large
phagocytic cells (p) are still present. The CNPase staining (o) shows some re-
maining oligodendrocytes in the left optic nerve. q–t (day 28), Both optic
nerves show extensive demyelination (q) and ongoing inflammation (r and t).
CNPase staining shows some reactivity in the left optic nerve (s), which may
indicate remyelination. All figures have a100 original magnification with the
exception of q (26), s (70), and the inset in g (1000).
FIGURE 4. Detection of CD8-mediated oligodendrocyte killing in the spi-
nal cords and optic nerves of DKI animals on day 9. a and b, GFP (green) and
CNPase (red) double staining (450). a, SomeGFPHA-specific CD8T cells
lie in close apposition to oligodendrocytes (arrowheads) in the optic nerve. b,
An HA-specific CD8 T cell in contact (arrowhead) with an oligodendrocyte. c
and d, Triple staining for GrB (green), GFP (blue), and CAII (red) (1400). c,
A GrB HA-specific CD8 T cell is next to a row of oligodendrocytes. d, An-
other example of a HA-specific T cell in close apposition to an oligodendrocyte,
with its GrB-containing granules polarized toward the surface of the oligoden-
drocyte. e–h, Staining for oligodendrocytes (green), with TO-PRO-3 nuclear
counterstain. e, One of the CAII oligodendrocytes shows nuclear condensa-
tion (arrowhead), indicative of apoptosis (850). f, Apoptosis (arrowhead) of a
CAII oligodendrocyte in the optic nerve (2000). g, Nuclear condensation
(arrowhead) in a CNPase oligodendrocyte. The inset shows this condensed
nucleus without CNPase staining (1500). h, An oligodendrocyte with nuclear
condensation and fragmentation into apoptotic bodies (1800).
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cord. In addition, staining for nonphosphorylated neurofila-
ment revealed severe axonal damage in active demyelinating le-
sions by day 19 (Fig. 5, C and D). Importantly, Ab-mediated
depletion of CD4 T cells in vivo had no impact on the severity
of CNS inflammation and demyelination (data not shown), ex-
cluding their pathogenic contribution in this model. Collec-
tively, our data show that demyelinating lesions, sharing many
of the attributes of an active MS plaque, can arise when CD8 T
cells target oligodendrocytes.
The experimental system described here allows the clear as-
sessment of the individual role of cytotoxic CD8 T cells by un-
coupling them from other adaptive immune mechanisms. Ge-
netic GFP labeling of the transferred CD8T cells permitted the
unequivocal tracing of theHA-specific CTLs in situ. Strikingly,
we show that numerous HA-specific CD8 T cells enter the
CNS and optic nerve parenchyma and colocalize with oligo-
dendrocytes, with occasional figures of tight apposition be-
tween the two cell types. These data strongly suggest that direct
cell contact-mediated cytotoxicity plays a central role in oligo-
dendrocyte death and demyelination. It is, however, possible
that soluble inflammatory mediators synergize to induce tissue
lesions.
In conclusion, we generated a mouse model to study the con-
tribution of T cell subsets on CNS tissue damage. An analogous
transgenic model has been recently used to investigate CD4 T
cell reactivity toOVA expressed specifically in oligodendrocytes
(16). We focused on oligodendrocyte-specific CD8 T cells be-
cause little in vivo information is currently available regarding
the pathogenicity of this subset and because both CD8 T cell
infiltration and loss of oligodendrocytes are essential features of
MS lesions. The novel finding provided by this study is that
effector CD8 T cells exhibit a potent deleterious effect on oli-
godendrocytes, resulting in an inflammatory demyelinating pa-
thology resembling active MS lesions. The exclusive expression
of HA in oligodendrocytes is very reminiscent of some myelin
self-Ags such as MOG, which are not (or barely) expressed in
the lymphoid tissue and therefore fail to tolerize the T cell rep-
ertoire (17). This carries an obvious risk of activation of auto-
reactive CD8 T cells with subsequent development of autoim-
munity. Collectively, these data reinforce the idea that CD8 T
cells represent relevant therapeutic targets in MS (1, 2).
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FIGURE 5. T cell infiltration and axonal damage in the CNS of DKI mice.
A, Quantification of CD3 T cells in the spinal cord and optic nerve of DKI
mice at different time points after Tc1 cell injection (Table I). B, 2-Micro-
globulin expression by oligodendrocytes in the spinal cord on day 9 (650). C
andD, Axonal injury in demyelinating lesions of the optic nerve, detected with
SMI311 staining nonphosphorylated neurofilaments (250). By day 9 (C)
only some axonal spheroids are present (arrows), whereas at day 18 (D) massive
axonal destruction is observed.
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Results 
 
Neural self-mimicry: Cumulative autoimmunity 
 
Summary 
 
To assess the impact of the limited MOG expression in lymphoid tissues on the 
ontogeny of MOG-reactive T cells we obtained the 2D2 TcR transgenic mice, in which the 
CD4+ T cell population expresses an I-Ab-restricted-TcR specific for the immunodominant 
MOG35-55 peptide and crossed them with MOG-/- mice. We unexpectedly discovered that 
2D2 TcR mice develop spontaneous EAE irrespective of the presence or absence of the 
target self-antigen MOG.   
Therefore we hypothesized, that 2D2 TcR specific for MOG35-55 recognizes a second 
autoantigenic target in the CNS. In order to identify the cross-reactive antigen in MOG-/- 
mice, our collaborators in Germany, fractionated the CNS tissue from these MOG-/- mice 
and this material was presented to 2D2-transgenic T cells. They identified a response of 
2D2 T cells to one of the fraction, which was later found by conventional biochemical 
method and subsequent mass spectrometry, to contain an axonal protein, NF-M, a cross-
reactive agonist for the 2D2 TcR. 
An epitope derived from NF-M (NF-M15-35), when presented in the context of I-Ab, 
has similar TcR contact residues compared to MOG35-55.  Consequently, antigen-
presentation of this epitope permitted the full activation of CD4+ T cells from 2D2 TcR 
transgenic mice. This cross-reactivity extends to other MOG-specific TcR from C57BL/6 
mice. 
To test the in-vivo relevance of these observations, we transferred in-vitro 
differentiated Th1 cells from 2D2-Rag2-/- mice, in C57BL/6, MOG-/- and MOG-/- x NF-M-/- 
mice. We observed no clinical sign of disease in MOG-/- x NF-M-/- mice, while MOG-/- mice 
develop EAE with delayed onset, as compared to C57BL/6 mice, which developed early 
classical EAE.  We referred to this novel observation as ‘cumulative autoimmunity’ to 
designate autoreactive T cells clones that target more than one cognate self-epitope and 
consequently exhibit additive pathogenicity. 
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Myelin-specific T cells also recognize neuronal
autoantigen in a transgenic mouse model of
multiple sclerosis
Gurumoorthy Krishnamoorthy1, Amit Saxena2, Lennart T Mars2, Helena S Domingues1,3, Reinhard Mentele4,5,
Avraham Ben-Nun6, Hans Lassmann7, Klaus Dornmair1,4,9, Florian C Kurschus1,8,9, Roland S Liblau2,9 &
Hartmut Wekerle1
We describe here the paradoxical development of spontaneous experimental autoimmune encephalomyelitis (EAE) in transgenic
mice expressing a myelin oligodendrocyte glycoprotein (MOG)-specific T cell antigen receptor (TCR) in the absence of MOG. We
report that in Mog-deficient mice (Mog–/–), the autoimmune response by transgenic T cells is redirected to a neuronal cytoskeletal
self antigen, neurofilament-M (NF-M). Although components of radically different protein classes, the cross-reacting major
histocompatibility complex I-Ab–restricted epitope sequences of MOG35–55 and NF-M18–30 share essential TCR contact positions.
This pattern of cross-reaction is not specific to the transgenic TCR but is also commonly seen in MOG35–55–I-A
b–reactive T cells.
We propose that in the C57BL/6 mouse, MOG and NF-M response components add up to overcome the general resistance of this
strain to experimental induction of autoimmunity. Similar cumulative responses against more than one autoantigen may have a role
in spontaneously developing human autoimmune diseases.
Organ-specific autoimmune disease is a key group of inflammatory
disorders that includes rheumatoid arthritis, type 1 diabetes mellitus,
thyroiditis and multiple sclerosis. The prevailing thinking is that the
pathogenic changes are typically initiated and driven by T cells, which
express receptors for autoantigens restricted to, or enriched within, the
particular target tissues.
Unfortunately, it has been impossible so far to identify, with
certainty, which autoantigens are the targets in individual humans.
One reason for this limitation is the complexity of the human
autoimmune response. Indeed, there is evidence that in one person
more than one self antigen may be the target of the autoimmune
attack and that, in addition, the profile of target autoantigens may
fluctuate over time1. Furthermore, the peripheral immune repertoire
of healthy humans contains a large number of T cells specific for
many, if not all, autoantigens potentially related to autoimmune
diseases2. There is no practical assay to distinguish T cells with high
pathogenic potential from nonpathogenic counterparts and, more-
over, to identify in humans the T cells participating in the patho-
genesis from those that are uninvolved.
We report here a new mechanism of autoimmunity, ‘cumulative
autoimmunity’, that may provide a solution to this dilemma.
Cumulative autoimmunity designates an autoimmune response that
targets more than one particular cognate autoantigenic target at the
same time, and the accumulation of these responses results in a tissue
attack of enhanced vigor.
We observed a cumulative autoimmune response in transgenic mice
with a TCR selected for reactivity to MOG peptide35–55, who develop
spontaneous EAE in the presence of MOG and, unexpectedly, also in
its absence. We found that in Mog-deficient mice, the transgenic T cells
recognize a peptide fragment of the medium-sized neurofilament NF-M.
RESULTS
Spontaneous EAE in the absence of MOG
In an experiment designed to detail the role of the autoantigen in
spontaneous autoimmunity, we bred transgenes encoding the MOG-
specific TCR 2D2 (ref. 3) and immunoglobulin heavy chain specific
for MOG (IgHMOG) (ref. 4) either separately or together into Mog–/–
mice5 (Fig. 1). To our surprise, spontaneous EAE developed in Mog-
deficient 2D2 transgenic mice (2D2  Mog–/–) with incidence and
kinetics indistinguishable from those of wild-type (WT) counterparts.
Between 15% and 20% of 2D2  Mog–/– mice developed spontaneous
EAE (Fig. 1a and Supplementary Table 1 online). Mog–/– mice and
the Mog-deficient IgHMOG mice (IgHMOG  Mog–/–), whose B cells,
but not T cells, are specific for MOG, remained healthy (Fig. 1a
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and Supplementary Table 1). Fifty percent of double-transgenic
2D2 IgHMOG mice (also known as OSE/Devic mice6) spontaneously
develop opticospinal myelitis3,6, but, in a limited cohort of
MOG-deficient 2D2  IgHMOG mice, fewer than 15% of the mice
developed spontaneous EAE, a proportion similar to the one seen
with Mog-deficient 2D2 mice but substantially lower than that
in 2D2  IgHMOG Mog-sufficient counterparts (Fig. 1a and
Supplementary Table 1).
Clinically, spontaneous EAE was indistinguishable between Mog-
sufficient and Mog-deficient transgenic mice. In all groups, disease
started between 7 and 10 weeks of age, with classical paralytic EAE
signs and, in a minority of cases, with a spastic component (Supple-
mentary Table 1 and Supplementary Movies 1–6 online).
The lesions in Mog-sufficient and Mog-deficient groups were indis-
tinguishable (data not shown), and they were restricted to the optic
nerve and spinal cord6,7. In addition, we have now observed inflam-
matory infiltrates in the trigeminal ganglia, spinal ganglia, spinal roots
and peripheral nerves, despite the absence of MOG within these
tissues (Fig. 1c and Supplementary Table 2 online). However, in
mice immunized with MOG35–55, the acute EAE lesions were present
only in the central nervous system (CNS) and not in the peripheral
nervous system (PNS; Fig. 1d).
2D2-transgenic T cells recognize a non-MOG CNS autoantigen
EAE in the Mog–/– mice might be explained by the incomplete deletion
of Mog. The Mog knockout strain initially used in this study was
created by the insertion of a cassette containing the LacZ and
neomycin resistance genes behind the Mog promoter, leaving the
MOG coding sequence intact5, which could leave some aberrant
MOG expression in 2D2  Mog–/– mice. However, in line with the
original description of the Mog–/– mice5, western blot analyses with
monoclonal as well as polyclonal antibodies did not detect any
residual MOG protein expression in Mog–/– mice (Supplementary
Fig. 1 online). To further exclude faulty MOG expression, we bred
2D2 TCR–transgenic mice with another line of Mog-knockout mice in
which the 5¢ end of MOG exon 2 encoding the immunodominant
MOG35–55 epitope was deleted and replaced by the Cre recombinase
gene (MogCre/Cre)8 (Supplementary Fig. 2 online). 2D2-transgenic
mice crossed onto the MogCre/Cre background also developed sponta-
neous EAE at the same rate as 2D2-transgenic mice (Fig. 1b).
Spontaneous EAE in 2D2  Mog–/– mice could also have been
caused by T cells recruited from the endogenous repertoire or by
T cells with dual TCR expression—expressing both 2D2 and endo-
genous receptor chains. Indeed, whereas in 2D2-transgenic mice most
CD4+ T cells use the transgenic TCR, there is also a considerable
population with endogenous receptors (data not shown). In the
absence of MOG, alternative TCRs might be stimulated to mount
an attack against an alternative CNS target autoantigen. However,
FACS analysis of 2D2 and 2D2  Mog–/– thymus and spleen did not
reveal any considerable differences in cell number or in activation
markers such as CD25, CD44 and CD62 ligand (Supplementary
Fig. 3 online) or MOG-specific forkhead box P3–positive T regulatory
cells (Supplementary Fig. 4 online). In addition, the CNS infiltrates
were predominantly composed of transgenic T cells with only a minor
population of endogenous T cells (Supplementary Fig. 5 online).
Furthermore, we noted spontaneous EAE in two out of six triple-
transgenic Rag2-deficient 2D2  Mog–/– mice (2D2  Mog–/– 
Rag2–/–), whose T cells express exclusively the transgenic TCR,
indicating that transgenic T cells, not endogenous T cells, are the
principal agents in the observed EAE.
Finally, the transgenic TCR might recognize an endogenous cross-
reactive epitope. We tested some of the known encephalitogenic
proteins and peptides such as myelin basic protein (MBP), S-100
calcium-binding protein, beta chain (S100b) and proteolipid protein
(PLP) amino acids 139–151, but none of them activated the
2D2-expressing T cells (Fig. 2a). Then we compared crude myelin
preparations from Mog+/+ and Mog–/– CNS isolated by classical
protocols9,10. Both preparations activated MOG-specific 2D2-expres-
sing cells to a comparable degree when presented by syngeneic bone
marrow–derived dendritic cells (BMDCs) (Fig. 2a) but did not
stimulate ovalbumin-specific OT-II TCR transgenic T cells, which
we used as negative controls. Furthermore, myelin-induced prolifera-
tion of 2D2-transgenic T cells was blocked by antibodies to CD4 and
major histocompatibility complex (MHC) class II but not by antibody
to CD1d or control rat antibodies (Fig. 2b).
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Figure 1 Paradoxical development of spontaneous EAE in MOG-specific 2D2
TCR–transgenic mice in two different Mog-deficient strains. (a) Spontaneous
incidence of EAE-like disease observed in transgenic mice carrying MOG-
specific TCR (2D2), B cell receptor (IgHMOG) or both, on Mog-sufficient and
Mog-deficient C57BL/6 backgrounds. Shown is the survival curve analysis of
the mice that were observed for a minimum of 7 weeks after birth. 2D2,
n ¼ 440; 2D2  Mog–/–, n ¼ 218; 2D2  IgHMOG, n ¼ 258; 2D2 
IgHMOG  Mog–/–, n ¼ 48; IgHMOG  Mog–/–, n ¼ 63; Mog–/–, n ¼ 279.
(b) Incidence of spontaneous EAE in MOG-specific 2D2–transgenic mice
on a Mog-deficient background (different than in a). 2D2, n ¼ 199;
2D2  MogCre/Cre, n ¼ 140; MogCre/Cre, n ¼ 23. (c) Nervous system
pathology of 2D2-transgenic mice with spontaneous EAE. Infiltration,
demyelination and axonal damage in trigeminal ganglia were revealed by
H&E, luxol fast blue (LFB) and Bielschowsky silver impregnation (Biel),
respectively. The infiltrates are composed of macrophages (Mac3) as well
as CD3+ T cells. Scale bars, 100 mm. (d) Nervous system pathology of
C57BL/6 mice immunized with MOG35–55. The acute EAE lesions of CNS
and PNS parts of the trigeminal nerve and ganglion were visualized by
staining for macrophages (Mac3) and CD3+ T cells. The bottom images
show the respective isotype control antibody staining. Scale bars, 100 mm.
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NF-M peptide cross-reacts with MOG-specific T cells
We systematically fractionated CNS tissue from Mog–/– mice (Fig. 3).
We employed a purification regime composed of homogenization,
lipid extraction and purification of the urea-dissolved proteins by ion-
exchange and gel chromatography (Supplementary Fig. 6 online).
Among the chromatography fractions presented to 2D2-expressing
T cells by syngeneic antigen-presenting cells (BMDCs), we eluted
several antigenic fractions from the anion-exchange column (Fig. 3a).
Fractionation of Mog-sufficient CNS tissue led to a similar profile
(Fig. 3b). Parallel fractionation of extracts from WT and Mog–/– CNS
with the cation exchange column yielded similar results (Supplemen-
tary Fig. 7a,b online).
Gel filtration chromatography of both pooled positive fractions
(fractions 16 and 17) from the anion exchange column resulted in one
fraction (fraction 9) that was recognized by 2D2-expressing T cells
(Fig. 4a). SDS-PAGE analysis revealed two prominent bands with
molecular masses of approximately 68 kDa and 150 kDa (Fig. 4b). We
excised both bands from the gel, in-gel digested them with trypsin
and subjected them to matrix-assisted laser desorption-ionization–
time-of-flight mass spectrometry. We identified the 68-kDa protein as
the light chain of mouse neurofilament (NF-L) and the 150-kDa
protein as NF-M.
We tested the exclusive cross-reactivity of the NF-M with MOG-
specific 2D2-transgenic T cells by an analysis of CNS proteins from
NF-M–deficient (Nefm–/–) mice. None of the ion-exchange chroma-
tography fractions from Nefm–/– mice activated 2D2-transgenic T cells
(Fig. 3c and Supplementary Fig. 7c). In addition, we also found that
the crude myelin preparations from both Mog–/– and WT mice that
contained abundant amounts of NF-M (Supplementary Fig. 8a
online), and not those from the Mog–/–  Nefm–/– mice, activated
2D2-transgenic T cells (Fig. 2a and Supplementary Fig. 9 online).
Full-length MOG, which is highly hydrophobic owing to its three
membrane-spanning helices, was found mainly in the urea-insoluble
fraction (data not shown). We detected only trace amounts of
MOG in the urea-soluble extract but not in any of the 2D2-transgenic
T cell–activating fractions from Mog-sufficient mice (Supplementary
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Figure 2 MOG-specific T cells respond to myelin from Mog–/– mice.
(a) Proliferation, as measured by 3H-thymidine incorporation assay, of spleen
cells from 2D2-transgenic or control OT-II mice (2  105 cells per well)
together with BMDCs (5  104 cells per well) cultured with the indicated
proteins, peptides (20 mg ml–1) or myelin preparations (1 ml per well) from
Mog–/– and WT mice. pC1, rat MBP68–84; pC2, guinea pig MBP45–67; p81,
guinea pig MBP69–83. (b) Proliferation, as measured by
3H-thymidine
incorporation assay, of 2D2-transgenic spleen cells together with BMDCs
incubated with rat MOG (20 mg ml–1) or myelin suspension (1 ml per well)
preparations from Mog–/– and WT mice. The antibodies to MHC II (Anti-MHC
II), CD1d (Anti-CD1d) or CD4 (Anti-CD4) or control rat IgG2a and rat IgG2b
antibodies were added at 10 mg ml–1. Proliferation of T cells from a and b
was measured by labeling with 3H-thymidine during the last 16 h of a 72-h
assay. Shown is the mean ± s.e.m. of triplicate measurements. Statistical
significance was analyzed by analysis of variance. ***P o 0.001.
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Fig. 8b). Hence, MOG is lost quantitatively during lipid extraction
and urea solubilization, and these data exclude the presence of
additional cross-reactive antigens, at least in the urea-soluble fraction
we examined.
An in silico search identified a seven–amino acid peptide of NF-M
nearly identical to the core region of the antigenic peptide MOG38–50
(Fig. 4c), which spans from Tyr40 to Val47
and contains the amino acids Arg41, Phe44,
Arg46 and Val47, which are known to be the
crucial contact amino acids for the 2D2 TCR
and other MOG-specific T cell lines11,12.
These amino acids are completely preserved
at identical positions in NF-M18–30; that is,
positions Arg21, Phe24, Arg26 and Val27.
Another candidate peptide, NF-M225–237,
also showed some homology to MOG but
lacked the essential residues of the core
region (Fig. 4c).
2D2 T cells responded vigorously to the
synthetic peptide NF-M18–30 but not to
NF-M225–237 (Fig. 5a). In addition,
NF-M18–30 induced strong proliferation of
2D2  Rag2–/– transgenic T cells, indicating
that the cross-reactivity is intrinsic to the
transgenic 2D2 TCR (Fig. 5b). This cross-
reactivity is not limited to the synthetic
MOG and NF-M peptides. 2D2 T cells also
recognized the naturally processed recombi-
nant MOG and NF-M proteins produced in
E. coli (Fig. 5a,b). Notably, NF-M and MOG
peptides mixed in a 1:1 ratio induced pro-
liferation and cytokine secretion of 2D2-
expressing T cells isolated either from the
spleen or from the CNS of mice with
spontaneous EAE without any signs of toler-
ance or anergy (Fig. 5a and Supplementary
Fig. 10 online).
2D2-transgenic T cell responses to MOG
and NF-M peptides were similar but not
identical. In dose-dependent proliferation
tests, NF-M18–30 peptide was superior to
MOG35–55 and MOG38–50 peptides in indu-
cing proliferation (Fig. 5a,b). We confirmed
this finding in cytokine assays, in which NF-M stimulated larger
interferon-g (IFN-g), interleukin-17 (IL-17), IL-2 and IL-10 releases
than did MOG (Fig. 5c).
To clarify whether the cross-reactivity of 2D2-expressing T cells with
NF-M reflects a ‘private’ clonotypic response (a response by a single
T-cell clone) or represents a more general cross-reactivity between
MOG35–55- and NF-M–specific T cells, we isolated fresh MOG35–55-
specific T cells from C57BL/6 mice, expanded them and tested them
for reactivity with NF-M. Indeed, a polyclonal MOG35–55-specific
a b
Bla
nk 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
0
250
500
750
c MOG35–55
MOG38–50
NF-M18–30
NF-M225–237
Fractions
2D2
3 H
 in
co
rp
or
at
io
n 
(c.
p.m
.)
1,000
22
36
50
64
98
148
250
F9
Af
te
r
co
n
ce
n
tra
tio
n
M E V G W Y R S P F S R V V H L Y R N G K
G W Y R S P F S R V V H L
T E T R S S F S R V S G S
L Q D E V A F L R S N H E
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were pooled and further separated by gel filtration chromatography.
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Figure 5 NF-M reacts specifically with 2D2-transgenic T cells. (a) Proliferation, as measured by
3H-thymidine incorporation assay, of 2D2 splenocytes cultured with increasing concentrations of the
indicated proteins, peptides or mixtures. Shown is a representative of more than three individual
experiments consisting of more than six mice. (b) Proliferation, as measured by 3H-thymidine
incorporation assay, of splenocytes from 2D2  Rag2–/– mice cultured with the indicated proteins and
peptides. Means ± s.e.m. of triplicate measurements are shown. (c) Quantification of cytokines released
by MOG-specific 2D2-transgenic T cells in response to cross-reactive NF-M peptide and protein. 2D2
splenocytes were cultured for 3 d with the indicated peptides and proteins in a dose-dependent fashion.
The concentrations of the cytokines secreted by the T cells were measured in the supernatants in a
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T cell line, which used Va and Vb regions distinct from the 2D2 TCR
(Supplementary Fig. 11a online), readily responded to NF-M18–30 but
not to NF-M225–237 or ovalbumin (Ova) amino acids 323–339
(Fig. 6a). Conversely, T cell lines from NF-M–immunized mice,
also with Va and Vb gene segments different from those in the 2D2
TCR (Supplementary Fig. 11b), cross-reacted with MOG protein and
peptides (Fig. 6b).
In vivo recognition of NF-M by MOG-specific T cells
To determine whether 2D2-transgenic T cells find their alternative
target (that is, NF-M) in vivo during EAE, we transferred MOG
peptide–activated, 2D2-transgenic CD4+ T cells to Rag2–/– or
Rag2–/–  Mog–/– mice. Whereas both recipient groups developed
EAE, in Mog-deficient Rag2–/– mice the disease was delayed (Supple-
mentary Fig. 12 online).
We next examined whether NF-M–activated 2D2-T cells can also
induce EAE. NF-M–activated 2D2-expressing T cells triggered EAE in
WT hosts, which by incidence and kinetics was comparable to EAE
caused by MOG-activated 2D2-expressing T cells (Supplementary
Fig. 13a,b online). To assess the impact
of soluble MOG peptide tolerization, we
transferred in vitro MOG peptide–activated
2D2-transgenic T cells into irradiated WT
or Mog–/– mice and injected Ova323–339 or
MOG35–55 peptides intravenously. We
observed that treatment with MOG peptide
delayed the onset of EAE in WT C57BL/6
recipients and, more notably, also in Mog–/–
mice (Supplementary Fig. 13a). Similarly,
MOG peptide tolerization lowered the
encephalitogenic activity of 2D2-expressing
T cells activated in vitro with NF-M peptide
(Supplementary Fig. 13b).
Furthermore, we tested the encephalito-
genic potential of ‘genuine’ NF-M–specific
T cell lines, that is, CD4+ T cells isolated
from NF-M–primed C57BL/6 mice and pro-
pagated by serial NF-M–specific activation.
T cells from an NF-M–specific line trans-
ferred to C57BL/6 mice induced severe EAE
(Fig. 6c). The pathology in these mice was
closely similar to that seen after transfer of
2D2-expressing cells in MOG-deficient mice.
Lesions were most pronounced in the spinal
cord and featured inflammation by T cells
and macrophages (Fig. 6c), confluent demye-
lination and severe axonal loss (data not
shown). We transferred NF-M peptide–
activated transgenic T cells derived from
2D2  Rag2–/– mice into both Mog–/– and
WT mice. These monoclonal 2D2  Rag2–/–
T cells induced EAE in Mog–/– mice, albeit
with a delayed onset as compared to WT
recipients, confirming the autonomous cap-
ability of 2D2-expressing T cells to recognize
the alternative target, NF-M (Fig. 6d).
The lesions developing in Mog–/– recipient
mice injected with 2D2  Rag2–/– T cells
were severe, with large infiltrates in the spinal
cord and cerebellum (Fig. 6d) and, remark-
ably, also in the trigeminal ganglia and in
peripheral nerves (data now shown). These findings are reminiscent of
the pathology seen in the spontaneous EAE of 2D2  Mog–/– mice.
To confirm that the 2D2-transgenic T cell–mediated lesions in
the Mog–/– recipient mice are due to in vivo recognition of NF-M,
we transferred activated 2D2  Rag2–/– T cells into Mog–/–  Nefm–/–
double-knockout mice. None of the double-knockout mice showed
any clinical signs of EAE, and there were no lesions in the CNS
(Fig. 6d).
DISCUSSION
C57BL/6 mice are resistant to the induction of most T cell–mediated
organ-specific autoimmune diseases. In these mice, immunization
with classical autoantigens elicits vigorous T cell responses but
commonly fails to produce a clinical autoimmune disease. In contrast,
immunization with MOG35–55 peptide reliably induces clinical EAE,
thus overcoming resistance of C57BL/6 mice13. Our observations may
provide an unexpected clue explaining the unusual autoimmune
potential of MOG35–55. We show that CD4
+ T cells selected from
C57BL/6 mice for reactivity to MOG35–55 also respond to an epitope
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microglia. Scale bars, 100 mm. (d) EAE induced by 2D2 T cells in WT C57BL/6 and Mog–/– but not in
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knockout (n ¼ 9) C57BL/6 mice. Left, EAE clinical score of mice from three (WT, Mog–/–) or two
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Right, representative images comprising inflammatory infiltrates in the spinal cord of Mog–/– and
Mog–/–  Nefm–/– mice revealed by H&E, CD3 and Mac3 staining. Scale bars, 1 mm.
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of the medium-sized neurofilament, NF-M. We propose that the
combined response to the two target structures may overcome the
innate resistance of C57BL/6 mice to autoimmune diseases.
It has previously been reported that the 2D2-transgenic C57BL/6
mice that harbor large populations of MOG-specific CD4+ T cells tend
to spontaneously develop optic neuritis and EAE3. This trend
is markedly increased in the presence of MOG-specific transgenic
B lymphocytes6,7. Paradoxically, however, as reported here, 2D2 mice
develop spontaneous EAE also in the absence of MOG, the primary
encephalitogenic target.
This was discovered in mice with disrupted exon 1 of the Mog
gene5, and it was confirmed in another cohort of Mog-deficient 2D2-
transgenic mice, whose Mog gene was deleted by an independent
knock-in strategy8, excluding residual, atypical MOG material in these
knockout animals as a possible encephalitogenic target.
We fractionated CNS tissue from Mog-knockout mice and found
material that was presented to and recognized by 2D2-transgenic
T cells. We identified the autoantigenic component, by classical
biochemical methods and subsequent mass spectrometry, as NF-M.
The salient target epitope of NF-M was finally determined by an
in silico search for sequences related to the MOG35–55 motif recognized
by the 2D2 clone11. Given the marked degeneracy of peptide recogni-
tion by T cells14, cross-reaction of NF-M by 2D2 at the peptide level
may not be very unexpected. However, less trivially, we confirmed NF-
M as the stimulatory autoantigen at the protein level using both CNS
white matter protein extracts and recombinant proteins.
Neurofilaments, including NF-M, are produced by neurons and
also by some glial cells15. They were characterized recently as auto-
antigens in actively induced EAE and as possible targets in multiple
sclerosis, too. Immunization of Biozzi ABH (antibody high, AB/H,
ABH) mice with the light form of neurofilament, NF-L, causes EAE in
a moderate proportion of treated animals16. Also, autoantibodies to
NF-M have been detected in the cerebrospinal fluid of some indivi-
duals with multiple sclerosis17.
The CD4+ T cell repertoire of 2D2-transgenic mice is dominated by
the transgenic, MOG-reactive TCR but is by no means monoclonal.
The NF-M–specific response could have been effected either by T cells
from the residual endogenous repertoire or by T cells that escaped
allelic exclusion and use endogenous TCR chains along with the
transgenic one. We ruled out both possibilities, as 2D2-expressing
T cells from Rag2-knockout mice showed a similar heteroclitic
(stronger) cross-recognition of NF-M in vitro and in vivo, indistin-
guishable from their Rag2-sufficient counterparts. Furthermore, we
observed spontaneous EAE in 2D2  Rag2–/–  Mog–/– mice, suggest-
ing the autonomous role of transgenic T cells in the cross-recognition.
EAE was readily mediated by T cell lines selected for reactivity to
either MOG (2D2) or NF-M and by 2D2-expressing T cells activated
by NF-M. In contrast, we were unable to induce disease by immuniza-
tion with NF-M using protocols that allow active disease induction by
MOG35–55 (data not shown). This discrepancy between active and
passive EAE induction is, however, not exceptional. It has been
previously described for other models, including EAE induced in
Lewis rats by glial fibrillary acidic protein18 and S100-b19 and
MBP-induced EAE in BALB/c mice20.
Autoimmune cross-reactivity between MOG and NF-M has been
discovered and analyzed in one clonal model, 2D2-transgenic T cells,
but has been confirmed in other I-Ab–restricted MOG- and
NF-M–specific CD4+ T cells. MOG- or NF-M–primed polyclonal
T cell populations isolated from WT C57BL/6 mice show extensive
cross-reactivity between NF-M and MOG proteins and their salient
epitopes, respectively. Of note, these populations rarely use Va3.2 and
Vb11, the variable chains used by the 2D2 clone, indicating that MOG
and NF-M cross-reactivity is not limited to the 2D2 TCR.
Our in vitro results formally establish the cross-reactivity of 2D2 and
other MOG35–55 peptide–specific T cells with NF-M, but do these
T cells respond to NF-M in vivo, and might there be additional cross-
recognized autoantigens? In vivo NF-M–specific responses are suggested
by several lines of evidence. We found lesions in trigeminal and spinal
ganglia, tissues which even in WT mice are devoid of MOG autoantigen
but contain NF-M. Furthermore, 2D2  Rag2–/– T cells transferred into
Mog–/–  Nefm–/– double-knockout recipients failed to develop EAE.
This latter observation, together with the loss of autoantigenic potential
of myelin from double-knockout white matter, also rules out unknown
autoantigens acting in addition to MOG and NF-M.
How would cross-reactive T cells respond to the simultaneous
presence of both MOG and NF-M? Would the response components
add up or would there be tolerization? Several observations suggest
that MOG35–55-specific T cells respond both to the MOG epitopes as
well as to the cross-reactive NF-M epitopes at the same time. In vitro,
T cells isolated from CNS and spleen respond to both antigens in an
additive fashion. In vivo, transfer of activated 2D2-expressing T cells
caused substantially earlier appearance of EAE in Mog-sufficient mice
compared to Mog–/– mice. Also, the clinical picture of Mog-sufficient
and Mog-deficient 2D2-transgenic mice is very similar. However, a
selective anti-MOG response component seems to prevail in trans-
genic mice with transgenic TCRs plus B cell receptors. In the presence
of MOG, in T-B double-transgenic mice the incidence of spontaneous
EAE rises to rates of 50% and more. In the absence of MOG,
these double-transgenic mice develop EAE at proportions similar
to their single-TCR transgenic counterparts. The MOG-dependent
elevation of spontaneous EAE frequency, noted in double-transgenic
2D2  IgHMOG mice6, is not seen in the absence of MOG.
To our knowledge, this is the first description of immunological
self-mimicry, that is, the response of one T cell population to two
independent target autoantigens in the same tissue, MOG and NF-M.
Is such a response an exception to the norm or is it common? As
mentioned, the MOG and NF-M response does not seem to be unique
to the MOG-reactive 2D2 clone studied here but is also noted in
polyclonal MOG- and NF-M–reactive T cell populations from C57BL/6
mice. Furthermore, another case of self mimicry, though between
structures from different tissues was reported by another group, who
described in the Dark Agouti (DA) rat cross-reaction between MOG-
specific T cells and an epitope of the milk protein butyrophilin21.
The dual response of T cells against two target autoantigens expressed
within the same target tissue could have major implications for organ-
specific autoimmune disease. It could have an additive role in deter-
minant spreading (development of an immune response distinct from
the initial disease-causing epitope) in the course of an autoimmune
response. Beyond this, we propose that in C57BL/6 mice autoimmune
response components directed against MOG and NF-M may accumu-
late to overcome the general resistance of these mice to induction of
EAE. T cells with similar cumulative double self-reactivity could act as
dominant pathogens in human multiple sclerosis, and genetic factors
favoring bireactive T cells would enhance susceptibility to the disease.
This study should provide a way to identify such T cells in humans and
appreciate their role in the pathogenesis of multiple sclerosis.
METHODS
Methods and any associated references are available in the online
version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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ONLINE METHODS
Transgenic mice. We bred MOG-specific TCR transgenic mice (2D2)3 and
B cell knock-in IgHMOG (also known as Th)4 on a C57BL/6 background into
Mog–/– mice5 to obtain 2D2  Mog–/– and IgHMOG  Mog–/– and 2D2 
IgHMOG  Mog–/– mice. We obtained WT C57BL/6 mice from the animal
facility of the Max Planck Institute of Biochemistry. We bred Rag2–/– mice and
OT-II mice (Jackson Laboratories) in the conventional animal facilities along
with other transgenic mice. We bred a second Mog–/– strain (MogCre/Cre)
harboring the insertion of the gene encoding Cre recombinase in the first
exon of Mog8 with the 2D2-transgenic mice in the specific pathogen–free
animal facility of Institut Fe´de´ratif de Recherche (IFR30). We also maintained
Nefm–/– mice22 in the specific pathogen–free animal facility of IFR30.
We routinely monitored a cohort of transgenic mice of the above genotypes
at least one or two times a week for clinical EAE signs. The EAE disease scores
were according to the classic scale6. To determine other neurological abnorm-
alities, we lifted the mice by their tail and allowed them to grab the grid of a
cage by their front limbs (see Supplementary Movies 1–6). We noted the
clasping and hyperextension of hind limbs within 10–30 s of holding them by
the tail.
All animal procedures were in accordance with guidelines of the Committee
on Animals of the Max Planck Institute of Neurobiology or the Midi-Pyre´ne´es
Ethic Committee on Animal Experimentation and with the license of the
Regierung von Oberbayern (or from the French Ministry of Agriculture).
Peptides and proteins. Mouse MOG35–55 (MEVGWYRSPFSRVVHLYRNGK),
mouse MOG38–50 (GWYRSPFSRVVHL), mouse NF-M18–30 (TETRSSFSRVSGS),
mouse PLP139–151 (HSLGKWLGHPDKF), Ova323–339 (ISQAVHAAHAEINEAGR),
mouse MOG90–110 (SDEGGYTCFFRDHSYQEEAA), rat MBP pC1 (MBP68–84)
(HYGSLPQKSPRSQDENPV), guinea pig MBP pC2 (MBP45–67) (GSDRAAP
KRGSGKDSHHAARTT) or guinea pig MBP p81 (MBP69–83) (YGSLPQKSQR
SQDEN) were synthesized either by BioTrend or by the core facility of Max
Planck Institute of Biochemistry. We obtained mouse NF-M225–237 (LQDEVA
FLRSNHE) from Metabion. We purified the peptides by HPLC to 495%
purity and analyzed them by mass spectrometry.
We purified recombinant soluble rat MOG protein (MOG1–125)
23, mouse
full-length NF-L and mouse head domain fragment of NF-M (NF-M ‘head’;
NF-M1–102) (Supplementary Methods online) from bacterial inclusion bodies.
We purchased S100b and ovalbumin from Sigma. We purified guinea pig MBP
and rat MBP using standard protocols.
Histology. We perfused mice with 4% paraformaldehyde in PBS and stored
them in the same fixative for 24 h. We stained adjacent serial sections of CNS
and PNS with H&E, luxol fast blue or Bielschowsky silver impregnation. We
also stained some sections with CD3-specific (Serotec) and Mac3-specific (BD
Biosciences) antibodies. We stained adjacent sections with the respective
isotype controls.
Adoptive transfer EAE. For 2D2  Rag2–/– T cell transfer, we purified CD4+
T cells from 2D2  Rag2–/– mice and stimulated them in vitro with 20 mg ml–1
of NF-M15–35 peptide in the presence of 20 ng ml
–1 IL-12 and 1 ng ml–1 IL-2
(both from R&D Systems) and irradiated syngeneic splenocytes. On day 6, we
re-stimulated viable cells with splenocytes and 20 mg ml–1 of NF-M15–35 in
the presence of 20 mg ml–1 IL-12 and 1 mg ml–1 IL-2. On day 9, we
injected Ficoll-purified T helper type 1 cells into lightly irradiated (300 rad)
syngeneic recipients.
Myelin purification. We purified crude myelin from Mog–/–, WT C57BL/6 or
Mog–/–  Nefm–/– CNS tissues according to previously published protocols9,10.
Briefly, we pooled brain and spinal cord and homogenized it in 0.32 M sucrose
in 10 mM Tris HCl, pH 7.4. Then we centrifuged at 15,000g and washed the
pellet twice with 0.32 M sucrose solution. Finally, we suspended the pellet in
0.32 M sucrose and overlaid on to 0.85 M sucrose and centrifuged at 26,000g.
We collected the myelin at the interface, washed it twice and suspended it in
1 ml of sterile PBS.
Proliferation assay. For the analysis of fractions from biochemical separations,
we mixed spleen cells from 2D2 or OT-II mice (2  105 cells) with
LPS-activated BMDCs from WT C57BL/6 mice (5  104 cells) together with
1 in 50-diluted fractions.
Unless otherwise mentioned, in all other T cell proliferation experiments, we
cultured 2  105 spleen cells with 20 mg ml–1 peptides and proteins. We
performed all proliferation assays in triplicate. We measured the T cell
proliferation by the incorporation of 3H-labeled thymidine during the last
6 h of a 48-h culture or the last 16 h of a 72-h culture.
Enzyme-linked immunosorbent assay. We assayed cell culture supernatants
with antibody pairs or kits for IFN-g, IL-2 (both from BD Biosciences), TNF-a
(Peprotech), IL-10 (R&D Systems) or IL-17 (eBioscience) according to the
manufacturer’s instructions.
T cell lines. We established antigen-specific T cell lines from C57BL/6 mice
immunized with MOG35–55, NF-M15–35 or NF-M ‘head’ in complete Freund’s
adjuvant supplemented with 5 mg ml–1 Mycobacterium tuberculosis (strain
H37Ra) using established protocols. We collected spleen and draining lymph
nodes 10–12 d after immunization and stimulated them with respective antigen
at 20 mg ml–1. We supplemented T cell cultures with recombinant mouse IL-2
(Peprotech) and supernatant from concanavalin A–stimulated mouse spleen
cells on days 0, 3 and 5. We purified live T cells by Nycoprep gradient (Progen
Biotechnik) and repeated stimulation every 7–10 d.
Statistical analyses. We analyzed spontaneous EAE incidence by Kaplan-Meier
survival curve analysis, and we analyzed adoptive transfer EAE data and
proliferation assays by analysis of variance. We used GraphPad Prism for all
statistical analyses. We considered P values less than 0.05 to be significant.
22. Jacomy, H., Zhu, Q.Z., Couillard-Despres, S., Beaulieu, J.M. & Julien, J.P. Disruption
of type IV intermediate filament network in mice lacking the neurofilament medium
and heavy subunits. J. Neurochem. 73, 972–984 (1999).
23. Amor, S. et al. Identification of epitopes of myelin oligodendrocyte glycoprotein for the
induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice.
J. Immunol. 153, 4349–4356 (1994).
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Supplementary Figure 1. Western blot analysis of brain and spinal cord homogenates from Mog–/–
and wild type (Wt) mice. Equal amounts of CNS homogenates were resolved on a 12.5% Tris-
Glycine gel and probed with rabbit antibody to MOG (N-terminal). The membrane was stripped and
re-probed with β-actin-specific antibody. The protein bands were visualized by ECL system. #1, #2-
wild type mice and #3 and #4-Mog
–/–
mice. β-actin is shown for loading control for homogenates.
Supplementary information:
Myelin-specific T cells co-recognize neuronal autoantigen in a transgenic mouse
model of multiple sclerosis
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Supplementary Figure 2. Sequence of the targeted locus in the Mog–/– mice (Hövelmeyer et al.,
2005). The Cre-recombinase was inserted in the Mog locus with concomitant deletion of exon 1 and
part of exon 2. The coding sequence of the MOG 35–55 was highlighted in red. Arrows delimit the
sequence which was deleted after homologous recombination.
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Supplementary Figure 3. Genetic ablation of Mog does not alter the development and activation
status of MOG-specific transgenic T cells. (a) Splenic and thymic cell numbers from age matched
2D2 and 2D2 x Mog–/– mice. n= 3–4 per group. (b) Representative FACS plot of thymic CD4 and
CD8 staining. Thymic cells from 2D2 (top panel) and 2D2 x Mog–/– (bottom panel) mice were stained
with fluorochrome labeled CD4 and CD8 antibodies. Numbers indicate the percentage of cells in the
respective quadrant. (c) Thymic T cell subsets. Thymic cells were stained as in b and the frequency
of the CD4
+
, CD8
+
, CD4
+
CD8
+
(DP; double positive), CD4
-
CD8
-
(DN; double negative) cells were
determined. n = 3– 4 per group. (d) and (e) Frequency and expression of activation markers in T
and B cells. Spleen cells from 2D2 and 2D2 x Mog
–/–
mice were stained with the indicated
antibodies. Frequency of the cells expressing the indicated lineage or activation markers was
plotted. n = 3 mice per group. The figures show mean ± s.e.m. Statistical significance was analyzed
by ANOVA. n.s; not significant
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Supplementary Figure 4. Genetic ablation of MOG does not alter the frequency and absolute
number of 2D2 Foxp3+ regulatory T cells. (a) Representative FACS plot illustrating the frequency of
Foxp3+ cells amongst TCR-Vα3.2+Vβ11+ 2D2 CD4+ peripheral T cells from age-matched 2D2 (left
panel) and 2D2 x Mog–/– (right panel) mice (n = 3 mice per group). (b) Absolute numbers of CD4+
2D2 T cells (left panel) and of regulatory Foxp3
+
CD4
+
2D2 T cells (right panel) in the spleen of age-
matched 2D2 and 2D2 x Mog
–/–
mice (n = 3 per group). n.s; not significant
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Supplementary Figure 5. CNS infiltrating mononuclear cells from sick 2D2 (a) and 2D2 x Mog–/– (b)
mice predominantly contain transgenic T cells. CNS mononuclear cells were isolated by percoll
gradient and stained with fluorochrome labeled antibodies. T cells expressing TCR transgenes
(V3.2, V11) were analyzed on the CD4+CD8- gated cells. Numbers indicate the percentage of
cells in the respective quadrant.
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Supplementary Figure 6. Fractionation scheme of CNS proteins from Mog–/–, WT and Nefm–/–
mice. Flow chart of the strategy applied to purify the CNS proteins. CNS tissues were homogenized,
de-lipidated, and solubilized in urea. Mog, a transmembrane protein is found in the urea-insoluble
fraction. Urea-soluble material was used for ion-exchange chromatography and tested for T cell
activating potential and finally separated with gel filtration. The positive fractions were separated by
SDS-PAGE and proteins were identified by mass spectrometry.
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Supplementary Figure 7. Cation exchanger fractions from wild type and Mog–/– but not Nefm–/–
mice showed similar activation profiles. (a) Mog–/–, (b) WT C57BL/6 and (c) Nefm–/– mice CNS
tissue extracts were separated through a Source S column and fractions were tested in a T cell
proliferation assay (4 l/well) using 2D2 or OT-II spleen cells as responders. T cell proliferation of
was measured by labeling with
3
H-thymidine during the last 16 h of 72 h assay. Shown is the mean
± s.e.m of triplicate measurements representative of two individual protein purifications (with
different pools of Mog
–/–
mice, WT mice or Nefm
–/–
mice) and stimulation experiments. c.p.m, counts
per minute.
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Supplementary Figure 8. Localization of NF-M and MOG in CNS extracts and in the ion-exchange
chromatography fractions. (a) CNS homogenate, urea-soluble extracts and crude myelin from Mog–/–
, WT and Nefm–/– mice were separated on a SDS-PAGE and probed with NF-M specific antibody.
The same membrane was stripped and re-probed with antibody to GFAP antibody. Myelin, whole
homogenate and urea-soluble extracts from WT and Mog
–/–
mice contained abundant amounts of
NF-M whereas Nefm
–/–
mice CNS urea extract was devoid of any detectable NF-M protein. Anti-
GFAP immunoblot shows the presence of similar amounts of GFAP protein in all the urea extracts
and in the crude myelin of the WT and Mog
–/–
mice. (b) Whole CNS homogenate, urea soluble
proteins and fractions of the ion-exchange chromatography from WT mice were separated on a 10%
Tris-Glycine gel. Equal volumes of the fractions were loaded on the gel. Antibody to MOG (N-
terminal) was used to probe for MOG. The protein bands were visualized by ECL system.
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Supplementary Figure 9. Mog–/– x Nefm–/– myelin do not contain 2D2 T cell activating material.
Spleen cells from (a) 2D2 or (b) control OT-II mice (2 x 105 cells/well) together with irradiated
syngenic BM-DCs (5 x 104 cells/well) were cultured with the indicated myelin preparations (3, 1 or
0.3  l/well) from Mog–/–, WT and Mog–/– x Nefm–/– mice. Proliferation was measured by 3H-thymidine
incorporation assay. While myelin preparations from WT and Mog
–/–
mice stimulated 2D2 and not
control OT-II T cells in a dose dependent manner, myelin from Mog
–/–
x Nefm
–/–
mice failed to
activate 2D2 T cells. c.p.m, counts per minute.
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Supplementary Figure 10. CNS-infiltrating T cells from sick 2D2 mice respond to both NF-M and
MOG. (a) The mononuclear cells were isolated from pooled brain and spinal cords of sick 2D2
transgenic mice by percoll gradient. 5 x 104 mononuclear cells were mixed with 2 x 105 irradiated
spleen cells from C57BL/6 mice. Cultures were added with 20 μg ml-1 of MOG 38–50, NF-M 18–30,
Ova 323–339 or 1:1 mixture of MOG and NF-M peptides. T cell proliferation was measured by
3
H-
thymidine incorporation during the last 16 h of 72 h assay. The figure shows mean ± s.e.m of
triplicate measurements. c.p.m, counts per minute (b) CD4
+
T cells were isolated from percoll
purified CNS-infiltrating mononuclear cells of sick 2D2 transgenic mice (n = 3). 2 x 10
4
CD4
+
T cells
were cultured with 12.5 x 10
4
irradiated T cell-depleted C57BL/6 splenocytes. The cultures were
stimulated with either 10 g ml
-1
of MOG 35–55, 10 μg ml
-1
of NF-M 15–35, or a 1:1 mixture of both
peptides. Unstimulated (blank) cultures were used as controls. IFN- and IL-17A secretion was
measured in culture supernatants after 72 h. The histogram presents the mean  s.e.m of triplicate
measurements.
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Supplementary Figure 11. TCR repertoire analysis of a MOG 35–55 specific and NF-M specific T
cell lines. (a) MOG 35–55 specific (b) NF-M specific T cell lines were generated from WT C57BL/6
after immunization and repeated rounds of in vitro stimulation with MOG 35–55 or rNF-M. TCR
expression was analyzed using V & V screening panel antibodies by FACS. Shown are the % live
cells expressing the indicated TCR chain. The T cell lines were primarily of CD4
+
phenotype.
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Supplementary Figure 12. 2D2 T cells induce EAE in Mog–/– mice. Transgenic 2D2 spleen cells
were polarized in vitro into Th1 and Th17 cells as described in methods. Th1 and Th17 cells were
mixed at 1:4 ratio. 5 x 106 mixed cells were transferred i.v to Rag–/– (n = 4) or Rag–/– x Mog–/– (n = 4)
recipients and clinical EAE was monitored. The experiment was repeated once with similar results.
Statistical significance was analyzed by ANOVA. **p<0.01, *** p<0.001.
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Supplementary Figure 13. Tolerance induced by high dose soluble MOG inhibits 2D2 T cell
induced EAE. 2D2 spleen cells were stimulated with MOG 35–55 (a) or NF-M 18–30 (b) and
polarized in vitro into effector Th1 and Th17 cells. 3 - 5 x 106 mixed cells (Th1:Th17; 1:4) were
transferred i.v to irradiated WT C57BL/6 mice (B6) or Mog–/– mice (n = 3 per group) and these mice
injected with 100μg of the indicated peptide i.v on days 1, 3 and 5. Clinical signs of EAE were
monitored in these groups of mice. MOG 35–55 peptide treatment delayed the EAE onset in WT and
Mog
–/–
recipients in both MOG and NF-M stimulated 2D2 T cell induced EAE.
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Strain Clinical signs Incidence Onset
(weeks)
2D2 EAE 62/440
Clasping & hyperextension of limbs 7/440
EAE + clasping & hyperextension 13/440
Total signs 82/440 (18.6%) 7.2 ± 2.1
2D2 x Mog
–/–
EAE 27/218
Clasping & hyperextension of limbs 6/218
EAE + clasping & hyperextension 7/218
Total signs 40/218 (18.3%) 8.1 ± 1.9
2D2 x IgH
MOG
EAE 141/258 (54.7%) 7.8 ± 5.4
2D2 x IgH
MOG
x Mog
–/–
EAE 4/48
Clasping & hyperextension of limbs -
EAE + clasping & hyperextension 3/48
Total signs 7/48 (14.5%) 10.2 ± 3.8
IgH
MOG
x Mog
–/–
NA 0/63 (0%) NA
Mog
–/–
NA 0/279 (0%) NA
Supplementary Table 1. Neurological abnormalities observed in transgenic mice.
Mice of the indicated genotypes were monitored regularly for the appearance of signs of EAE, hind
limb clasping and spasticity (hyperextension of the hind limbs). Clasping and hyperextension were
noted when the mice were lifted by their tail. Mice that were observed for a minimum of 7 weeks
after birth were included in the analysis. The onset of clinical signs were expressed as postnatal
weeks  SD. NA- Not applicable
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Animal
No
Genotype
Clinical
score
Other neurological symptoms SC Inf SC DM Brain Inf Brain DM PNS
7778 2D2 0 - 0.1 PV FO, 0 TG, RO
10106 2D2 0 - 0 0 0 0 0
9916 2D2 1 hind limb clasping/hyperextension M dors 2 M, Trig Trig TG, RO
9911 2D2 1 hind limb clasping/hyperextension M dors 1 M, Trig 0 TG, RO
9399 2D2 1.5 hind limb clasping 0 0 FO, ON ON 3 RO
9912 2D2 1.5 hind limb clasping/hyperextension 0.2 dors 2 ON ON 3 TG, RO
9408 2D2 4 - 0.8 3 ON ON 3 TG, RO
7961 2D2 4 - 2.3 2 M, ON 1 TG, RO
7682 2D2 x Mog
–/–
0 - 0 0 0 0 0
9364 2D2 x Mog
–/–
0 - 0 0 0 0 0
9337 2D2 x Mog
–/–
0 - 0 0 0 0 0
9369 2D2 x Mog
–/–
0 hind limb clasping/hyperextension 0 dors 1 0 0 TG, RO
9366 2D2 x Mog
–/–
0 hind limb hyperextension 0.1 0 0 0 TG, RO
9567 2D2 x Mog
–/–
1 hind limb clasping 0 0 ON 0 TG, RO
7678 2D2 x Mog
–/–
2 - 2.1 3 Cer 0 0
9352 2D2 x Mog
–/–
2.5 Front limb extension 0.3 2 ON ON 3 TG, RO
7767 2D2 x Mog
–/–
4 - 0.3 2 ON ON 3 TG, RO
7763 2D2 x Mog
–/–
4 - 5 4 Cer 0 TG, RO
9730 2D2 x Rag
–/–
X Mog
–/–
3.5 - 0.1 2 Cer Cer 2 RO
10062 2D2 x IgH
MOG
x Mog
–/–
1 hind limb clasping/hyperextension 0 dors 1 0 0 TG, RO
9693 2D2 x IgH
MOG
x Mog
–/–
1 hind limb clasping/hyperextension 0 dors 1 0 0 TG, RO
9363 2D2 x IgH
MOG
x Mog
–/–
3.5 - 0.4 3 Trig, ON ON 4 Trig 3 TG, RO
10053 2D2 x IgH
MOG
/ IgH
MOG
x Mog
–/–
0 hind limb clasping/hyperextension 0 0 0 0 TG, RO
9038 Mog
–/–
0 - 0 0 0 0 0
9362 Mog
–/–
0 - 0 0 0 0 0
Supplementary Table 2. Histological analysis of CNS and PNS in transgenic mice.
Mice of the indicated genotypes and clinical phenotypes were analyzed for the histological signs of inflammation and demyelination
in the CNS and PNS. SC Inf: Perivascular infiltrates and SC cross section; DM1: single perivascular fibers demyelinated; DM2:
perivascular or subpial DM; DM3: profound confluent DM (1/3 to half of spinal cord, one optic nerve); DM4: extensive demyelination
(more than half of SC cross section, both optic nerves); Dors 1–2: demyelination exclusively in superficial dorsal column (probably
secondary Wallerian degeneration due to pathology in spinal roots); M: meninges; Trig: central protion of trigeminal root; FO: fornix;
ON: optic nerve; Cer: cerebellum; Obl: oblongata; PNS: inflammation and damage in peripheral nervous system; TG: trigeminal
ganglia; RO: spinal roots
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Supplementary methods 
Intracellular staining 
For intracellular cytokine staining, we stimulated T cells for 4 h with PMA (50 
ng ml–1), ionomycin (500 ng ml–1) and Brefeldin A (5 μg ml–1) (Sigma Aldrich). We 
first stained extracellularly with PercP-conjugated CD4-specific antibody (RM4-5), 
fixed and permeabilized with 2% paraformaldehyde and saponin buffer. Then we 
stained intracellularly with FITC or allophycocyanin (APC)-conjugated antibody to 
IFN-γ (XMG1.2) and PE-conjugated antibody to IL-17 (TC11-18H10) (all from BD 
Pharmingen). We acquired Samples on a FACSCalibur (BD Biosciences) and 
analysed with CellQuest software (BD Biosciences). 
 
Purification of CNS proteins by chromatography 
We pooled brain and spinal cord from Mog–/–, Nefm–/–, or WT mice (5 mice each), 
homogenized in 5 ml water and 45 ml chloroform/methanol (1:2). We constantly 
stirred the homogenates overnight at 4 °C. We centrifuged the sample, removed the 
aqueous and chloroform phase, and the insoluble material was lyophilized. We 
dissolved the de-lipidated, lyophilized CNS material in 6 M urea, 20 mM NaCl, in 20 
mM phosphate buffer and centrifuged. We subjected urea-soluble proteins to cation 
(“Source S”) or anion (“Source Q”) exchange column chromatography at a flow rate 
of 1 ml min–1. We eluted Bound proteins from the columns by linear salt gradients 
from 20 mM to 2 M NaCl and 1 ml fractions were collected. Fractions which induced 
the 2D2 T cell proliferation were identified by a proliferation assay (see below). We 
pooled positive fractions from the Source Q column, dialyzed against 6 M urea, 20 
mM NaCl, in 20 mM degassed phosphate buffer pH 7.4 in the presence of 1.2 mM 
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dithiothreitol, and loaded on a Mono Q anion exchanger that was equilibrated in the 
above buffer, but contained 0.5 mM dithiothreitol. We eluted at 1 ml min–1 by a linear 
gradient from 20 mM to 2 M NaCl for 40 ml. We further separated the fractions that 
were positive in the T cell activation assay by gel filtration chromatography on a 
Superose 12 column at a flow rate of 0.5 ml min–1. We collected 1 ml fractions and 
tested for 2D2 TCR activation. We concentrated the positive fraction by re-
chromatography on a Mono Q column. All columns were from GE Healthcare. In 
some experiments we omitted the initial non-reducing anion-exchange 
chromatography without any changes in the elution and T cell activation profiles.  
 
Antibodies and flow cytometry 
We purchased antibodies to IA/IE (2G9), CD4 (GK1.5) and CD1d (1B1), rat 
IgG2a isotype control (R35-95) and rat IgG2b isotype control (A95-1) from BD 
Biosciences and used at 10 μg ml–1 for blocking experiments. For FACS analysis, we 
purchased the following fluorochrome labeled antibodies against mouse antigens 
from BD Biosciences: CD4 (RM4-5), CD3e (145-2C11), CD69 (H1.2F3), CD62L 
(MEL-14), CD44 (IM7), CD8a (53-6.7), Vα3.2 (RR3-16), Vβ11 (RR3-15), CD19 
(1D3), CD25 (PC61), Foxp3 (FJK-16S). Vα and Vβ TCR screening panel antibodies 
were from BD Biosciences.  We acquired samples on a FACSCalibur (BD 
Biosciences) and data were analysed with CellQuest software (BD Biosciences). 
 
 
T cell polarization and adoptive transfer EAE 
We polarized 2D2  T cells in vitro towards Th1 and Th17 phenotype using 
previously published protocols with some modifications21, 22. Briefly, we mixed 20 x 
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106 spleen cells (per well in 6 well plates, total volume of 3 ml) from 2D2 mice with 
20 x 106 irradiated (3000 rad) spleen cells from IgHMOG mice and stimulated with 20 
μg ml–1 rMOG plus Th1 and Th17 polarizing cytokines and antibodies: IL-12 (10 ng 
ml–1), IL–18 (25 ng ml–1) and antibody toIL-4 (10 μg ml–1, clone 11B11) for Th1 
polarization; human TGF-β1 (3ng ml–1), IL-6 (20 ng ml–1), IL-23 (10 ng ml–1), 
antibodies to IL-4 (10 μg ml–1) and IFN-γ (10 μg ml–1, clone R4-6A2) for Th17 
polarization. Th1 cells were supplemented with IL-2 (10 ng ml–1) and Th17 cells with 
IL-23 (10 ng ml–1) at day 3. We purchased all cytokines are from Peprotech except 
IL-23 (R&D Systems) and IL-18 (MBL), and purified from hybridoma culture 
supernatants by protein G chromatography.  We purified CD4+ T cells on day 5 by 
Dynal CD4 negative selection kit (Invitrogen), and stimulated again like above on day 
6. We used irradiated (3000 rad) spleen cells from IgHMOG mice as APCs for second 
stimulation. Three days after second stimulation, we purified live activated blast cells 
by Nycoprep gradient (Progen Immuno Diagnostica) and injected 5 x 106 cells mixed 
Th1 & Th17 cells (1:4; Th1:Th17) intravenously (i.v) via tail vein into Rag2–/–, Mog–/– x 
Rag–/– or irradiated (400 rad) WT and Mog–/– mice. For tolerance induction, we 
injected 100μg of Ova 323-339 or MOG 35-55 or MOG 38-50 peptide intravenously 
on 1, 3 and 5 days post T cell transfer. We monitored the polarization efficiency on 
day 5 and day 9 by intracellular cytokine staining (see flow cytometry).  
 
Western blotting and gel staining 
We analyzed column fractions and CNS extracts by SDS PAGE on 10% or 12.5% 
gels. Gels were stained by silver for analytical purposes, by Coomassie Blue for 
mass spectrometry, or blotted onto nitrocellulose membranes and proteins were 
detected either by antibodies to MOG (N-terminal) (Sigma; M0695 or R&D systems; 
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BAM2439) or NF-M (Acris antibodies; NF-09). We stripped the membranes and re-
probed with β-actin (Sigma; AC-74) or GFAP-specific (Santa cruz; sc-6170) 
antibodies for loading controls. 
 
Mass spectrometry 
We destained coomassie blue stained gels and excised appropriate bands. The 
disulfide bonds were reduced by dithiothreitol, alkylated with iodoacetamide, and 
proteins in-gel digested by trypsin (Roche) as described23. We analyzed peptides by 
MALDI-TOF using a Bruker ultraflex II TOF/TOF spectrometer (Bruker Daltronik). We 
analyzed peptide masses using the program "Mascot" (Matrix Science) and the non-
redundant NCBI mouse database.  
 
Construction of mouse NF-L and NF-M expression vector and 
purification  
We amplified full-length mouse NF-L from mouse brain cDNA by PCR using 
the following primers (5’-ATT ACA TAT GAG TTC GTT CGG CTA CGA-3’ and 5’- 
ATT ACT CGA GAT CTT TCT TCT TAG CCA CCT-3’) and cloned in-frame into 
pET21c vector.  After sequence verification, we transformed the plasmid into 
BL21star competent cells. For protein expression, we grew NF-L transformed 
bacteria in LB medium containing 1% glucose overnight.  We seeded the overnight 
culture (1:10) into fresh LB medium and grown till OD600 reaches 0.6 and cultures 
were induced with 1 mM IPTG. After 3 h, we harvested the cells and suspended in 
lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0). We lysed 
the cells by sonication and centrifuged at 20,000 g for 15 min at 4 °C. We washed 
the pellet containing the aggregated NF-L twice and dissolved in binding buffer (8 M 
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Urea, 100 mM NaH2PO4, 40 mM imidazole pH 7.4). We cleared the sample by 
centrifugation and loaded into the Ni2+ charged chelating sepharose column. We 
washed the column with the binding buffer and eluted the column bound NF-L with 
elution buffer (8M Urea, 100 mM NaH2PO4, 0.5 M imidazole pH 7.4). Finally we 
dialyzed the fractions containing NF-L against 10 mM sodium phosphate, pH 7.4 
buffer.  
We amplified mouse NF-M 1-102 aa (head domain) from mouse brain cDNA 
using primers (5’-TGC ATA TGA GAG GAT CGC ATC ACC ATC ACC ATC ACA 
TGA GCT ACA CGC TGG AC-3’ and  5’-TTA AGC TTT ACT GCT CTT TCT CGT 
TAG AGC-3’) containing N-terminal 6-his tag coding sequences. We cloned The 
PCR product into pRSET-B vector and sequence verified. We transformed a 
sequence verified plasmid clone into BL21-AI competent cells (Invitrogen) and frozen 
as glycerol stocks. For the purification of the recombinant protein, we inoculated 
bacteria in LB medium contaning 0.1% glucose and grew until the OD600 reached 
0.6–1.0. We inoculated this pre-culture (1:10) into fresh LB medium and allowed to 
grow until 0.4 OD600, then induced with 1 mM IPTG and 0.2 % arabinose. Bacterial 
cultures were grown further for 3 h at 37 °C and processed as above. Finally, we 
dialyzed the protein against 20 mM sodium acetate pH 3.0 or 5.0. We analyzed the 
purity of the recombinant proteins by coomassie stained gel. 
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Implication of oligodendrocyte-specific CD8 T cells in MS 
Emerging genetic data highlight the independent role of HLA class-I genes in 
conferring susceptibility to chronic human inflammatory diseases such as T1D (Nejentsev 
et al., 2007) and MS (Brynedal et al., 2007). These data provide strong incentive to further 
investigate the contribution of MHC class-I-restricted CD8+ T cells in the induction and 
development of these diseases.  
We addressed these issues in a mouse model of CNS inflammation in which CD8+ T 
cells specifically target oligodendrocytes. In addition, as described in the introduction 
several evidence points to the role of CD8+ T cells in MS (Friese and Fugger, 2009; 
Perchellet et al., 2004). To understand the possible contribution of CD8+ T cells in CNS 
tissue damage. Several groups have investigated their implication and role in experimental 
inflammatory diseases of the CNS. CD8+ T cells are necessary for the development of a 
full-fledged pathology in animal models of neuroinflammation, but their antigen specificity 
is still unknown (Brisebois et al., 2006; Ip et al., 2006; Neumann et al., 2002). Myelin-
specific CD8+ T cells can adoptively transfer autoimmune encephalomyelitis, but the 
lesions were reminiscent of ischemic injury with the demyelination associated with more 
global tissue damage, and few CD8+ T cells actually infiltrated the CNS parenchyma 
(Huseby et al., 2001a; Sun et al., 2001). Furthermore it has been shown recently that a 
myelin-specific TcR, derived from a CD8+ T cell clone from a MS patient, actuates MS-like 
disease in humanized mice expressing the MS-associated MHC class I alleles HLA-A*0301 
and the HLA-A*0201 allele, which has a protective effect (Friese et al., 2008). These data, 
although based on humanized animals, further strengthen the involvement of CD8+ T cells 
in MS pathogenesis. However, the exact targets of infiltrating CD8+ T cells in the CNS and 
how they might exert their neurotoxicity remains to be defined. 
It has been described before, that CD8+ T cells can cause demyelination by targeting 
oligodendrocytes. Using a model system in which lymphocytic choriomeningitis virus 
(LCMV) proteins were selectively expressed in oligodendrocytes by transgenesis, it was 
possible to test whether LCMV Armstrong infection, which does not infect the CNS 
parenchyma, could initiate CNS autoimmune demyelination due to the imposed molecular 
137
Discussion & Perspectives 
 
mimicry. Indeed, CD8+ T cell-mediated demyelination was clearly illustrated in this viral 
model but the effector mechanisms involved have remained unexplored (Evans et al., 
1996).  
 Recent reports suggested, that CD8+ T cells could control herpes simplex virus type 
1 (HSV-1) infection via both lytic and non-cytolytic mechanisms. CD8+ T cell lytic 
granules can block the HSV-1 life cycle through a non-lytic mechanism, and granzyme B 
can directly cleave ICP4, a viral protein required for efficient transcription of early and late 
viral genes (Knickelbein et al., 2008). However, neuronal damage in LCMV acute 
meningoencephalitis was not mediated by lytic activity of CD8+ T cells, but rather by their 
recruitment and activation of myelomonocytic cells (Kim et al., 2009). Thus, the part 
played by perforin and granzyme B in neurodegeneration may vary according to the model 
used. Therefore, the direct effect of CD8+ T cells on oligodendrocyte lysis and the 
consequent myelin damage in vivo remains elusive. 
In order to assess whether CNS-infiltrating CD8+ T cells can directly induce 
oligodendrocyte death and demyelination, we developed a mouse model combining 
selective expression of influenza HA as a neo-self-antigen in oligodendrocytes (using the 
MOG promoter) with transgenic mice expressing a HA-specific TcR on CD8+ T cells 
(Bercovici et al., 2000; Morgan et al., 1996). Given the fact, that MOG is the sequestered 
CNS antigen (Bruno et al., 2002), we first assessed whether in our mouse model HA is also 
expressed as a sequestered antigen. Therefore we crossed our MOG-HA mice with CL4-
TcR transgenic mice and followed them for any development of spontaneous disease. 
Interestingly we did not observe any neurological sign. We did not observe evidence for T 
cell tolerance such as TcR downregulation or deletion of HA-specific CD8+ T cells, which 
is consistent with the lack of expression or possible cross presentation of HA in the 
lymphoid organs. 
Perhaps the innocuous behavior of HA-specific CD8+ T cells in the CL4-TcR x 
MOG-HA mice despite their high avidity for HA (Cabarrocas et al., 2003) could be due to 
low levels of HA expression, its strict expression beyond the BBB and/or the weak local 
expression of MHC class-I. Indeed, it has been clearly shown, that below a certain antigen 
dose, specific CD8+ T cells do not respond to tissue self-antigen (Kurts et al., 1999). 
However, other parameters could determine the CD8+ T-cell fate as a seemingly indifferent 
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phenotype, which has been reported for high avidity MBP-specific CD8+ T cells (Perchellet 
et al., 2004) despite detectable MBP expression in lymphoid organs. In addition, CFSE-
labeled naïve CL4-TcR CD8+ T cells failed to proliferate following their adoptive transfer 
in MOG-HA mice. This result was notably different from an earlier study, showing that in 
GFAP-HA mice expression of HA by lymph node stromal cells induced strong proliferation 
of HA-specific CD8+ T cells in vitro and in vivo (Magnusson et al., 2008). This further 
accentuates the lack of expression or cross-presentation of HA in the lymphoid organs of 
MOG-HA mice. Therefore, HA protein expression driven by MOG promoter behaves as a 
sequestered antigen, thus supporting the model to mimic MOG in the involvement of 
autoimmune demyelinating disease.  
As shown previously, in-vitro activated HA-specific CD8+ T cells can readily cross 
the BBB (Cabarrocas et al., 2003). Consequently we transferred HA-specific Tc1 cells in 
immunocompetent MOG-HA mice. A plaque-like demyelination pathology was induced. In 
addition, staining for amyloid precursor protein (APP) revealed some axonal pathology. 
Importantly, we demonstrate, that demyelinating lesions, sharing many of the attributes of 
an active MS plaque, can arise when CD8+ T cells target oligodendrocytes.  
Our system allows the clear assessment of the individual role of CD8+ T cells by 
uncoupling the impact of cytotoxic CD8+ T cells from other adaptive immune mechanisms. 
Genetic GFP-labeling of the transferred CD8+ T cells also permitted to unequivocally trace 
the HA-specific cytotoxic T cells in situ. Strikingly, we show here that CD8+ T cells enter 
the CNS and optic nerve parenchyma and form close anatomical interactions with 
oligodendrocytes. The data strongly suggest, that direct cell contact-mediated cytotoxicity 
plays a central role in the oligodendrocyte death and demyelination observed in our model. 
Indeed, numerous T cells, among which an important proportion is of HA-specific cytotoxic 
T cells, were invading the CNS of MOG-HA mice. There was a strong co-localization 
between HA-specific CD8+ T cells and oligodendrocytes with occasional figures suggesting 
close apposition between the two cell types. It is however possible that soluble 
inflammatory mediator contributes in several synergistic ways to tissue lesions. Indeed, 
IFN-γ and TNF promote up-regulation of MHC class-I molecules on oligodendrocytes 
(Sobottka et al., 2009; Turnley et al., 1991), rendering these cells more susceptible to CD8-
mediated cytotoxicity. In addition, chemokines and MMP create the appropriate milieu to 
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favor migration across the BBB of additional immune cells. Finally, inflammatory 
cytokines favor the activation of resident microglial cells and enhance their phagocytic 
properties. In line with this hypothesis, our unpublished data showed, that transfer of IFN-γ-
deficient HA-specific preactivated CD8+ T cells in MOG-HA mice led to a much-reduced 
phenotype. 
It has been shown in vitro, that myelin-specific cytotoxic CD8+ T cells can kill 
isolated HLA-matched oligodendrocytes (Jurewicz et al., 1998) but data in vivo were less 
compelling. Similarly, a role for CD8+ T cells in demyelination has been clearly illustrated 
in viral models of CNS inflammation but the mechanisms involved have remained elusive 
(Evans et al., 1996; Rivera-Quinones et al., 1998), as even activated CD8+ T cells of 
irrelevant specificity can mediate bystander demyelination in this setting (Dandekar et al., 
2004).   
In the same line of research another independent group describe the similar outcome 
of CD8+ T cell mediated oligodendrocyte lysis, while using ovalbumin (OVA) sequestered 
as a neo-self antigen in the cytosol of oligodendrocytes (Na et al., 2008). They show, that 
endogenously generated CD8 T-cells expressing the MHC class I-restricted, OVA-specific 
OT-I receptor are highly encephalitogenic in ODC-OVA mice, inducing demyelinating 
lesions reminiscent of MS plaque. This encephalitogenic property mainly depends on the 
production of IFN-γ by the OVA-specific CD8+ T-cells, similar to our observation. 
The investigation on the role of CD8 T cells in CNS inflammatory diseases is not 
confined to animal models. Indeed, in MS patients, a German team suggests that at least a 
part of the pervasive T-cell clones belong to the CD8+ compartment. Because of the shared 
TcR usage it is assumed that some of these T cells respond to a common antigen (Junker et 
al., 2007). Therefore our findings could provide a helpful link to understand MS pathology.   
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Implication of self-molecular mimicry in MS 
Activation of autoreactive T cells is critical for the induction of autoimmune 
diseases. In humans, T cell clones specific for myelin antigens are present in the circulation 
of both MS patients and healthy individuals. Autoreactive T cell clones demonstrate a 
significant degree of functional degeneracy in antigen recognition. Cross-reactivity against 
other myelin antigens has been observed in MBP-reactive T cell clones (Mycko et al., 
2004). Furthermore, recent studies characterizing TcR degeneracy have determined, that the 
frequency of T cells with degenerate TcR is higher in patients with MS than in healthy 
controls, and that a subset of these cells recognize myelin antigen (Zhang et al., 2008). 
These findings support the hypothesis, that non-self antigens may activate cross-reactive T 
cells during the course of an infection. 
A number of viral epitopes that trigger autoreactive T-cell clones, including a 
peptide from human cytomegalovirus have been identified (Hemmer et al., 1997). Other 
infectious agents, including EBV, Chlamydia pneumoniae, hepatitis B virus, and 
Haemophilus influenzae, have also been reported to express cross-reactive epitopes 
(Croxford et al., 2005; Fujinami et al., 1983; Lang et al., 2002; Lenz et al., 2001). Such 
molecular mimicry by viral or bacterial proteins could initiate autoimmune pathogenesis by 
myelin-reactive T cells (Fujinami and Oldstone, 1985; Wucherpfennig and Strominger, 
1995). Molecular mimicry during the course of an infection could provoke development of 
MS in genetically susceptible individuals. However, there is little direct support providing a 
link between infection and MS. The most studied epidemiological candidate to date is EBV, 
which has a slightly higher prevalence rate in MS patients than in healthy controls 
(Ascherio and Munger, 2007). Recently it has been suggested, that prevalence of EBV 
infection, as measured by EBV seropositivity, was linked to HLA haplotype (De Jager et 
al., 2008). 
A number of T cell clones specific for foreign epitopes lacked significant multi-
specificity, suggesting that the recognition of multiple epitopes is more frequent among 
autoreactive T cell clonotypes (Cai and Hafler, 2007). In the same line it has been shown 
that single TcR also bind to distinct self-peptides from different autoantigens or non-
overlapping peptides derived from the same autoantigen. For instance CD4+ T cells cloned 
from peripheral blood of healthy subjects and expanded in an autologous-mixed 
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lymphocyte response recognizing multiple autoantigenic epitopes, which include a number 
of peptides derived from autoantigens associated with T1D and MS, such as GAD, insulin, 
proinsulin, and MBP (Cai and Hafler, 2007). In addition, a relatively high frequency of 
GAD65-specific CD4+ T-cell clones recognizes two non-overlapping GAD65 peptides and 
this promiscuity correlates with increased avidity/affinity and an enhanced capacity to 
mediate insulitis (Li et al., 2008). 
Collectively these studies described, that multiple cross-reactivity persists towards 
self-antigens among autoreactive T cells in both human and mice, therefore self-mimicry 
may play a role in T-cell mediated autoimmunity. Interestingly, it has been demonstrated 
that TcRs specific for viral or other foreign antigens recognize non-overlapping epitopes 
from the same antigen and these promiscuous T-cell clones may represent a subset of CD4+ 
and CD8+ T-cells with enhanced effector functions (Brehm et al., 2002; Chen et al., 2001; 
Riedl et al., 2006). 
MOG differs from other myelin autoantigens because of its immunodominance 
(Amor et al., 1994; Genain et al., 1995) and its highly encephalitogenic properties upon 
immunization of susceptible animals (Bernard et al., 1997; Iglesias et al., 2001; Mendel et 
al., 1995). In addition it has been shown, that MOG is a direct target for humoral response 
(Litzenburger et al., 1998), and that the anti-MOG response is a major pathogenic 
component of the autoimmune response directed against myelin, which is associated with 
lack of immune tolerance to MOG (Delarasse et al., 2003).  
The 2D2 TcR-transgenic C57BL/6 mice, which harbor large populations of MOG-
specific CD4+ T cells, tend to spontaneously develop optic neuritis and more rarely bona 
fide EAE (Bettelli et al., 2003). Strikingly, when we crossed these 2D2 mice with MOG-/- 
mice, we observed, that about 16% of the 2D2 TcR-transgenic mice developed spontaneous 
EAE regardless of the presence or absence of MOG. Therefore we hypothesized, that 2D2 
TcR specific for MOG35-55 recognizes a second autoantigenic target. This paradoxical 
observation was made independently in two different cohorts of 2D2-transgenic mice, one 
with disrupted exon1 of the MOG gene (Delarasse et al., 2003), and the other in which the 
MOG gene was deleted by an independent knock-in strategy (Hovelmeyer et al., 2005), 
excluding residual, atypical MOG material in these knockout animals as a possible 
encephalitogenic target. 
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In silico search for sequence related to the MOG35-55 motif recognized by the 2D2 T 
cell clone (Petersen et al., 2004) revealed the stimulatory autoantigenic epitope of NF-M. 
Unexpectedly, this NF-M18-30 peptide induced proliferation and cytokine secretion by 2D2 
CD4+ T cells at lower concentrations than MOG35-55 peptide. We used 2D2 TcR transgenic 
cells from Rag2-/- mice to exclude a role for dual TcR expression and for the endogenous 
TcR repertoire. These results further strengthen our observation that 2D2 cross-reactive T 
cells recognize their alternative autoantigenic target in the absence of MOG, and that this 
cross-recognition is restricted to MOG specific TcR. Given the marked degeneracy of 
peptide recognition by T cells, this observation was not very surprising (Wucherpfennig and 
Strominger, 1995). Nevertheless we confirmed NF-M as the stimulatory autoantigen at the 
protein level using both CNS white matter protein extracts and recombinant proteins.  
Polyclonal T cell populations primed with either MOG or NF-M isolated from 
C57BL/6 mice show extensive cross-reactivity between NF-M and MOG proteins and their 
salient epitopes, respectively. Of note, these populations rarely use Vα3.2 and Vβ11, the 
variable chains used by the 2D2 clone, indicating that MOG and NF-M cross-reactivity is 
not limited to the 2D2 TcR. Indeed, we now have evidence for such cross-reactivity in other 
I-Ab-restricted MOG and NF-M specific CD4+ T cells expressing distinct TcRs. This 
implies that the peripheral T cell repertoire of C57BL/6 mice contains both a MOG35-55 and a 
NF-M15-35 specific T cell pool and both pools may overlap. The size of this overlap can be 
assessed by I-Ab restricted tetramers specific for MOG and NF-M. In addition, the 
frequency of cross-reactive clones can be assessed after MOG35-55 and NF-M15-35 
immunization. These cells will then be used to study the pathogenicity afforded by single or 
cross-reactive TcRs in autoimmune diseases. This can be achieved by using retro-transgenic 
mice. 
Neurofilaments, including NF-M, are produced by neurons and also by some glial 
cells (Kelly et al., 1992). It can be the target of autoantibodies in a number of autoimmune 
situations. For example, the acetylcholine receptor-like epitope of the NF-M was identified 
by peptide epitope mapping as an autoantigenic determinant of myasthenia gravis (Schultz 
et al., 1999). A significant proportion of rheumatoid arthritis patients with neuropathy had 
abnormal antibody levels to one or more neurofilaments (Salih et al., 1998). Neurofilaments 
were recently characterized as autoantigens in actively induced EAE. Immunization of 
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Biozzi ABH (antibody high, AB/H, ABH) mice with the light form of neurofilament, NF-L, 
causes EAE in a moderate proportion of treated animals (Huizinga et al., 2007). 
Furthermore, autoantibodies to NF-M have been detected in the cerebrospinal fluid of some 
individuals with MS (Bartos et al., 2007). 
Based on our results, showing cross-reactivity between two different neural self-
antigens i.e. MOG and NF-M, one could ask what is the relative pathogenic impact of MOG 
and NF-M as target antigens for the 2D2 T cells? Therefore we generated mouse lines 
lacking one or both autoantigenic target antigens and showed, that MOG was important for 
rapid onset of EAE. In the same line our unpublished data revealed that, when transferring 
in-vitro differentiated Th1 cells from 2D2-RAG-/- donor mice into recipients lacking NF-M, 
an EAE with the same kinetics as wild type recipients was induced. Disease severity was 
however decreased in this situation, suggesting that NF-M may play a role in disease 
severity. 
In contrast, we were unable to induce disease in wild type C57BL/6 mice by 
immunization with NF-M using protocols that consistently allow active disease induction 
by MOG35–55. This discrepancy between active and passive EAE induction is, however, not 
exceptional. It has been previously described for other models, including EAE induced in 
Lewis rats by glial fibrillary acidic protein (GFAP) (Berger et al., 1997) and S100-β 
(Kojima et al., 1994) and MBP-induced EAE in BALB/c mice (Abromson-Leeman et al., 
1993). It has been shown that when EAE was induced by the adoptive transfer of CD4+ T 
cell lines specific for the MBP, MOG and S100-β antigen, as in the MBP induced EAE, the 
spinal cord was more severely affected with only minor inflammation in the forebrain. In 
contrast, MOG induced a far higher density of lesions in the periventricular and cerebellar 
white matter. S100-β and GFAP mediated severe inflammation particularly in the gray 
matter. In addition to these topographic differences, antigen specificity also influenced the 
extent of both parenchymal inflammation and macrophage activation in the CNS.  
We refer to the observation of self-mimicry, as ‘Cumulative autoimmunity’ where 
an autoimmune response targets two self-autoantigens in the same tissue, consequently 
exhibit additive pathogenicity resulting in enhanced CNS tissue damage. A similar kind of 
additive pathogenicity has been described among GAD65 multispecific CD4+ T cell clones, 
which exhibit increased pathogenicity upon adoptive transfer in NOD.scid recipients (Li et 
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al., 2008). One important mechanistic issue is whether cumulative autoimmunity galvanizes 
tissue destruction by increasing the availability of auto-antigen at a given site or by 
diversifying the cellular and anatomical targets of the autoimmune response. MOG and NF-
M co-localize in the CNS white matter, with the axons expressing NF-M and 
oligodendrocytes expressing MOG. Therefore the cross-presentation of both antigens by 
local APCs could exacerbate the intensity of a given demyelinating lesion by increasing the 
density of agonistic ligands (both I-Ab:MOG35-55 and I-Ab:NF-M15-35). However, MOG is 
absent from the myelin sheath in the PNS making NF-M the only target antigen, which 
could indicate that cumulative autoimmunity permits the broadening of anatomical and 
cellular targets aggravating disease by multiplying inflammatory lesions. Indeed, while 
transferring in-vitro differentiated Th1 cells from 2D2-Rag2-/- mice, we found lesions in the 
tissues which are devoid of MOG autoantigen but contain NF-M, such as the trigeminal and 
spinal ganglia, spinal roots and peripheral nerves. This observation is reminiscent of our 
histological observations in diseased 2D2 TcR transgenic mice, having inflammatory 
lesions at sites devoid of MOG. 
This cumulative autoimmunity is attributed to TcR cross-reactivity. Although much 
is known about TcR recognition of foreign antigens (Rudolph et al., 2006), the structural 
and biophysical principles governing TcR recognition of self have only recently begun to be 
elucidated. Recent studies of self-recognition by autoreactive TcR suggested, that 
unconventional topologies are possible because of the unique CDR3 sequences created 
during rearrangement (Hahn et al., 2005; Li et al., 2005b; Maynard et al., 2005; Nicholson 
et al., 2005). This topology reduces the interaction surface with peptide and alters the 
geometry for CD4 association. Several structures of autoimmune TcR pMHC complexes 
have now been reported, such as the complex between human TcR Ob.1A12 and MBP85–99 
presented by HLA-DR2b (Hahn et al., 2005) the complex between human TcR 3A6 and 
MBP89–101 presented by HLA-DR2a (Li et al., 2005b) and the complex between mouse TcR 
172.10 and MBP1–11 presented by I-Au (Maynard et al., 2005). TcR Ob.1A12 and 3A6 were 
isolated from MS patients, and humanized mice transgenic for these TcR and for DR2b or 
DR2a develop symptoms typical of EAE. TcR 172.10 was derived from a T-cell clone that 
causes EAE following transfer into mice. Significantly, all three autoimmune TcRs engage 
pMHC class II with unconventional binding topologies compared with TcR specific for 
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foreign antigens. However, current structural database for MHC class II-restricted TcR is 
limited as compared to MHC class I restricted TcR (Rudolph et al., 2006) therefore it is 
difficult to define the full range of docking topologies for MHC-class II-restricted TcR. The 
3A6–MBP–DR2a complex provides further evidence of unusual interactions between 
autoimmune TcR and self-pMHC. Similar to Ob.1A12, 3A6 TcR binds its self-ligand with 
low affinity (KD > 200 µM) (Li et al., 2005b). Therefore, it would be interesting to assess 
whether 2D2 TcR binds self-peptides such as MOG and NF-M with different affinity. 
Would this, as a consequence, influence disease severity or onset? All these important 
issues need to be addressed in detail. 
We have demonstrated immunological self-mimicry in the same tissue, where one T 
cell population with specific TcR to MOG35–55, recognizes another independent target self-
autoantigen, i.e. NF-M. However, another case of self-mimicry between structures from 
different tissues was reported in the Dark Agouti (DA) rat in which MOG-specific T cells 
reacted to an epitope of the milk protein butyrophilin (Stefferl et al., 2000). Transmucosal 
exposure to butyrophilin peptide can modulate disease activity in MOG-induced EAE. If 
transferable to humans, this may suggests, that in the context of an appropriate HLA 
haplotype, dietary exposure to butyrophilin may modulate the pathogenic autoimmune 
response to MOG in MS. 
Furthermore, whether molecular mimicry between neural self-antigens could 
contribute to cross-reactive T cell tolerance is not defined. As mentioned earlier, MOG is 
barely expressed in the thymus and periphery, consequently, no detectable T and B cell 
tolerance can be observed against MOG in C57BL/6 mice (Delarasse et al., 2003). 
However, NF-M expression can be detected in human thymic medulla by immuno-
histochemistry (Marx et al., 1996) and in murine non-lymphoid thymic stromal cells 
(Screpanti et al., 1992). Moreover due to its presence in the PNS, NF-M is likely to be 
present in local draining lymph nodes (Grant and Pant, 2000; Oldstone, 1987; Perrot et al., 
2008). Therefore our future study will assess whether the expression of NF-M can impact 
the capacity of the T cell repertoire to respond to MOG35-55 and vice versa. 
Finally identification of neural self-mimicry as a cumulative trigger in CNS 
autoimmunity defines a novel mechanism that perpetuates EAE. This mechanism permits 
the spreading of antigenic and cellular targets due to the plasticity of the TcR. Molecular 
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mimicry between auto-antigens is therefore likely to be a universal mechanism propagating 
organ-specific autoimmune disease.    
 
Concluding remarks 
Gene-modified mouse models have been extremely useful to decipher the 
mechanisms involved in immune tolerance and inflammatory disease development. We 
generated a mouse model to study the contribution of individual T-cell subsets on CNS 
tissue damage. We have focused on oligodendrocyte-specific CD8+ T cells, as little in vivo 
information was available regarding the pathogenicity of this subset at the beginning of this 
study. Furthermore, both CD8+ T-cell infiltration and loss of oligodendrocytes are essential 
features of MS lesions. The novel findings provided by my work are that, whereas naïve 
CD8+ T-cells specific for a CNS-restricted self-antigen persist but remain innocuous, 
effector CD8+ T cells exhibit a potent deleterious effect on oligodendrocytes, resulting in an 
inflammatory demyelinating pathology reminiscent of active MS lesions. The exclusive 
expression of HA in oligodendrocytes, and the resulting lack of T-cell silencing, is very 
reminiscent of some natural myelin self-antigens such as MOG, which is barely expressed 
in the thymus and therefore fails to exert efficient censoring of the T cell repertoire 
(Delarasse et al., 2003; Fazilleau et al., 2006). Tolerance to these sequestered antigens, 
which relies solely on passive mechanisms (sequestration, low antigen dose), carries an 
obvious risk of activation of autoreactive CD8+ T cells, with subsequent development of 
autoimmunity.  Identification of the stimuli that may reverse this operationally tolerant state 
will be a matter of further studies. Adoptive transfer of activated oligodendrocyte-specific 
CD8+ T cells in MOG-HA mice has provided unequivocal evidence of their in vivo potential 
to induce oligodendrocyte apoptosis and resulting demyelination, a likely consequence of 
direct antigen-recognition. Since our data show, that CD8+ T cells induce inflammatory 
demyelinating lesions closely resembling active MS lesions, they reinforce the idea that 
CD8+ T cells represent attractive therapeutic targets in MS (Friese and Fugger, 2005, 2009; 
Liblau et al., 2002; Neumann et al., 2002; Sobottka et al., 2009).  
In addition, we discovered the implication of self-mimicry in CNS autoimmunity 
due to the paradoxical development of spontaneous EAE in 2D2 x MOG-/- mice despite the 
absence of its target antigen, MOG. A cross-reactive epitope was identified as NF-M. 
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Importantly, this cross-reactivity is not restricted to the transgenic TCR but is commonly 
seen in short term cell lines from MOG35-55 or NF-M15-35 immunized mice. Our collaborative 
study reveals the identification of neural self-mimicry as a cumulative trigger, which 
defines a novel mechanism in CNS autoimmune disease. However, it is not clear, how the 
effector mechanisms targeting MOG and NF-M in vivo cumulate during CNS 
autoimmunity. Similarly it is important to understand the impact of neural self-mimicry on 
immune tolerance. These are obvious directions for future studies in our laboratory. 
Overall, we propose that in C57BL/6 mice autoimmune response components 
directed against MOG and NF-M may accumulate to overcome the general resistance of 
these mice to induction of EAE. T cells with similar cumulative double self-reactivity could 
act as dominant pathogens in human MS, and genetic factors favoring bi-specific T cells 
(possibly the HLA class II alleles) would enhance susceptibility to the disease. Our study 
should provide a way to identify such T cells in humans and acknowledge their role in the 
pathogenesis of MS. 
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Insulin Modulates Protease-Activated Receptor 2 Signaling:
Implications for the Innate Immune Response
Eric Hyun,* Rithwik Ramachandran,* Nicolas Cenac,†,‡ Steeve Houle,* Perrine Rousset,†,‡
Amit Saxena,†,‡ Roland S. Liblau,†,‡ Morley D. Hollenberg,* and Nathalie Vergnolle*,†,‡
Given the anti-inflammatory effects of insulin in human and animal studies done in vivo and given the signaling pathways in com-
mon between insulin and the protease-activated receptor 2 (PAR2), a G protein-coupled receptor, we hypothesized that insulin
would have an impact on the inflammatory actions of PAR2. We found that low doses or concentrations of insulin in the
subnanomolar range reduced PAR2-induced inflammation in a murine paw edema model, attenuated PAR2-induced leukocyte
trafficking in mouse intestinal venules, and reduced PAR2 calcium signaling in cultured dorsal root ganglion neurons and
endothelial cells. This effect of insulin to attenuate PAR2-mediated inflammation was reversed when cells were preincubated with
LY294002 (a PI3K inhibitor) and GF 109203X (a pan-protein kinase C inhibitor). The enhanced inflammatory effect of PAR2
observed in vivo in an insulin-deficient murine type 1 diabetes model was attenuated by the local administration of insulin at the
inflammatory site. Our data point to an anti-inflammatory action of insulin that targets the acute innate inflammatory response
triggered by PAR2. The Journal of Immunology, 2010, 184: 2702–2709.
I ncreasing evidence points to an association between diabetesand chronic activation of the innate immune system, withelevated low-grade inflammation. Insulin has been shown to
exert anti-inflammatory properties in a number of settings, in-
cluding several animal models of inflammation (summarized in
Ref. 1). To date, the anti-inflammatory action of insulin has been
attributed to its effects on mononuclear cells (2), possibly via the
suppression of endotoxin-induced proinflammatory transcription
factors and their gene targets. In a cardiac ischemia‑reperfusion
model, the ability of insulin to reduce infarct size has been at-
tributed to its antiapoptotic action, mediated via PI3K, Akt (pro-
tein kinase B), Bcl-2–associated death promoter, and reduced NO
production via NO synthase phosphorylation (reviewed in Ref. 1).
However, a modulatory role for insulin on inflammatory signals
induced by mediators signaling through G protein-coupled re-
ceptors is still largely unknown. Serine proteases, through the
activation of protease-activated receptors (PARs), are now con-
sidered as key mediators of the innate immune response (3).
Several studies have shown the involvement of this family of G
protein-coupled receptors in both acute and chronic inflammatory
states (3, 4). PARs belong to a unique four-member G protein-
coupled receptor family (PAR1–4), which are proteolytically ac-
tivated by the unmasking of a cryptic N-terminal sequence that
becomes a tethered receptor-activating ligand (5). In isolation,
synthetic peptides having sequences in common with the pro-
teolytically revealed tethered ligand (e.g., SLIGRL-NH2, derived
from PAR2) can selectively activate PARs in the absence of en-
zymatic cleavage. By cleaving and activating PAR2, trypsin and
other serine proteases, such as tryptase or tissue kallikreins, have
been found to trigger a variety of inflammatory responses, in-
cluding edema, leukocyte infiltration, and pain (6–8). These in-
flammatory actions of trypsin, due in large part to a neurogenic
mechanism (9), are mimicked by the receptor-selective PAR2-
activating peptide (PAR2-AP) SLIGRL-NH2. A number of studies
have highlighted, particularly for PAR2, a prominent inflammatory
role as a mediator of innate immunity, singling out PAR2 as a new
molecular target for anti-inflammatory and analgesic treatments
(10, 11). Although some studies have identified factors that are
able to control the expression of PAR2, no studies have identified
so far the endogenous signaling pathways that can modulate its
proinflammatory effects.
In the context of an association among diabetes, low insulin
levels, and an inflammatory state and in view of the prominent role
of proteases in initiating inflammatory processes via PAR2, we
hypothesized a potential interaction between insulin and PAR2
agonists to affect inflammation. This possible interaction between
insulin and PAR2 signaling might relate pathophysiologically to
inflammation in the setting of diabetes.
To test the hypothesis that PAR2 and insulin signaling pathways
can interact in the triggering of an acute inflammatory response, we
used: 1) a PAR2-selective agonist, SLIGRL-NH2, to activate PAR2
without affecting other PARs, like trypsin would do, and 2) ap-
propriately low doses or concentrations of insulin (1 nM in vitro;
150 pmol, administered locally in vivo) with or without activation
of PAR2 by SLIGRL-NH2. The PAR2-selective agonist and insulin
were used to evaluate several inflammation-related targets: 1) an
in vivo paw edema inflammation model for which we have pre-
viously documented the inflammatory action of trypsin and PAR2
(6), 2) an in vivo leukocyte‑endothelium interaction model, docu-
mented with intravital microscopy (7), and 3) a PAR2-stimulated
calcium signaling model, using the two cell types that have been
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shown to play an important role in PAR2-induced inflammation,
isolated dorsal root ganglion (DRG) neurons (12) and cultured
microvascular endothelial cells (13). Further, we evaluated the in-
flammatory action of SLIGRL-NH2 in mice rendered diabetic via
pancreatic b cell elimination.
Materials and Methods
Mice
Six- to eight-week-old C57BL/6 mice were obtained from Charles River
Laboratories (Wilmington, MA) or Janvier (St. Quentin Fallavier, France).
RIP-HA mice expressing influenza hemagglutinin (HA) on pancreatic islet
b cells under the control of a rat insulin promoter (14) were bred at the
INSERM U563 Animal Care Facility. CL4-TCR transgenic mice express
on most CD8 T cells a TCR specific for the influenza virus HA512–520
peptide‑Kd complex (15). RIP-HA and CL4-TCR transgenic mice were
backcrossed at least 10 times onto the BALB/c background. Animals were
kept under pathogen-free conditions and given free access to food and
water. All of the experimental protocols were approved by local Animal
Care and Ethic Committees and followed the guidelines of the Canadian
and French Councils on Animal Care.
Chemicals
SLIGRL-NH2 (a receptor-selective PAR2-AP) and a control peptide
LRGILS-NH2 (the reverse sequence of PAR2-AP that cannot activate
PAR2) were obtained from the protein synthesis facility at the University of
Calgary (Calgary, Alberta, Canada). HPLC and mass spectrometry were
used to assess the purity of the peptides. Peptides that were .95% pure
(HPLC and mass spectrometry criteria) were dissolved for paw edema
studies in isotonic 0.9% NaCl (saline) or for intravital studies in an
80:10:10 (v/v/v) saline solution supplemented with Tween 80 and ethanol
(80% saline, 10% ethanol, and 10% Tween 80). This vehicle is necessary
to enable the peptide to gain access to the tissue. Carrageenan and re-
combinant yeast-produced human insulin (I2643, 27.5 U/mg) were from
Sigma-Aldrich (St. Louis, MO). The PI3K inhibitor LY294002 was from
Cayman Chemical (Ann Arbor, MI), and the protein kinase C (PKC) in-
hibitor GF 109203X was from Tocris Bioscience (Ellisville, MO).
Paw edema
Paw edema was monitored with an electronic caliper (resolution 0.01;
Mitutoyo,Aurora, IL) usingC57BL/6mice, in keepingwith previous studies
with rats (6). Basal paw thickness (at time 0)wasmeasured, and immediately
thereafter 10 ml solution containing various test compounds was adminis-
tered via intraplantar injection. The test substances included vehicle (iso-
tonic saline), SLIGRL-NH2 (50 mg), LRGILS-NH2 (50 mg), insulin (150
pmol), and carrageenan (200 mg). The inflammatory agonists (peptides or
carrageenan) were administered either alone, or in combination with insulin
(e.g., SLIGRL-NH2 plus insulin [50 mg and 150 pmol, respectively] and
carrageenan plus insulin [200 mg and 150 pmol, respectively]). Isotonic
saline served as a vehicle control for all of the experiments using insulin. The
change in paw thickness wasmeasured every hour for 6 h and recorded as the
differences between the measurement at each time point and the basal
measurement done immediately prior to the intraplantar injections. After the
last paw edema measurement, the animals were sacrificed by cervical dis-
location, and paws were removed for the extraction and measurement of
myeloperoxidase (MPO) activity as an index of granulocyte infiltration.
Similar procedures were followed for in vivo experiments with kinase in-
hibitors, but 15 min prior to the intraplantar injections with SLIGRL-NH2 or
SLIGRL-NH2 plus insulin, mice received an intraplantar injection of 2 ml
distilled water to cause osmotic shock, immediately followed by a 5ml in-
traplantar injection of LY294002 (1 mg) or GF 109203X (1 mg).
MPO activity
Tissues collected forMPO assay were processed as outlined previously (16).
In brief, dissected paw samples were homogenized in 0.5% hexadecyl-
trimethylammonium bromide solution (dissolved in phosphate buffer so-
lution). The homogenized tissues were centrifuged at 13,000 3 g for 4
min. Supernatants were placed into a 96-well plate, and 1% hydrogen
peroxide/O-dianisidine dihydrochloride-containing buffer was added. OD
readings were at a wavelength of 450 nm for 1 min at 30 s intervals.
Intravital microscopy
Mice were anesthetized by a mixture of xylazine (10 mg/kg; MTC
Pharmaceuticals, Cambridge, Ontario, Canada) and ketamine (200 mg/kg;
Rogar/STB, London, Ontario, Canada) by i.p. injection. Mice were given
100 ml rhodamine 6G (Sigma-Aldrich) in NaCl 0.9% (0.3 mg/kg, ad-
ministered i.v. in 0.1 ml). The dosage of rhodamine 6G used in this study
has been shown to have no effect on leukocyte kinetics while effectively
labeling leukocytes and platelets (17). Microcirculation was observed
using an inverted fluorescent microscope (Nikon, Melville, NY) with
a 203 objective lens by epi-illumination at 510‑560 nm, using a 590 nm
emission filter. After anesthesia, a midline abdominal incision was made,
and a segment from the small intestine (jejunum) was exteriorized care-
fully. The exposed intestine was placed on top of a viewing pedestal and
superfused with bicarbonate-buffered saline (pH 7.4). After 10 min of
equilibration, single venules (20–40 mm in diameter) were selected and
visualized, with images recorded for 5 min. The end of the first 5 min of
recording was designated as time 0. Immediately thereafter at the jejunal
site of visualization, agonist or control peptides were administered by an
intraluminal injection: SLIGRL-NH2 (100 mg), LRGILS-NH2 (100 mg),
or SLIGRL-NH2 plus insulin (150 pmol). The polypeptides were ad-
ministered in 0.1 ml physiological isotonic saline (pH 7.4), supplemented
with 10% (v/v) absolute ethanol and 10% (v/v) Tween 80. The control
mice were treated with vehicle alone. Additional images of the selected
venules then were recorded for 5 min intervals at times 20, 35, 50, 65, and
80 min. Upon video playback, leukocyte rolling, adherence, and vessel
diameter were measured. Leukocyte flux was defined as the number of
leukocytes per minute moving at a velocity less than that of the eryth-
rocytes that passed a reference point in the venule. A leukocyte was
considered adherent to the vessel wall if it remained stationary for 30 s or
longer. The change in vessel diameter and leukocyte flux was evaluated as
the differences between the values at each interval and the basal value
observed at time 0. The parameters measured were plotted over the 80 min
time interval of observation, and the area under the curve was calculated.
Endothelial and primary afferent neuronal DRG cell cultures
Human microvascular endothelial cells (HMEC-1) (Centers for Disease
Control and Prevention, Atlanta, GA) were grown in a cell culture flask
containing growth medium MCDB 131 (Invitrogen, Burlington, Ontario,
Canada) supplemented with epidermal growth factor (10 ng/ml), hydro-
cortisone (1 mg), 10% FBS, and 1% penicillin/streptomycin.
DRG neurons were isolated from C57BL/6 mice as described previously
(12, 18, 19). DRGs were rinsed in HBSS and incubated in this solution
containing 27 mg/ml papain (Sigma-Aldrich) for 10 min at 37˚C. After
being washed first with L-15 buffer (Leibovitz’s L-15 medium [In-
vitrogen], supplemented with 2 mM glutamine [Sigma-Aldrich] and 10%
FBS [Invitrogen]) and then with HBSS, DRGs were incubated in HBSS
containing 1 mg/ml collagenase type I (Sigma-Aldrich) and 4 mg/ml
dispase II (Sigma-Aldrich). L-15 wash buffer then was added to neutralize
enzymatic activities, and the suspension was centrifuged at 600 3 g for 5
min. Neurons in the pellet were suspended in DMEM (Invitrogen) con-
taining 2.5% FBS, 2 mM glutamine, 1% penicillin/streptomycin, and 10
mM each of cytosine arabinoside, flurodeoxyuridine, and uridine (all from
Sigma-Aldrich). Cells were plated on CC2 LabTek II culture slides (Nunc,
Domique Dutscher, Brumath, France) for measurements of calcium sig-
naling assay Ca2+ (see below). Neuronal cultures were maintained for 24 h
or more to enable a regeneration of cell surface receptors, such as the
PARs, that may have been affected by papain treatment.
Imaging to measure calcium transients in HMECs and DRGs
Mobilization of intracellular Ca2+ in HMECs was measured using cell
monolayers in accord with methods described previously (20). In brief,
HMECs were seeded in glass-bottom petri dishes (MatTek, Ashland, MA).
HMECs grown to 90% confluence were incubated for 30 min at 37˚C with
serum-free MCDB 131 growth medium containing sulfinpyrazone (0.25
mM) and fluo-3-acetoxymethyl ester (2.5 mM) (Molecular Probes, Eugene,
OR). Cell monolayers then were washed briefly with dye-free calcium
assay buffer (pH 7.4) containing NaCl (150 mM), KCl (3 mM), CaCl2 (1.5
mM), glucose (10 mM), HEPES (20 mM), and sulfinpyrazone (25 mM)
and then covered with 500ml assay buffer. Test agonists diluted in this assay
buffer were added to the monolayers, and the elevation of the intracellular
calcium concentration was monitored. Increase in fluo-3-acetoxymethyl
ester fluorescence, an index of increased intracellular calcium concentration,
was measured using an inverted microscope with a 320 objective. The
fluorescence signal was analyzed by ImageMaster system software (Photon
Technology International, London, Ontario, Canada) with excitation at 480
nm and emission recorded at 530 nm through a dichroic filter cube with the
appropriate filter and an intensified charge-coupled device video camera
(Photon Technology International). The magnitude of the calcium signal
observed was expressed as a percentage (% A23187) of the signal caused in
the same cell monolayers by the calcium ionophore A23187 (4 mM; Sigma-
Aldrich).
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The uptake of calcium indicator dye by DRG neurons was achieved over
a 30min incubation at 37˚C inHBSS (pH7.45) (Invitrogen) containing 0.1%
BSA (Sigma-Aldrich) and 2.5 mM probenecid (Sigma-Aldrich), supple-
mentedwith 10mMfluo-3-acetoxymethyl (Invitrogen), and 20%pluronic F-
127 (Sigma-Aldrich). After the incubation period, the plates were washed
twice with the dye-free solution and placed into a 37˚C incubator in the dark
for 30 min. The increase in cellular fluorescence (excitation at 460‑490 nm;
emission at 515 nm) was recorded using an inverted microscope (Zeiss,
Oberkochen, Germany) and a (310, 0.5 numerical aperture objective). Im-
ages were acquired using a charge-coupled device camera (Zeiss) and
Metamorph software (Molecular Devices, Sunnyvale, CA). Acquisition
parameters were kept constant within each experiment. A kinetic of 200
recordings (one per second) was performed. From 10 to 65 s, neurons were
exposed to agonists, then from 65 to 155 s, neurons were exposed to
HBSS‑BSA‑probenecid buffer containing 50mMthapsigargin (Calbiochem,
SanDiego, CA), 5mM ionomycin (Calbiochem), and 10mMEGTA (Sigma-
Aldrich). Finally, from 155 to 200 s, neurons were exposed to
HBSS‑BSA‑probenecid buffer containing 120 mM CaCl2. Regions of in-
terest were fitted around the perimeter of one neuron, and intensity variations
for each region of interest were measured using Metamorph software. In-
tracellular calcium concentrations [Ca2+]i in nanomolar were calculated
using the equation [Ca2+]i = Kd (F 2 Fmin)/(Fmax 2 F), where Kd is the
dissociation constant of the Ca2+‑fluo-3-acetyoxymethyl ester complex (390
nM) and F represents the fluorescence intensity of the cells expressed as the
ratio between the highest fluorescencemeasurement between 10 and 65 s and
the baseline. Fmin corresponds to the minimum fluorescence between 65 and
155 s, and Fmax represents the maximum fluorescence between 155 and 200
s. The data were expressed as the increase in fluorescencewith respect to the
baseline fluorescence intensity measured during the 10 s time period before
the addition of agonists. Cells were treated with various compounds in-
cluding SLIRGRL-NH2 (100 mM) with or without added native or boiled
insulin (1 nM). The impact of insulin on signaling was monitored in the
absence or presence of the PI3K inhibitor LY294002 (10 mM), the PKC
inhibitor GF 109203X (10 mM), or both. When assessed for its effects in the
calcium signaling assays, insulin was added to the monolayers for 5 min
before the addition of an agonist. The effects of the PI3K and PKC inhibitors
on the effects of insulin were assessed for monolayers treated for at least 30
min with the inhibitors before the addition of insulin or any other test
compounds.
Induction of diabetes in mice
To induce diabetes, influenza HA-specific Tc1 cells were generated. A total
of 107 spleen and lymph node cells from CL4-TCR transgenic mice were
stimulated with 1 mg/ml HA512–520 peptide in DMEM supplemented with
10% FCS, 1 ng/ml IL-2, and 20 ng/ml IL-12 (R&D Systems, Minneapolis,
MN) with irradiated syngeneic spleen cells. At day 6, viable cells were
collected by Ficoll density separation and used in adoptive transfer ex-
periments to mediate b cell destruction so as to induce insulin-deficient
diabetes. These cells routinely contained .98% pure CD8+CD3+Vb8.2+
T cells coexpressing IFN-g and granzyme B (21). A total of 5 3 106 of
these effector Tc1 cells were injected i.v. (retro-orbital vein) into immu-
nocompetent recipient mice. Control (nondiabetic) mice were injected i.v.
with isotonic PBS (pH 7.4). Glycosuria levels were assessed daily (Glu-
kotest strips; Roche Diagnostic Systems, Mannheim, Germany) to monitor
the onset of diabetes, and experiments were performed with diabetic mice
for which urine glucose levels were $3 g/dl for more than two consecutive
days. Saline-treated nondiabetic littermate mice served as controls.
Statistical analysis
One-way ANOVA followed by the Student-Newman-Keuls test was used to
assess statistical difference among experimental groups. All of the results
are expressed as mean 6 SEM. Statistical significance was assessed ac-
cording to a p value ,0.05.
Results
PAR2-induced inflammation is modulated by insulin treatment:
reduced paw edema
Intraplantar injection of PPAR2-AP (SLIGRL-NH2) induced in-
flammation that was characterized by edema and granulocyte in-
filtration, as indicated by increases in paw thickness and MPO
activity, respectively (Fig. 1A, 1B). Mice that received a co-
injection of insulin along with PAR2-AP also showed a significant
increase in paw thickness as compared with saline-treated mice,
but the edema observed in the presence of insulin was significantly
lower at the 2, 3, 5, and 6 h time points, as compared with the mice
treated with PAR2-AP alone (Fig. 1A, open circles). The increase
in MPO activity induced by PAR2-AP injection (Fig. 1B, gray bar)
was abolished when insulin was coadministered along with PAR2-
AP (Fig. 1B, black bar). These anti-inflammatory effects were not
caused by insulin that had been treated by boiling before its co-
administration with SLIGRL-NH2 (Fig. 1C, 1D for edema and
MPO activity, respectively). The anti-inflammatory effect of in-
sulin in the paw edema assay seen with PAR2-AP-induced in-
flammation was not observed when inflammation was caused by
the intraplantar injection of carrageenan (Fig.1E, 1F).
Insulin treatment reduces PAR2-triggered leukocyte recruitment
Because the inflammatory action of PAR2 in the pawedemamodel is
known to involve the endothelium-dependent recruitment of in-
flammatory leukocytes (7, 11), we evaluated the effects of insulin on
PAR2-induced leukocyte rolling and adhesion onto the endothelial
wall in vivo. Leukocyte trafficking in the microcirculation of in-
testinal venules was monitored both before and at different times
after the intraluminal administration of PAR2-AP alone or in com-
bination with insulin. Intraluminal administration of PAR2-AP,
SLIGRL-NH2, but not the reverse PAR2-inactive peptide, induced
a significant increase in the area under the curve for the fluxof rolling
leukocytes and their adherence to the vessel wall (Fig. 2A, 2B).
FIGURE 1. Effects of insulin on paw inflammation. Changes in paw
thickness (A, C, E) were measured every hour for 6 h using an electronic
caliper and reported as a difference between the measurement at each time
point and the basal measurement. MPO activity (B, D, F), a marker of
granulocyte infiltration, was measured from the paws isolated 6 h after the
injection of indicated solutions. A–F, C57BL6 mice received intraplantar
injections of saline, PAR2-AP (SLIGRL-NH2, 50 mg per paw), insulin (150
pmol), PAR2-AP (50 mg per paw) plus insulin (150 pmol) (native or
boiled), carrageenan (200 mg), or carrageenan (200 mg) plus insulin (150
pmol). #p, 0.05, significantly different from mice injected with saline; pp
, 0.05, significantly different from mice injected with PAR2-AP alone.
Values are shown as mean 6 SEM (n = 8).
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These prominent effects of PAR2-AP on leukocyte trafficking were
abolishedwhen insulinwas coadministered with PAR2-AP (Fig. 2A,
2B). The data demonstrated that low doses of insulin were able to
reverse the marked effects of PAR2 activation on increasing leuko-
cyte recruitment to the venule.
Insulin reduces endothelial cell Ca2+ signaling in response to
PAR2 activation
Because leukocyte trafficking along intestinal venules depends on
endothelial function and the expression by both leukocytes and the
endotheliumofadhesionmoleculesandbecausePAR2beenshownto
play a role in the upregulation of ICAMs in endothelial cells (22),we
hypothesized that insulinwould be able to affect PAR2-AP signaling
in HMECs (23). To test this hypothesis, we evaluated the ability of
insulin tomodulate PAR2-triggered calcium signaling in these cells.
Treatment of HMECs with PAR2-AP elicited an elevation of in-
tracellular calcium concentration in the HMECs (Fig. 3A, 3C). The
increase in HMEC intracellular calcium concentration caused by
PAR2-AP observed after PAR2 activation was attenuated signifi-
cantly by preincubation of the cells with insulin for either 1 or 5 min
(0.1, 1, and 10 nM; Fig. 3A). The inhibitory effects of insulin on the
PAR2 agonist-induced calcium signal in endothelial cells appeared
to be receptor-specific because the elevation of HMEC intracellular
calcium concentration caused by activation of PAR1 with the PAR1-
activating peptide (PAR1-AP) TFLLR-NH2 was not reduced by
pretreatment with insulin (0.1 and 1 nM) but, in contrast, was in-
creased slightly at the highest concentration of insulin used (10 nM)
(Fig. 3B). Similarly, in vivo, PAR1-AP-induced edema was not re-
duced by coinjection with insulin at all of the time points after in-
traplantar injection, except at the first hour, where insulin treatment
slightly increased PAR1 agonist-induced edema (Fig. 3D).
Insulin reduces PAR2-stimulated Ca
2+ signaling in primary
cultures of DRG neurons
Our previous studies have shown that PAR2 agonist-induced paw
edema involves a neurogenic mechanism, with activation of the
receptor on sensory neurons that in turn releases the vasoactive
neurokinin substance P and calcitonin gene-related peptide through
a calcium-dependent mechanism (9). Given the ability of insulin to
reduce the edema response (Fig. 1), we wondered whether insulin
might modulate the action of PAR2 in sensory neurons. To explore
this possibility, we evaluated the effect of insulin on PAR2-mediated
calcium signaling in isolated sensory DRG cells. As described
previously (12, 18, 19), activation of PAR2 in sensory neurons
FIGURE 3. Effects of insulin on calcium flux in en-
dothelial cells and onPAR1-AP-induced edema.Calcium
flux in endothelial cells induced by PAR2-AP (SLIGRL-
NH2, 100mM)with orwithout insulin (at 0.1, 1, or 10 nM
with 1 or 5 min preincubation) (A,C) and in the presence
or absence of the PI3K inhibitor (LY294002, 50 mM) or
PKC inhibitor (GF 109203X, 100 mM) (C) or in endo-
thelial cells stimulated by PAR1-AP (TFLLR-NH2, 100
mM)with orwithout insulin treatment (0.1, 1, and 10 nM,
1 min preincubation) (B). pp , 0.05; pppp , 0.005,
significantly different from PAR2-AP treatment (A,C) or
from PAR1-AP treatment (B).Values, representing the
increase in intracellular calcium concentration (E530), as
a percentage of the increase caused by 4 mMA23187 (%
A23187) are shown as mean6 SEM. Observations were
made for a minimum of 44 cells for each condition. D,
Changes in paw thickness were measured every hour for
6 h using an electronic caliper and reported as the dif-
ferences between the measurements at each time point
and the basal measurement. C57BL6 mice received in-
traplantar injections of PAR1-AP (TFLLR-NH2, 50 mg
per paw), insulin (150 pmol), or PAR1-AP (50 mg per
paw) plus insulin (150 pmol). pp , 0.05, significantly
different frommice injectedwith PAR1-APalone.Values
are shown as mean6 SEM (n = 8 in each group).
FIGURE 2. Effects of insulin on PAR2 agonist-induced changes in leukocyte flux and leukocyte adherence. Changes in the flux of rolling leukocytes (A)
and the number of leukocytes adherent to the vessel wall (B) in mouse intestinal venules were measured by intravital microscopy under basal conditions and
immediately after intraluminal administration of vehicle (80% saline, 10% ethanol, and 10% Tween 80), PAR2-AP (SLIGRL-NH2, 100 mg), reverse peptide
(LRGILS-NH2, 100 mg), or PAR2-AP plus insulin (100 mg and 150 pmol, respectively). Graphs represent the area under the curve of values measured over
a 5 min time span at 15 min intervals, over a period of 80 min (a total of six readings). #p , 0.05, significantly different from vehicle administration; pp ,
0.05, significantly different from PAR2-AP administration. Values are shown as the mean 6 SEM (n = 7–10).
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isolated frommouse DRGs led to rapid mobilization of intracellular
calcium (Fig. 4). Cultured DRGs preincubated with insulin (1 nM)
for either 1 (data not shown) or 5min showed a substantial reduction
in the elevation of intracellular calcium concentration caused by
PAR2-AP (Fig. 4A). The proportion of cultured neurons that re-
sponded to PAR2-AP with an increase in calcium signaling alsowas
reduced significantly when the cultures were treated with insulin (1
nM) (Fig. 4B). In contrast, when the cultured DRG neuronal cells
were preincubatedwith boiled insulin (1 nM), thePAR2-AP–induced
elevation of intracellular calcium concentrationwas not significantly
different from that of cells treated with PAR2-AP alone (data not
shown).
Intracellular signaling pathways associatedwith insulin-induced
reduction of PAR2 signals
To assess the mechanism(s) by which insulin was able to diminish
PAR2 calcium signaling at a cellular level, either HMECs or pri-
mary afferent neurons were preincubated with either LY294002
(an inhibitor of PI3K) or GF 109203X (a nonselective inhibitor of
PKC) prior to monitoring the effects of insulin on PAR2-induced
calcium mobilization in those cell types. The PI3K and PKC in-
hibitors on their own had no effect on the ability of PAR2-AP to
elevate intracellular calcium concentration in either HMECs (Fig.
3C) or DRGs (Fig. 4A). However, in the presence of either in-
hibitor, the ability of insulin to reverse the PAR2-triggered in-
crease in intracellular calcium concentration was blocked in both
the HMECs (Fig. 3C) and the cultured DRGs (Fig. 4A). This re-
versal of the inhibitory action of insulin also was reflected in terms
of the proportion of responding cells in the DRG cultures (Fig.
4B). Thus, in both the HMECs and the cultured primary afferent
neurons, the ability of insulin to diminish the cell response to
PAR2-AP (elevated intracellular calcium concentration) appeared
to depend on the PI3K and PKC signaling pathways.
We have investigated in vivo whether PI3K or PKC inhibitors,
when injected into the mouse paw before the injection of PAR2
agonist, or the coinjection of PAR2 agonist and insulin can modify
the inflammatory parameters of edema and granulocyte infiltration
(MPO activity). Pretreatment with the PI3K or PKC inhibitors
showed no significant effect on PAR2-induced paw edema and
increased MPO activity (Fig. 5A, 5B). However, in mice that re-
ceived a pretreatment with those inhibitors into the paw, the ability
of insulin to significantly reduce PAR2-induced paw edema, and
increased MPO activity was blocked (Fig. 5C, 5D). This result
suggests that in vivo as well the ability of insulin to reduce PAR2
agonist-induced inflammation depends on the PI3K and PKC
signaling pathways.
Inflammatory response to PAR2-AP in the paw edema model is
increased in mice with type 1 diabetes
Because our data showed that insulin could diminish PAR2-in-
duced inflammation, ostensibly via an effect on the endothelium
and sensory nerve components, we hypothesized that the in-
flammatory effect of PAR2 activation might be affected in the
setting of insulin-deficient diabetes. To test this hypothesis, we
evaluated PAR2-triggered paw inflammation in mice rendered
diabetic via the immune destruction of pancreatic b cells. In
keeping with the data in Fig. 1, nondiabetic RIP-HA transgenic
mice that received an intraplantar injection of the PAR2 agonist
SLIGRL-NH2 developed an inflammatory response characterized
by an increase in paw diameter (Fig. 6A, open squares) and an
influx of inflammatory cells (increased MPO activity; Fig. 6B,
white bars). In support of our working hypothesis, the in-
flammatory response of the diabetic RIP-HA mice to the intra-
plantar administration of SLIGRL-NH2 was enhanced, in terms of
both edema (Fig. 6A, solid squares) and increased neutrophil in-
filtration (enhanced MPO activity; Fig. 6B, solid histograms).
Thus, the insulin-deficient diabetic mice appeared to be more
prone to a PAR2-mediated inflammatory response. Acute admin-
istration of insulin together with the PAR2 agonist in diabetic mice
was able to inhibit PAR2 agonist-induced edema significantly, to
the same extent as in control mice (Fig. 6C). This result suggests
further that the increased inflammatory response associated with
PAR2 activation is due to the lack of modulatory effects of insulin
in the diabetic mice.
Discussion
The main finding of our study was that insulin, at low doses, can
attenuate PAR2-mediated inflammation. The concentrations of
insulin used in vitro were in the physiological range (1 nM). It is
difficult to predict the absolute concentrations of insulin reached
in the experiments done in vivo, even though comparatively low
doses were administered. This action of insulin to mitigate the
acute inflammatory effects of PAR2 activation was reflected not
only by diminished edema and neutrophil infiltration(MPO ac-
tivity) caused by the intraplantar administration of a PAR2 agonist
but also in terms of markedly attenuated PAR2-induced leukocyte
trafficking and a reduction in intracellular calcium signaling
triggered by PAR2 in sensory neuronal cells (DRGs) and endo-
thelial cells. Thus, insulin action can be seen to diminish the in-
flammatory effects of PAR2 in an intact tissue by targeting
a number of key sites: the endothelium (intracellular signaling and
leukocyte adherence), the sensory nerve that can release vasoac-
tive neuropeptides (calcium signaling), and vascular permeability
(edema in vivo). All of these sites have been documented to play
roles in PAR2-triggered neurogenic inflammation (9, 24). The time
frame of the PAR2-triggered effects on leukocyte trafficking (seen
within 15‑20 min) suggests a rapid P-selectin–initiated process
followed by interactions with constitutively expressed endothelial
VLA4-VCAM1/LFA1-ICAM1 (25). This mechanism, reversed by
insulin, would merit further study.
Our data provide a new link between the action of insulin and the
innate immune response system, a topic that has attracted con-
siderable attention over the past decade (1, 26). To date, in the
FIGURE 4. Effects of insulin on the increase in in-
tracellular calcium concentration (nanomolar) (A) and
number of responding neurons (B) in primary afferent
DRG cultures stimulated by PAR2-AP (SLIGRL-NH2,
100mM) in the presence or absence of insulin (1 nM,with
5minpreincubation), and in thepresenceorabsenceof the
PI3K inhibitor (LY294002, 50 mM) or the PKC inhibitor
(GF 109203X, 100 mM) (C). ppp , 0.01, significantly
different from PAR2-AP–treated neurons. Values, repre-
senting the increase in calcium concentration (nano-
molar), are shown as mean 6 SEM. Observations were
made for a minimum of 92 cells for each condition.
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setting of diabetes, the role of the innate immune system has been
viewed as diminishing insulin responses, due to inflammatory
cytokine action (24). In contrast, our data now reveal that re-
ciprocally insulin action can diminish a number of inflammatory
parameters triggered by an acute stimulation of the innate immune
system itself, as typified by PAR2 activation. Because the PAR2
system appears to play a prominent role in inflammatory diseases,
such as arthritis (27) and intestinal inflammatory disease (3, 4, 11,
28), one can suggest that PAR2 activation also may enhance in-
flammatory responses in type 1 and type 2 diabetes. It is thus of
much interest that insulin itself can be a negative regulator of the
acute inflammatory action of PAR2. This action of insulin is in
keeping with its anti-inflammatory and cardioprotective effects
observed in several animal models in vivo (1) and with the clinical
use of rigorous insulin therapy in humans in an intensive care
setting (29). However, it can be noted that rigorous treatment
of patients with type 2 diabetes with insulin or metformin to op-
timize blood glucose levels failed to reduce chronic inflammatory
biomarkers compared with those of control patients [e.g., high-
sensitivity C-reactive protein (30)]. Thus, the data that we report
may apply only to an acute and not a chronic inflammatory pro-
cess in diabetic humans. This issue merits further study.
The increased paw inflammation caused by SLIGRL-NH2 in
insulin-deficient diabetic mice was in complete accord with our
other data, because in these animals the anti-inflammatory action
of insulin would be diminished due to the reduced insulin levels.
Indeed, local treatment of the diabetic mice with low doses of
insulin, administered at the inflammatory site so as not to affect
systemic insulin levels, attenuated PAR2-induced inflammation.
Notwithstanding, the enhanced inflammation triggered by PAR2 in
the diabetic animals also might have been influenced by hyper-
glycemia, which also is recognized to have proinflammatory ef-
fects (1). Thus, in a type 1 diabetes setting mimicked by the
murine model that we used, one can suggest that increased in-
flammation resulting from an acute activation of the innate im-
mune response would be due to both hyperglycemia and a relative
FIGURE 5. Proinflammatory effects of intraplantar
injection with PAR2-AP (SLIGRL-NH2, 50 mg per
paw) or PAR2-AP plus insulin (150 pmol per paw) in
mice that had received a pretreatment into the paw
with vehicle, the PI3K inhibitor (LY294002, 1 mg), or
the PKC inhibitor (GF 109203X, 1 mg). Changes in
paw thickness (A, C) and increases in paw MPO ac-
tivity (B, D). Changes in paw thickness (electronic
caliper) were measured every hour over a 6 h time
period and are reported as the differences between the
measurements at each time point and the basal mea-
surement at time 0. MPO activity, a marker of gran-
ulocyte infiltration, was measured from paws taken 6 h
after the injection of the indicated solutions. Signifi-
cant differences caused by the PI3K and PKC in-
hibitors compared with mice injected with PAR2-AP in
combination with insulin alone were observed: pp ,
0.05; ppp , 0.01. Values are shown as means 6 SEM
(n = 6 for diabetic groups and n = 4 for controls).
FIGURE 6. Proinflammatory effects of intra-
plantar injection with PAR2-AP (SLIGRL-NH2, 50
mg per paw), PAR2-AP plus insulin (150 pmol per
paw), or control peptide (LIGILS, 50 mg/paw) in
diabetic or controlmice. Changes in paw thickness (A,
C) and increases in pawMPO activity (B). Changes in
paw thickness (electronic caliper) were measured
every hour over a 4 h time period and are reported as
the differences between the measurements at each
time point and the basal measurement at time 0. MPO
activity, a marker of granulocyte infiltration, was
measured frompaws taken 6 h after the injection of the
indicated solutions. #p, 0.05, significantly different
from mice of the corresponding group but injected
with control peptide (LRGILS-NH2) inA or SLIGRL-
NH2alone inC.pp,0.05, significantly different from
control mice injected with PAR2-AP (SLIGRL-NH2)
(A, C). Values are shown as means6 SEM (n = 6 for
diabetic groups and n = 4 for controls).
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reduction in the anti-inflammatory action of insulin. This increase
in inflammation, due to protease activation of the innate immune
response, also may occur in a type 2 diabetes setting, where hy-
perglycemia is accompanied by a reduced sensitivity to the action
of insulin. Thus, an interaction between the actions of insulin and
the inflammatory effects of endogenous activation of PAR2 may
be of importance in both type 1 and type 2 diabetes.
The mechanism(s) whereby insulin was able to mitigate the in-
flammatory response to the PAR2 agonist appears complex, in-
volving both the PI3K and PKC signaling pathways. Reciprocal
interactions between signaling by insulin and G protein-coupled
receptors have been known for over 30 y, best typified by the in-
hibitory effect of insulin on norepinephrine, adrenocorticotropic
hormone, and glucagon-stimulated lipolysis in isolated adipocytes
(31). More recently, it has been demonstrated that for certain G
protein-coupled receptor-mediated increases in intracellular calcium
concentration (vasopressin, bradykinin, angiotensin II, neurotensin,
and bombesin) insulin can enhance rather than inhibit signaling
via a mammalian target of rapamycin-dependent pathway (32, 33).
However, our data demonstrating an insulin-mediated decrease
rather than an increase in PAR2-triggered calcium signaling are in
keeping with the ability of insulin-like growth factor I and insulin to
induce phosphorylation and desensitization of the G protein-cou-
pled a1B and a1D adrenergic receptors (34, 35). In those studies, as
in ours, inhibitors of PI3K and PKC blocked receptor phosphory-
lation (on serines in the a1D adrenoceptor) caused by the growth
factors. It can be noted that the concentrations of insulin used in
other studies done in vitro (100 nM or higher) all have been well
above the near-physiological concentrations that we employed for
our cell culture work (∼1 nM). Significantly, our data showed that
insulin treatment desensitized PAR2-mediated HMEC calcium sig-
naling but did not decrease or even slightly increased calcium
signaling via PAR1 (Fig. 3). Thus, in summary, activation of the
insulin receptor may differentially affect signaling not only by the
PARs but also by other G protein-coupled receptors. This ability of
insulin to affect G protein-coupled receptor signaling in a differen-
tial manner may explain why inflammation triggered by carra-
geenan was not affected by insulin treatment, whereas PAR2-
induced inflammation was reduced.
To conclude, our data reveal an unexpected inhibitory interaction
between insulin and the acute inflammatory arm of the innate
immune response triggered by PAR2. The data bring into focus
a potential pathophysiological role for serine proteases, such as
those of the coagulation pathway. In principle, those enzymes, via
PAR2, can trigger the innate inflammatory response in the setting
of type 1 and type 2 diabetes. Thus, in the setting of the insulin
deficiency of type 1 diabetes or the insulin signaling resistance in
type 2 diabetes, the diminished impact of insulin signaling may
enhance the inflammatory effects of the innate immune response.
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Multiple sclerosis (MS) is a complex demyelinating disease associated with chronic inflammation 
of the central nervous system (CNS), axonal loss, and brain atrophy. The CD4+ and CD8+ T cells that are 
present in the demyelinating lesions are considered to mediate demyelination and axonal damage. 
I developed an original mouse model combining selective expression of influenza hemagglutinin 
(HA) as a neo-self-Ag in oligodendrocytes with transgenic mice expressing a HA-specific TcR on CD8+ 
T cells. I demonstrate directly the potential of CD8+ T cells to induce oligodendrocyte death in-vivo, as a 
likely consequence of direct antigen-recognition. 
I investigated the pathogenic traits of the CD4+ T cell response targeting the immunodominant 
epitope of myelin oligodendrocyte protein (MOG). To this end we obtained 2D2 TcR-transgenic 
C57BL/6 mice, which harbor a large population of MOG-specific CD4+ T cells. Strikingly when we 
crossed these 2D2 mice with MOG-deficient mice (MOG-/-), we discovered that the 2D2 TcR-transgenic 
mice developed spontaneous EAE regardless of the presence or absence of the target self-antigen MOG. 
Therefore we hypothesized, that the 2D2 TcR specific for MOG35-55 recognizes a second CNS antigen. 
Furthermore, we were able to reveal, that MOG35-55 peptide shares sequence homology with a stretch of 
neurofilament-medium (NF-M), a cytoskeletal protein expressed in neurons and axons. In addition, this 
epitope derived from NF-M shares 2D2 TcR contact residues with MOG35-55 when presented in the 
context of I-Ab. Surprisingly, NF-M15-35 peptide showed heteroclitic response when presented to 2D2 T 
cells. Using gene-deficient mice, we demonstrate that the co-recognition of MOG and NF-M by the 2D2 
CD4+ T cells contributes individually to disease phenotype and severity. 
We refer to this novel observation of self-mimicry, as ‘Cumulative autoimmunity’ where clonal 
autoimmune response targets two self-autoantigens in the same tissue, results in enhanced CNS tissue 
damage. 
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